Supporting Information

Modulating chitin synthesis in marine algae with iminosugars obtained by SmI_2 and $FeCl_3$ -mediated diastereoselective carbonyl ene reaction

Marcel Holzwarth,^{a¶} Jan Ludwig,^{b¶} Alexander Bernz,^a Birgit Claasen,^a Asma Majoul,^b Julia Reuter,^b Anna Zens,^a Brigitte Pawletta^c, Ursula Bilitewski^c, Ingrid M. Weiss*^{b,d,e} and Sabine Laschat*^a

[¶] both coauthors contributed equally to this work.

Table of contents

1)	General information	S 3
2)	Synthetic procedures	S4
3)	Functionalizations of hydroxypiperidines	S65
4)	Stereochemical elucidation of the cyclic hydroxypiperidines	S69
5)	Chitin fiber synthesis assay with Thalassiosira rotula	S76
6)	Literature	S78
7)	NMR-spectra	S 79

1) General information

Moisture sensitive reactions were performed under nitrogen atmosphere using flame-dried

glassware and standard Schlenk techniques. NMR-spectra were recorded on a Bruker Avance

300, Avance 400, Avance 500 or Avance 700. NMR-spectra data were reported as δ values in

ppm relative to the NMR-solvent residue signals. Used solvents were specified for each

compound. New compounds were fully characterized using 2D-NMR techniques for signal

assignment. ¹H-NMR coupling constants (*J*) were reported in Hertz (Hz) and indicated with the

following short tags for multiplicity: s (singlet); d (dublet); t (triplet); q (quartet); m (multiplet)

and br (broad). Mass spectra were recorded on a Finnigan MAT MAT95 spectrometer (EI-

conditions at 70 eV) or a Bruker Daltonics micro-TOF-Q spectrometer (ESI-conditions). IR

spectra were recorded on a Bruker Alpha Platinum ATR with MKII Golden Gate Single

Reflection Diamant ATR-system. HPLC was performed using a Shimadzu system containing

LC-20AT pumps, a CBM-20A prominence communications bus module and a SPD-20A

UV/Vis-detector. Separation was accomplished via achiral Orbit- or chiral Chiracel®-OD-

column. Column chromatography was performed using Fluka silica (Type 60, diameter 40 –

70 µm). Solvents were distilled prior to use. Unless stated otherwise, all chemicals were used

as received from the suppliers. Reaction progress was tracked using Macherey-Nagel TLC

plates type 60 F 254 with fluorescence indicator. For non-UV-active compounds staining

solutions were used and the plates were slightly heated.

Staining solutions for TLC:

Anisaldehyde-solution: 0.5 mL 4-methoxybenzaldehyde, 50 mL glacial acetic acid, 1.0 mL

concentrated sulfuric acid, 300 mL ethanol.

Ninhydrin-solution: 0.3 g ninhydrin in 95 mL acetone.

S3

2) Synthetic procedures

GP1: Synthesis of amino acid methyl ester hydrochlorides from their respective D- or L-amino acid

The hydrochlorides were prepared according to the literature.^[1] Thionyl chloride (8.7 mL, 14.3 g, 120 mmol) was added dropwise to a solution of the amino acid (40.0 mmol) in methanol (40 mL) at 0 °C. After stirring for 48 h at room temperature the solvent was evaporated. The products were isolated as colorless solids and used in further reactions without additional purifications.

Methyl L-valinate hydrochloride (25a)

According to GP1 **25a** was prepared from L-valine **24a** (1.76 g, 15.0 mmol) and thionyl chloride (3.3 mL, 5.35 g, 45.0 mmol) as a colorless solid (2.52 g, NH₃Cl 15.0 mmol, quant.). $[\alpha]_D^{20} + 7$ (c 1.0 in H₂O). ¹H-NMR (400 MHz, DMSO-d₆) δ 0.94 (d, J = 6.9 Hz, 3H, 4-H/5-H), 0.99 (d, J = 6.9 Hz, 3H, 5-H/4-H), 2.13 – 2.29 (m, 1H, 3-H), 3.70 – 3.78 (m, 3H, OMe), 3.78 – 3.85 (m, 1H, 2-H), 8.42 – 9.00 (m, 3H, NH₃). ¹³C-NMR (101 MHz, DMSO-d₆) δ 17.5 (C-4/C-5), 18.4 (C-5/C-4), 29.3 (C-3), 52.5 (OMe), 57.2 (C-2), 169.2 (C-1). The spectral data are in accordance with previous reported literature. ^[2]

Methyl D-valinate hydrochloride (25b)

According to GP1 **25b** was prepared from D-valine **24b** (4.67 g, 40.0 mmol) and thionyl chloride (8.7 mL, 14.3 g, 120 mmol) as a colorless solid (6.60 g, NH₃Cl 39.4 mmol, 98 %). $[\alpha]_D^{20}$ - 17 (c 1.0 in H₂O). ¹H-NMR (400 MHz, DMSO-d₆) δ 0.94 (d, J = 7.0 Hz, 3H, 4-H/5-H), 0.99 (d, J = 7.0 Hz, 3H, 5-H/4-H), 2.13 – 2.28 (m, 1H, 3-H), 3.74 (s, 3H, OMe), 3.78 – 3.87 (m, 1H, 2-H), 8.30 – 9.10 (m, 3H, NH₃). ¹³C-NMR (101 MHz, DMSO-d₆) δ 17.5 (C-4/C-5), 18.5 (C-5/C-4), 29.3 (C-3), 52.5 (OMe), 57.3 (C-2), 169.1 (C-1). The spectral data are in accordance with previous reported literature. ^[2]

Methyl L-leucine hydrochloride (25c)

According to GP1 **25c** was prepared from L-leucine **24c** (2.62 g, 5 4 3 2 1 1 1 0 20.0 mmol) and thionyl chloride (4.4 mL, 7.14 g, 60.0 mmol) as a colorless solid (3.59 g, 19.8 mmol, 99 %). [α] 20 + 18 (c 1.0 in H₂O). 1 H-NMR (400 MHz, D₂O) δ 0.90 – 1.10 (m, 6H, 5-H, 6-H), 1.70 – 1.86 (m, 2H, 3-H_a, 4-H), 1.86 – 1.99 (m, 1H, 3-H_b), 3.86 – 3.93 (m, 3H, OMe), 4.15 – 4.25 (m, 1H, 2-H). 13 C-NMR (101 MHz, D₂O) δ 21.0 (C-5/C-6), 21.5 (C-6/C-5), 23.9 (C-4), 38.8 (C-3), 51.5 (C-6/C-5)

2), 53.5 (OMe), 171.3 (C-1). The spectral data are in accordance with previous reported literature.^[3]

Methyl D-leucine hydrochloride (25d)

According to GP1 **25d** was prepared from D-leucine **24d** (5.25 g, 5 4 2 1 1 0 40.0 mmol) and thionyl chloride (8.7 mL, 14.3 g, 120.0 mmol) as a colorless solid (6.80 g, 37.4 mmol, 94 %). [α] $_{D}^{20}$ - 7 (c 1.0 in H₂O). 25d 1 H-NMR (500 MHz, D₂O) δ 0.91 – 1.02 (m, 6H, 5-H, 6-H), 1.70 – 1.82 (m, 2H, 3-H_a, 4-H), 1.83 – 1.93 (m, 1H, 3-H_b), 3.86 (s, 3H, OMe), 4.12 – 4.22 (m, 1H, 2-H). 13 C-NMR (126 MHz, D₂O) δ 21.0 (C-5/C-6), 21.5 (C-6/C-5), 23.9 (C-4), 38.8 (C-3), 51.4 (C-2), 53.5 (OMe), 171.3 (C-1). The spectral data are in accordance with previous reported

Methyl L-isoleucinate hydrochloride (25e)

literature.^[3]

According to GP1 **25e** was prepared from L-isoleucine **24e** (5.25 g, 40.0 mmol) and thionyl chloride (8.7 mL, 14.3 g, 120 mmol) as a colorless solid (7.19 g, 39.6 mmol, 99 %). $[\alpha]_D^{20} + 15$ (c 0.6 in CHCl₃). ¹H-NMR **25e** (400 MHz, D₂O) δ 0.98 (t, J = 7.4 Hz, 3H, 5-H), 1.05 (d, J = 7.1 Hz, 3H, 6-H), 1.30 – 1.46 (m, 1H, 4-H_a), 1.46 – 1.60 (m, 1H, 4-H_b), 2.02 – 2.20 (m, 1H, 3-H), 3.89 (s, 3H, OMe), 4.10 – 4.24 (m, 1H, 2-H). ¹³C-NMR (101 MHz, D₂O) δ 10.8 (C-5), 14.1 (C-6), 24.8 (C-4), 36.0 (C-3), 53.3 (OMe), 57.3 (C-2), 170.3 (C-1). The spectral data are in accordance with previous reported literature. ^[4]

Methyl L-phenylalaninate hydrochloride (25f)

According to GP1 **25f** was prepared from L-phenylalanine **24f** (6.60 g, 40.0 mmol) and thionyl chloride (8.7 mL, 14.3 g, 120 mmol) as a colorless solid (8.31 g, 38.5 mmol, 96 %). [α]_D²⁰ + 13 (c 4.6 in CHCl₃). **25f** 1 H-NMR (400 MHz, DMSO-d₆) δ 3.11 (dd, J = 13.9 Hz, 7.6 Hz, 1H, 3-H_a), 3.25 (dd, J = 13.9 Hz, 5.4 Hz, 1H, 3-H_b), 3.63 (s, 3H, OMe), 4.12 – 4.28 (m, 1H, 2-H), 7.18 – 7.40 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H), 8.87 (s, 3H, NH₃). 13 C-NMR (101 MHz, DMSO-d₆) δ 35.8 (C-3), 52.4 (OMe), 53.3 (C-2), 127.2 (C-4'), 128.5 (C-2', C-6'), 129.4 (C-3', C-5'), 134.8 (C-1'), 169.3 (C-1). The spectral data are in accordance with previous reported literature. [5]

Methyl D-phenylalaninate hydrochloride (25g)

According to GP1 **25g** was prepared from D-phenylalanine **24g** (6.61 g, 40.0 mmol) and thionyl chloride (8.7 mL, 14.3 g, 120 mmol) as a colorless solid (8.47 g, 39.3 mmol, 98 %). [α]_D²⁰+ 64 (c 1.0 in H₂O). ¹H-NMR (500 MHz, DMSO-d₆) δ 3.09 (dd, J = 14.0 Hz, 7.4 Hz, 1H, 3-

H_a), 3.18 (dd, J = 14.0 Hz, 5.4 Hz, 1H, 3-H_b), 3.66 (s, 3H, OMe), 4.21 – 4.30 (m, 1H, 2-H), 7.21 – 7.37 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H), 8.64 (s, 3H, NH₃). ¹³C-NMR (126 MHz, DMSO-d₆) δ 35.9 (C-3), 52.6 (OMe), 53.2 (C-2), 127.3 (C-4'), 128.6 (C-2', C-6'), 129.4 (C-3', C-5'), 134.6 (C-1'), 169.4 (C-1). The spectral data are in accordance with previous reported literature.^[5]

GP2: N-Protection of amino group using o-nitrobenzenesulfonyl chloride

The *N*-protected amino acid methyl esters were prepared according to the literature. A round bottom flask was charged with a solution of the amino acid methyl ester hydrochloride (10.0 mmol) in dichloromethane (20 mL) under nitrogen atmosphere. Upon cooling to 0 °C solutions of triethylamine (3.5 mL, 25.0 mmol, 2.5 M in dichloromethane) and o-nitrobenzenesulfonyl chloride (2.88 g, 13.0 mmol, 2.6 M in dichloromethane) were added dropwise. After stirring for 20 h at room temperature the organic phase was washed with water (3 × 20 mL) and dried over magnesium sulfate. The solvents were evaporated and the crude product was purified using column chromatography. The products were isolated as oils or solids.

Methyl-((2-nitrophenyl)sulfonyl)-L-valinate (26a)

26a

According to GP2 **26a** was prepared from methyl L-valinate hydrochloride **25a** (1.68 g, 10.0 mmol), *o*-nitrobenzenesulfonyl chloride (2.88 g, 13.0 mmol) and triethylamine (3.5 mL, 2.53 g, 25.0 mmol) as a yellow oil (2.88 g, 9.11 mmol, 91 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (5:1 \rightarrow 3:1). [α]²⁰_D - 194 (*c* 1.0 in CHCl₃). R_f = 0.34 (hexanes/EtOAc,

7 : 3, UV). FT-IR (ATR): $\tilde{v} = 3314$ (w, br), 3098 (w), 2967 (w), 1739 (vs), 1594 (w), 1541 (vs), 1442 (m), 1427 (m), 1392 (w), 1357 (vs), 1301 (m), 1265 (m), 1209 (m), 1173 (vs), 1141 (s), 1126 (m), 1062 (w), 1017 (w), 996 (w), 965 (w), 917 (w), 879 (w), 854 (m), 784 (m), 760 (w), 742 (m), 701 (w), 655 (m), 598 (s), 567 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.94 (d, J = 6.8 Hz, 3H, 4-H/5-H), 1.01 (d, J = 6.8 Hz, 3H, 5-H/4-H), 2.16 (dqq, J = 6.8 Hz, 6.8 Hz, 5.2 Hz, 1H, 3-H), 3.44 (s, 3H, OMe), 4.02 (dd, J = 9.7 Hz, 5.2 Hz, 1H, 2-H), 6.03 (d, J = 9.7 Hz, 1H,


NH), 7.69 - 7.76 (m, 2H, 4'-H, 5'-H), 7.90 - 7.96 (m, 1H, 3'-H), 8.03 - 8.09 (m, 1H, 6'-H). 13 C-NMR (126 MHz, CDCl₃) δ 17.5 (C-4/C-5), 19.0 (C-5/C-4), 31.6 (C-3), 52.2 (OMe), 62.2 (C-2), 125.6 (C-3'), 130.4 (C-6'), 132.8 (C-5'), 133.6 (C-4'), 134.2 (C-1'), 147.7 (C-2'), 171.1 (C-1). HRMS (ESI): calc (found) for $C_{12}H_{16}N_2O_6S$ ([M+Na]⁺): 339.0621 (339.0630). The spectral data are in accordance with previous reported literature. $^{[6]}$

Methyl-((2-nitrophenyl)sulfonyl)-D-valinate (26b)

5 0 1 6' NH 5' NO₂ 26b According to GP2 **26b** was prepared from methyl D-valinate hydrochloride **25b** (1.68 g, 10.0 mmol), *o*-nitrobenzylsulfonyl chloride (2.88 g, 13.0 mmol) and triethylamine (3.5 mL, 2.53 g, 25.0 mmol) as a yellow oil (2.85 g, 9.00 mmol, 90 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (5:1 \rightarrow 3:1). [α]_D²⁰ + 205 (*c* 1.0 in CHCl₃). $R_f = 0.21$ (hexanes/EtOAc, 3:1,

UV). FT-IR (ATR): $\tilde{v} = 3321$ (w, br), 3099 (w), 2966 (w), 1737 (vs), 1594 (w), 1539 (vs), 1441 (s), 1425 (s), 1392 (w), 1354 (vs), 1300 (s), 1263 (s), 1208 (s), 1169 (vs), 1139 (s), 1125 (s), 1060 (m), 1016 (m), 996 (m), 964 (w), 914 (m), 878 (m), 854 (s), 783 (s), 759 (m), 731 (vs), 701 (m), 654 (s), 592 (vs), 563 (vs), 468 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.92 (d, J = 7.0 Hz, 3H, 4-H/5-H), 1.01 (d, J = 7.0 Hz, 3H, 5-H/4-H), 2.10 – 2.23 (m, 1H, 3-H), 3.44 (s, 3H, OMe), 4.01 (dd, J = 9.8 Hz, 5.3 Hz, 1H, 2-H), 6.04 (d, J = 9.8 Hz, 1H, NH), 7.69 – 7.77 (m, 2H, 4'-H, 5'-H), 7.90 – 7.97 (m, 1H, 3'-H), 8.03 – 8.09 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 17.5 (C-4/C-5), 19.0 (C-5/C-4), 31.6 (C-3), 52.2 (O-Me), 62.2 (C-2), 125.6 (C-3'), 130.4 (C-6'), 132.8 (C-5'), 133.6 (C-4'), 134.1 (C-1'), 147.7 (C-2'), 171.1 (C-1). HRMS (ESI): calc (found) for C₁₂H₁₆N₂O₆S ([M+Na]⁺): 339.0621 (339.0622). The spectral data are in accordance with previous reported literature. [7]

Methyl-((2-nitrophenyl)sulfonyl)-L-leucinate (26c)




According to GP2 **26c** was prepared from methyl L-leucine hydrochloride **25c** (2.73 g, 15.0 mmol), *o*-nitrobenzylsulfonyl chloride (4.32 g, 19.5 mmol) and triethylamine (5.2 mL, 3.80 g, 37.5 mmol) as a yellow oil (4.92 g, 14.9 mmol, 99 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1). $[\alpha]_D^{20}$ - 183 (*c* 1.0 in CHCl₃). $R_f = 0.64$ (hexanes/EtOAc, 1 : 1, UV). FT-IR

(ATR): $\tilde{v} = 3318$ (w, br), 3100 (w), 2959 (m), 2873 (w), 1743 (s), 1594 (w), 1542 (vs), 1442 (m), 1423 (m), 1357 (vs), 1305 (m), 1275 (m), 1234 (m), 1205 (m), 1173 (vs), 1148 (s), 1126 (m), 1090 (w), 1060 (w), 1021 (w), 980 (w), 900 (w), 854 (w), 821 (w), 785 (w), 742 (m), 701

(w), 655 (m), 597 (m), 575 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.95 (d, J = 6.6 Hz, 6H, 5-H, 6-H), 1.57 – 1.64 (m, 2H, 3-H), 1.79 – 1.91 (m, 1H, 4-H), 3.42 (s, 3H, OMe), 4.18 – 4.27 (m, 1H, 2-H), 5.95 (d, J = 9.9 Hz, 1H, NH), 7.70 – 7.76 (m, 2H, 4'-H, 5'-H), 7.92 – 7.96 (m, 1H, 3'-H), 8.05 – 8.09 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 21.3 (C-5/C-6), 22.7 (C-6/C-5), 24.3 (C-4), 42.0 (C-3), 52.2 (OMe), 55.4 (C-2), 125.6 (C-3'), 130.4 (C-6'), 132.9 (C-5'), 133.6 (C-4'), 134.1 (C-1'), 147.6 (C-2'), 172.0 (C-1). HRMS (ESI): calc (found) for C₁₃H₁₈N₂O₆S ([M+Na]⁺): 353.0778 (353.0788). The spectral data are in accordance with previous reported literature.^[8]


Methyl-((2-nitrophenyl)sulfonyl)-D-leucinate (26d)



According to GP2 **26d** was prepared from methyl D-leucine hydrochloride **25d** (2.73 g, 15.0 mmol) , *o*-nitrobenzylsulfonyl chloride (4.32 g, 19.5 mmol) and triethylamine (5.2 mL, 3.80 g, 37.5 mmol) as a yellow oil (2.90 g, 8.78 mmol, 59 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2:1). $[\alpha]_D^{20} + 188$ (*c* 1.0 in CHCl₃). $R_f = 0.63$ (hexanes/EtOAc, 1:1, UV). FT-IR (ATR): $\tilde{\nu} = 3321$ (w, br), 3100 (w), 2958 (m), 2872 (w), 1740 (s),

1594 (w), 1539 (vs), 1441 (m), 1422 (s), 1351 (vs), 1303 (m), 1273 (m), 1234 (m), 1204 (m), 1169 (vs), 1125 (s), 1089 (m), 1060 (m), 1020 (m), 981 (w), 901 (m), 854 (m), 819 (w), 784 (s), 740 (vs), 732 (s), 701 (m), 655 (s), 594 (vs), 574 (vs), 486 (w), 465 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.90 – 0.97 (m, 6H, 5-H, 6-H), 1.57 – 1.62 (m, 2H, 3-H), 1.78 – 1.88 (m, 1H, 4-H), 3.40 (s, 3H, OMe), 4.15 – 4.26 (m, 1H, 2-H), 5.96 (d, J = 9.6 Hz, 1H, NH), 7.69 – 7.77 (m, 2H, 4'-H, 5'-H), 7.89 – 7.95 (m, 1H, 3'-H), 8.03 – 8.09 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 21.3 (C-5/C-6), 22.7 (C-6/C-5), 24.4 (C-4), 42.0 (C-3), 52.2 (OMe), 55.4 (C-2), 125.6 (C-3'), 130.5 (C-6'), 132.9 (C-5'), 133.7 (C-4'), 134.1 (C-1'), 147.7 (C-2'), 172.0 (C-1). HRMS (ESI): calc (found) for C₁₃H₁₈N₂O₆S ([M+NH₄]⁺): 348.1224 (348.1225). The spectral data are in accordance with previous reported literature. ^[8]


Methyl-((2-nitrophenyl)sulfonyl)-L-isoleucinate (26e)



According to GP2 **26e** was prepared from methyl L-isoleucinate hydrochloride **25e** (1.82 g, 10.0 mmol), *o*-nitrobenzylsulfonyl chloride (2.88 g, 13.0 mmol) and triethylamine (3.5 mL, 2.53 g, 25.0 mmol) as a red oil (2.64 g, 8.00 mmol, 80 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (5:1 \rightarrow 4:1 \rightarrow 3:1). [α]_D²⁰ - 84 (*c* 2.4 in CHCl₃). $R_f = 0.26$ (hexanes/EtOAc,

3 : 1, UV). FT-IR (ATR): $\tilde{\nu}$ = 3325 (w, br), 3098 (w), 2965 (m), 2932 (w), 2879 (w), 1738 (vs), 1594 (w), 1540 (vs), 1442 (s), 1426 (s), 1355 (vs), 1299 (m), 1259 (m), 1207 (m), 1171 (vs), 1140 (s), 1125 (s), 1061 (m), 1014 (w), 988 (w), 880 (w), 854 (m), 784 (m), 742 (s), 702 (w), 655 (m), 593 (s), 569 (m), 467 (w) cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ 0.91 (t, J = 7.4 Hz, 3H, 5-H), 0.96 (d, J = 6.9 Hz, 3H, 6-H), 1.16 – 1.32 (m, 1H, 4-H_a), 1.40 – 1.54 (m, 1H, 4-H_b), 1.85 – 1.98 (m, 1H, 3-H), 3.42 (s, 3H, OMe), 4.06 (dd, J = 9.7 Hz, 5.4 Hz, 1H, 2-H), 6.04 (d, J = 9.7 Hz, 1H, NH), 7.68 – 7.76 (m, 2H, 4'-H, 5'-H), 7.88 – 7.96 (m, 1H, 3'-H), 8.02 – 8.10 (m, 1H, 6'-H). ¹³C-NMR (101 MHz, CDCl₃) δ 11.2 (C-5), 15.5 (C-6), 24.7 (C-4), 38.2 (C-3), 52.1 (OMe), 61.4 (C-2), 125.6 (C-3'), 130.5 (C-6'), 132.8 (C-5'), 133.6 (C-4'), 134.2 (C-1'), 147.7 (C-2'), 171.1 (C-1). HRMS (ESI): calc (found) for C₁₃H₁₈N₂O₆S ([M+Na]⁺): 353.0778 (353.0778). The spectral data are in accordance with previous reported literature. ^[9]

Methyl-((2-nitrophenyl)sulfonyl)-L-phenylalaninate (26f)



According to GP2 **26f** was prepared from methyl L-phenylalaninate hydrochloride **25f** (2.16 g, 10.0 mmol), *o*-nitrobenzylsulfonyl chloride (2.88 g, 13.0 mmol) and triethylamine (3.5 mL, 2.53 g, 25.0 mmol) as a yellow solid (2.22 g, 6.10 mmol, 61 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (5 : 1 \rightarrow 4 : 1 \rightarrow 3 : 1 \rightarrow 2 : 1). mp 88 °C. [α]_D²⁰ - 38 (c 2.8 in CHCl₃). R_f = 0.18 (hexanes/EtOAc, 3 : 1, UV). FT-IR (ATR): \tilde{v} = 3323 (w, br), 3097 (w),

3028 (w), 2954 (w), 1743 (s), 1594 (w), 1540 (vs), 1497 (w), 1440 (m), 1423 (m), 1359 (vs), 1302 (m), 1219 (m), 1169 (vs), 1105 (m), 1060 (w), 1032 (w), 962 (w), 903 (w), 854 (m), 784 (w), 740 (m), 702 (m), 655 (w), 599 (m), 575 (m), 538 (w), 494 (w) cm⁻¹. 1 H-NMR (400 MHz, CDCl₃) δ 3.08 (dd, J = 13.9 Hz, 6.9 Hz, 1H, 3-H_a), 3.16 (dd, J = 13.9 Hz, 5.7 Hz, 1H, 3-H_b), 3.52 (s, 3H, OMe), 4.40 – 4.55 (m, 1H, 2-H), 5.98 (d, J = 8.7 Hz, 1H, NH), 7.07 – 7.13 (m, 2H, 2'-H, 6'-H), 7.15 – 7.25 (m, 3H, 3'-H, 4'-H, 5'-H), 7.61 – 7.73 (m, 2H, 4"-H, 5"-H), 7.80 – 7.90 (m, 1H, 3"-H), 7.92 – 8.02 (m, 1H, 6"-H). 13 C-NMR (101 MHz, CDCl₃) δ 39.2 (C-3), 52.4 (OMe), 57.8 (C-2), 125.6 (C-3"), 127.4 (C-4'), 128.7 (C-3', C-5'), 129.3 (C-2', C-6'), 130.3 (C-6"), 132.9 (C-5"), 133.4 (C-4"), 134.3 (C-1"), 134.8 (C-1'), 147.5 (C-2"), 170.8 (C-1). HRMS (ESI): calc (found) for C₁₆H₁₆N₂O₆S ([M+Na]⁺): 387.0621 (387.0622). The spectral data are in accordance with previous reported literature. $^{[6]}$

Methyl-((2-nitrophenyl)sulfonyl)-D-phenylalaninate (26g)

According to GP2 **26g** was prepared from methyl D-phenylalaninate hydrochloride **25g** (3.24 g, 15.0 mmol), *o*-nitrobenzylsulfonyl chloride (4.32 g, 19.5 mmol) and triethylamine (5.2 mL, 3.80 g, 37.5 mmol) as a yellow solid (4.51 g, 12.4 mmol, 83 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1 \rightarrow 1 : 1). mp 80 °C. [α]_D²⁰ + 67 (c 1.0 in CHCl₃). FT-IR (ATR): $\tilde{\nu}$ = 3328 (w), 3103 (w), 3031 (w), 2956 (w), 2939 (w), 1738 (vs), 1594 (w), 1540 (vs), 1497 (m), 1450 (m), 1419 (s), 1346 (vs), 1301 (vs), 1253 (s), 1217 (s), 1200

(s), 1185 (s), 1167 (vs), 1124 (s), 1100 (vs), 1056 (m), 1033 (m), 1013 (m), 977 (m), 946 (m), 935 (m), 854 (s), 814 (m), 777 (s), 763 (m), 748 (s), 736 (vs), 704 (vs), 670 (m), 651 (s), 609 (m), 588 (vs), 555 (vs), 530 (s), 487 (m), 471 (m) cm⁻¹. 1 H-NMR (700 MHz, CDCl₃) δ 3.08 (dd, J = 13.9 Hz, 6.9 Hz, 1H, 3-H_a), 3.15 (dd, J = 13.9 Hz, 5.7 Hz, 1H, 3-H_b), 3.52 (s, 3H, OMe), 4.46 (ddd, J = 8.7 Hz, 6.9 Hz, 5.7 Hz, 1H, 2-H), 5.98 (d, J = 8.7 Hz, 1H, NH), 7.08 – 7.13 (m, 2H, 2'-H, 6'-H), 7.17 – 7.24 (m, 3H, 3'-H, 4'-H, 5'-H), 7.64 – 7.70 (m, 2H, 4"-H, 5"-H), 7.83 – 7.88 (m, 1H, 3"-H), 7.94 – 8.00 (m, 1H, 6"-H). 13 C-NMR (176 MHz, CDCl₃) δ 39.2 (C-3), 52.5 (OMe), 57.8 (C-2), 125.6 (C-3"), 127.5 (C-4'), 128.7 (C-3', C-5'), 129.3 (C-2', C-6'), 130.3 (C-6"), 132.9 (C-5"), 133.4 (C-4"), 134.2 (C-1"), 134.8 (C-1'), 147.5 (C-2"), 170.8 (C-1).). HRMS (ESI): calc (found) for C₁₆H₁₆N₂O₆S ([M+Na]⁺): 387.0621 (387.0623). The spectral data are in accordance with previous reported literature. $^{[6]}$

5-Bromo-2-methylpent-2-ene (S1)

The reaction was performed according to the literature. A round bottom flask was charged with a solution of methyl magnesium bromide (26.0 mL, 78.0 mmol, 3 M in Et₂O) under nitrogen atmosphere. Upon cooling to 0 °C a solution of methyl cyclopropyl ketone (5.9 mL, 5.05 g, 60.0 mmol) in diethyl ether (8 mL) was added dropwise and the resulting mixture was stirred for 30 min at 0 °C. Afterwards a mixture of concentrated sulfuric acid and water (36 mL, 1:2) was added slowly under ice-cooling, keeping the temperature under 7 °C. Stirring was continued for another 30 min at 0 °C. The organic phase was separated and the aqueous phase was extracted with diethyl ether (2 × 25 mL). The organic phases were washed with sodium hydrogen sulfite solution (5 %), saturated sodium bicarbonate solution and brine (each 1×45 mL). They were dried over magnesium sulfate and the solvents were evaporated. The product was obtained as a colorless oil (9.32 g, 57.2 mmol, 95 %) without further purification.

⁶
¹H-NMR (300 MHz, CDCl₃)
$$\delta$$
 1.63 (d, J = 1.4 Hz, 3H, 5-H/6-H), 1.69 –

⁸
¹H-NMR (300 MHz, CDCl₃) δ 1.63 (d, J = 1.4 Hz, 3H, 5-H/6-H), 1.69 –

1.76 (q, J = 1.4 Hz, 3H, 6-H/5-H), 2.56 (dt, J = 7.3 Hz, 7.3 Hz, 2H, 2-H),

3.34 (t, J = 7.3 Hz, 2H, 1-H), 5.13 (tdq, J = 7.3 Hz, 2.9 Hz, 1.4 Hz, 1H, 3-H).

¹³C-NMR (75 MHz, CDCl₃) δ 17.9 (C-2), 25.7 (C-1), 31.8 (C-5), 32.9 (C-6),

121.0 (C-4), 135.0 (C-3). The spectral data are in accordance with previous reported literature. [10]

GP3: *N*-Alkylation of amino acid methyl esters

The *N*-alkylated amino acid methyl esters were prepared according to the literature. ^[6] A round bottom flask was charged with a solution of the amino acid methyl ester (8.00 mmol) in dimethylformamide (60 mL) under nitrogen atmosphere. Cesium carbonate (3.91 g, 12.0 mmol) and 5-bromo-2-methylpent-2-ene (1.96 g, 12.0 mmol) were added and the mixture was stirred for 20 h at 60 °C. After cooling to room temperature diethyl ether (120 mL) was added. The organic phase was washed with water (2×60 mL) and brine (2×40 mL) and dried over sodium sulfate. The solvents were evaporated and the crude product was purified by column chromatography. The products were isolated as oils.

Methyl-N-(4-methylpent-3-en-1-yl)-N-((2-nitrophenyl)sulfonyl)- L-valinate (27a)

27a

According to GP3 **27a** was prepared from methyl-((2-nitrophenyl)sulfonyl)-L-valinate **26a** (2.83 g, 8.94 mmol), cesium carbonate (4.37 g, 13.4 mmol) and 5-bromo-2-methylpent-2-ene **S1** (2.19 g, 13.4 mmol) as a yellow oil (1.56 g, 3.92 mmol, 44 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1).

Reisolation of starting material **26a** was possible (0.55 g, 1.74 mmol, 19 %). $[\alpha]_D^{20}$ - 70 (c 1.0 in CHCl₃). R_f = 0.61 (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3096 (w), 2968 (m), 2933 (w), 2916 (w), 2878 (w), 1740 (s), 1590 (w), 1544 (vs), 1469 (m), 1372 (s), 1352 (s), 1291 (m), 1249 (w), 1204 (m), 1165 (s), 1146 (s), 1126 (s), 1067 (m), 1009 (m), 973 (m), 891 (w), 852 (m), 817 (w), 776 (m), 749 (m), 653 (w), 585 (s), 565 (m), 525 (w) cm⁻¹. 1 H-NMR (400 MHz, CDCl₃) δ 0.97 (d, J = 6.7 Hz, 3H, 4-H/5-H), 1.02 (d, J = 6.7 Hz, 3H, 5-H/4-H), 1.63 (s, 3H, 5"-H/6"-H), 1.69 (s, 3H, 6"-H/5"-H), 2.10 – 2.36 (m, 2H, 3-H, 2"-H_a), 2.37 – 2.56 (m, 1H, 2"-H_b), 3.24 – 3.47 (m, 2H, 1"-H), 3.54 (s, 3H, OMe), 4.15 (d, J = 10.3 Hz, 1H, 2-H), 5.01 – 5.07 (m, 1H, 3"-H), 7.52 – 7.61 (m, 1H, 3'-H), 7.61 – 7.74 (m, 2H, 4'-H, 5'-H), 7.90 – 8.10 (m, 1H, 6'-H). 13 C-NMR (101 MHz, CDCl₃) δ 17.8 (C-5"/C-6"), 19.6 (C-4, C-5), 25.7 (C-6"/ C-5"), 28.8 (C-3), 29.7 (C-2"), 45.8 (C-1"), 51.7 (OMe), 65.9 (C-2), 119.8 (C-3"),


123.8 (C-3'), 130.8 (C-6'), 131.2 (C-5'), 133.2 (C-1'), 133.5 (C-4'), 134.8 (C-4"), 148.4 (C-2'), 170.7 (C-1). HRMS (ESI): calc (found) for C₁₈H₂₆N₂O₆S ([M+Na]⁺): 421.1404 (421.1406).

Methyl-N-(4-methylpent-3-en-1-yl)-N-((2-nitrophenyl)sulfonyl)-D-valinate (27b)

According to GP3 **27b** was prepared from methyl-((2-nitrophenyl)sulfonyl)-D-valinate **26b** (2.76 g, 8.73 mmol), cesium carbonate (4.27 g, 13.1 mmol) and 5-bromo-2-methylpent-2-ene **S1** (2.14 g, 13.1 mmol) as a yellow oil (2.01 g, 5.05 mmol, 58 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1). Starting

material **26b** was reisolated (0.49 g, 1.54 mmol, 18 %). $[\alpha]_D^{20} + 58$ (c 1.0 in CHCl₃). $R_f = 0.44$ (hexanes/EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 3100$ (w), 2969 (m), 2933 (w), 2878 (w), 1741 (s), 1590 (w), 1546 (vs), 1438 (m), 1373 (s), 1352 (s), 1291 (m), 1204 (m), 1165 (s), 1146 (s), 1126 (m), 1068 (m), 1009 (m), 973 (m), 891 (w), 776 (m), 749 (m), 652 (w), 585 (s), 565 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.97 (d, J = 6.5 Hz, 3H, 4-H/5-H), 1.02 (d, J = 6.5 Hz, 3H, 5-H/4-H), 1.63 (s, 3H, 5"-H/6"-H), 1.69 (s, 3H, 6"-H/5"-H), 2.15 – 2.24 (m, 1H, 3-H), 2.24 – 2.34 (m, 1H, 2"-H_a), 2.39 – 2.51 (m, 1H, 2"-H_b), 3.28 – 3.43 (m, 2H, 1"-H), 3.54 (s, 3H, OMe), 4.15 (d, J = 10.2 Hz, 1H, 2-H), 5.01 – 5.09 (m, 1H, 3"-H), 7.54 –7.60 (m, 1H, 3'-H), 7.63 – 7.73 (m, 2H, 4'-H, 5'-H), 7.98 – 8.04 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 17.8 (C-5"/C-6"), 19.6 (C-4, C-5), 25.7 (C-6"/C-5"), 28.8 (C-3), 29.7 (C-2"), 45.8 (C-1"), 51.8 (OMe), 65.9 (C-2), 119.8 (C-3"), 123.8 (C-3"), 130.8 (C-6"), 131.2 (C-5"), 133.2 (C-1"), 133.4 (C-4"), 134.9 (C-4"), 148.3 (C-2"), 170.7 (C-1). HRMS (ESI): calc (found) for C₁₈H₂₆N₂O₆S ([M+Na]⁺): 421.1404 (421.1399).

Methyl-N-(4-methylpent-3-en-1-yl)-N-((2-nitrophenyl)sulfonyl)-L-leucinate (27c)




According to GP3 **27c** was prepared from methyl-((2-nitrophenyl)sulfonyl)-L-leucinate **26c** (4.85 g, 14.7 mmol), cesium carbonate (7.18 g, 22.0 mmol) and 5-bromo-2-methyl-pent-2-ene **S1** (3.59 g, 22.0 mmol) as a yellow oil (4.43 g, 10.7 mmol, 73 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1). Starting

material **26c** was reisolated (0.19 g, 0.58 mmol, 4 %). $[\alpha]_D^{20}$ + 13 (*c* 1.0 in CHCl₃). $R_f = 0.58$ (hexanes/EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 2957$ (m), 2871 (w), 1743 (s), 1591 (w), 1545 (vs), 1438 (m), 1373 (s), 1354 (s), 1253 (m), 1205 (m), 1154 (s), 1127 (m), 1068 (w), 1005 (w), 964 (w), 947 (w), 906 (w), 852 (w), 775 (m), 755 (m), 733 (m), 652 (w),

587 (m), 567 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 0.98 (d, J = 6.3 Hz, 3H, 5-H/6-H), 1.00 (d, J = 6.3 Hz, 3H, 6-H/5-H), 1.61 – 1.72 (m, 1H, 3-H_a), 1.65 (s, 3H, 5"-H/6"-H), 1.70 (s, 3H, 6"-H/5"-H), 1.72 – 1.90 (m, 2H, 3-H_b, 4-H), 2.18 – 2.28 (m, 1H, 2"-H_a), 2.50 – 2.61 (m, 1H, 2"-H_b), 3.00 (ddd, J = 15.4 Hz, 12.0 Hz, 5.3 Hz, 1H, 1"-H_a), 3.39 (ddd, J = 15.4 Hz, 12.0 Hz, 4.8 Hz, 1H, 1"-H_b), 3.50 (s, 3H, OMe), 4.69 (dd, J = 10.4 Hz, 4.5 Hz, 1H, 2-H), 5.02 – 5.09 (m, 1H, 3"-H), 7.53 – 7.58 (m, 1H, 3'-H), 7.65 – 7.71 (m, 2H, 4'-H/5'-H), 8.00 – 8.07 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃): δ 17.9 (C-5"/C-6"), 21.2 (C-5/C-6), 23.0 (C-6/C-5), 24.4 (C-4), 25.7 (C-6"/C-5"), 30.3 (C-2"), 39.3 (C-3), 46.6 (C-1), 52.1 (OMe), 59.1 (C-2), 119.8 (C-3"), 123.9 (C-3'), 131.0 (C-6'), 131.2 (C-5'), 132.8 (C-1'), 133.3 (C-4'), 134.8 (C-4"), 148.2 (C-2'), 171.7 (C-1). HRMS (ESI): calc (found) for C₁₉H₂₈N₂O₆S ([M+Na]⁺): 435.1560 (435.1557).

Methyl-N-(4-methylpent-3-en-1-yl)-N-((2-nitrophenyl)sulfonyl)-D-leucinate (27d)



According to GP3 **27d** was prepared from methyl-((2-nitrophenyl)sulfonyl)-D-leucinate **26d** (2.64 g, 8.00 mmol), cesium carbonate (3.91 g, 12.0 mmol) and 5-bromo-2-methyl-pent-2-ene **S1** (1.96 g, 12.0 mmol) as a yellow oil (2.02 g, 4.88 mmol, 61 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1). $[\alpha]_D^{20}$ - 21

(c 1.0 in CHCl₃). $R_{\rm f}=0.56$ (hexanes/EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}=2956$ (m), 2872 (w), 1741 (s), 1590 (w), 1543 (vs), 1438 (m), 1372 (vs), 1352 (vs), 1293 (w), 1252 (m), 1204 (m), 1152 (vs), 1126 (s), 1067 (m), 1004 (m), 963 (m), 946 (m), 906 (w), 852 (m), 838 (w), 775 (m), 754 (s), 732 (s), 652 (m), 586 (vs), 566 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.98 (d, J=6.3 Hz, 3H, 5-H/6-H), 1.00 (d, J=6.3 Hz, 3H, 6-H/5-H), 1.61 – 1.72 (m, 1H, 3-H_a), 1.65 (s, 3H, 5"-H/6"-H), 1.69 (s, 3H, 6"-H/5"-H), 1.74 – 1.89 (m, 2H, 3-H_b, 4-H), 2.16 – 2.30 (m, 1H, 2"-H_a), 2.50 – 2.61 (m, 1H, 2"-H_b), 3.01 (ddd, J=15.4 Hz, 12.0 Hz, 5.3 Hz, 1H, 1"-H_a), 3.39 (ddd, J=15.4 Hz, 12.0 Hz, 4.8 Hz, 1H, 1"-H_b), 3.50 (s, 3H, OMe), 4.69 (dd, J=10.4 Hz, 4.5 Hz, 1H, 2-H), 5.02 – 5.09 (m, 1H, 3"-H), 7.52 – 7.58 (m, 1H, 3'-H), 7.64 – 7.72 (m, 2H, 4'-H, 5'-H), 7.99 – 8.07 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5"/C-6"), 21.2 (C-5/C-6), 23.0 (C-6/C-5), 24.4 (C-4), 25.7 (C-6"/C-5"), 30.3 (C-2"), 39.3 (C-3), 46.6 (C-1), 52.1 (OMe), 59.1 (C-2), 119.8 (C-3"), 123.9 (C-3'), 131.0 (C-6'), 131.2 (C-5'), 132.8 (C-1'), 133.4 (C-4'), 134.8 (C-4"), 148.2 (C-2'), 171.7 (C-1). HRMS (ESI): calc (found) for C₁₉H₂₈N₂O₆S ([M+Na]+): 435.1560 (435.1561).


Methyl-N-(4-methylpent-3-en-1-yl)-N-((2-nitrophenyl)sulfonyl)-L-isoleucinate (27e)

According to GP3 **27e** was prepared from methyl-((2-nitrophenyl)sulfonyl)-L-isoleucinate **26e** (0.28 g, 0.84 mmol), cesium carbonate (0.41 g, 1.26 mmol) and 5-bromo-2-methyl-pent-2-ene **S1** (0.21 g, 1.26 mmol) as a yellow oil (0.26 g, 0.63 mmol, 75 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1). $[\alpha]_D^{20}$ - 70

(c 1.0 in CHCl₃). $R_f = 0.32$ (hexanes/EtOAc, 5 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu} = 2967$ (m), 2933 (w), 2878 (w), 1739 (s), 1590 (w), 1544 (vs), 1437 (m), 1372 (s), 1351 (vs), 1290 (w), 1257 (m), 1199 (m), 1168 (s), 1145 (vs), 1125 (s), 1067 (m), 996 (m), 960 (m), 912 (m), 889 (m), 851 (s), 775 (s), 731 (vs), 652 (m), 584 (vs), 567 (vs), 524 (w), 455 (w) cm⁻¹.

¹H-NMR (400 MHz, CDCl₃) δ 0.86 – 0.95 (m, 6H, 5-H, 6-H), 1.04 – 1.19 (m, 1H, 4-H_a), 1.62 (s, 3H, 5"-H/6"-H), 1.68 (s, 3H, 6"-H/5"-H), 1.70 – 1.80 (m, 1H, 4-H_b), 1.85 – 1.98 (m, 1H, 3-H), 2.14 – 2.32 (m, 1H, 2"-H_a), 2.40 – 2.54 (m, 1H, 2"-H_b), 3.27 – 3.45 (m, 2H, 1"-H), 3.49 (s, 3H, OMe), 4.20 (d, J = 10.1 Hz, 1H, 2-H), 5.04 (t, J = 7.3 Hz, 1H, 3"-H), 7.50 – 7.58 (m, 1H, 3'-H), 7.61 – 7.72 (m, 2H, 4'-H, 5'-H), 7.92 – 8.04 (m, 1H, 6'-H). ¹³C-NMR (101 MHz, CDCl₃) δ 11.0 (C-5), 15.6 (C-6), 17.8 (C-5"), 25.4 (C-4), 25.7 (C-6"), 30.0 (C-2"), 35.2 (C-3), 45.8 (C-1"), 51.6 (OMe), 64.8 (C-2), 119.8 (C-3"), 123.8 (C-3"), 130.8 (C-6"), 131.2 (C-5"), 133.0 (C-1"), 133.5 (C-4"), 134.7 (C-4"), 148.3 (C-2"), 170.7 (C-1). HRMS (ESI): calc (found) for C₁₉H₂₈N₂O₆S ([M+Na]⁺): 435.1560 (435.1565).

Methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-L-phenylalaninate (27f)




According to GP3 **27f** was prepared from methyl-((2-nitrophenyl)sulfonyl)-L-phenylalaninate **26f** (2.17 g, 5.94 mmol), cesium carbonate (2.90 g, 8.91 mmol) and 5-bromo-2-methylpent-2-ene **S1** (1.45 g, 8.91 mmol) as a yellow oil (1.42 g, 3.18 mmol, 53 %). Starting material **26f** was reisolated (0.08 g, 0.23 mmol, 4 %). Purification was accomplished via column chromatography on SiO₂ with

hexanes/EtOAc (3 : 1 \rightarrow 2 : 1). $[\alpha]_D^{20}$ - 24 (*c* 1.0 in CHCl₃). $R_f = 0.24$ (hexanes/EtOAc, 4 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 3030$ (w), 2954 (w), 2925 (w), 1742 (s), 1589 (w), 1543 (vs), 1497 (w), 1454 (m), 1438 (m), 1373 (s), 1352 (s), 1205 (m), 1164 (vs), 1127 (s), 1090 (m), 1070 (m), 1011 (m), 950 (w), 852 (m), 776 (m), 749 (s), 700 (m), 652 (w), 588 (m), 577 (m), 543 (w) cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ 1.62 (s, 3H, 5"'-H/6"'-H), 1.69 (s, 3H,

6"'-H/5"-H), 2.18 - 2.41 (m, 2H, 2"'-H), 3.04 (dd, J = 14.2 Hz, 7.2 Hz, 1H, 3-Ha), 3.16 - 3.30 (ddd, J = 15.2 Hz, 11.3 Hz, 5.5 Hz, 1H, 1"'-Ha), 3.34 - 3.48 (m, 2H, 1"'-Hb, 3-Hb), 3.55 (s, 3H, OMe), 4.90 (t, J = 7.2 Hz, 1H, 2-H), 5.00 - 5.08 (m, 1H, 3"'-H), 7.18 - 7.33 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H), 7.54 - 7.62 (m, 2H, 3"-H, 5"-H), 7.62 - 7.70 (m, 1H, 4"-H), 7.84 - 7.90 (m, 1H, 6"-H). 13C-NMR (101 MHz, CDCl₃) 8 17.9 (C-5"'/C-6"'), 25.7 (C-6"'/C-5"'), 29.4 (C-2"'), 36.8 (C-3), 46.2 (C-1"'), 52.3 (OMe), 61.3 (C-2), 119.7 (C-3"'), 124.0 (C-5"), 127.0 (C-4'), 128.6 (C-3', C-5'), 129.2 (C-2', C-6'), 130.9 (C-6"), 131.4 (C-3"), 133.4 (C-1", C-4"), 134.9 (C-4"'), 136.4 (C-1'), 148.3 (C-2"), 170.7 (C-1). HRMS (ESI): calc (found) for $C_{22}H_{26}N_2O_6S$ ([M+Na]+): 469.1404 (469.1403).

Methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-D-phenylalaninate (27g)




According to GP3 **27g** was prepared from methyl-((2-nitrophenyl)sulfonyl)-D-phenylalaninate **26g** (4.37 g, 12.0 mmol), cesium carbonate (5.86 g, 18.0 mmol) and 5-bromo-2-methylpent-2-ene **S1** (2.94 g, 18.0 mmol) as a yellow oil (3.03 g, 3.18 mmol, 56 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2:1). $[\alpha]_D^{20} + 21$ (*c* 1.0 in CHCl₃). $R_f = 0.58$ (hexanes/EtOAc, 2:1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu} = 3029$ (w), 2953 (w),

1741 (s), 1589 (w), 1542 (vs), 1497 (w), 1454 (m), 1438 (m), 1373 (s), 1350 (vs), 1205 (m), 1163 (vs), 1126 (s), 1090 (m), 1069 (m), 1008 (m), 949 (m), 895 (w), 852 (m), 838 (w), 775 (m), 748 (vs), 700 (s), 652 (m), 588 (s), 576 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.61 (s, 3H, 5"'-H/6"'-H), 1.68 (s, 3H, 6"'-H/5"'-H), 2.19 – 2.38 (m, 2H, 2"'-H), 3.04 (dd, J = 14.2 Hz, 7.2 Hz, 1H, 3-H_a), 3.21 (ddd, J = 15.2 Hz, 11.3 Hz, 5.5 Hz, 1H, 1"'-H_a), 3.34 – 3.45 (m, 2H, 1"'-H_b, 3-H_b), 3.54 (s, 3H, OMe), 4.89 (t, J = 7.2 Hz, 1H, 2-H), 4.99 – 5.07 (m, 1H, 3"'-H), 7.18 – 7.30 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H), 7.54 – 7.61 (m, 2H, 3"-H, 5"-H), 7.62 – 7.68 (m, 1H, 4"-H), 7.82 – 7.87 (m, 1H, 6"-H). ¹³C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5"'/C-6"'), 25.7 (C-6"'/C-5"'), 29.4 (C-2"'), 36.8 (C-3), 46.2 (C-1"'), 52.3 (OMe), 61.3 (C-2), 119.7 (C-3"'), 124.0 (C-5"), 127.0 (C-4'), 128.6 (C-3', C-5'), 129.2 (C-2', C-6'), 130.8 (C-6"), 131.5 (C-3"), 133.3 (C-1"), 133.4 (C-4"), 135.0 (C-4""), 136.4 (C-1'), 148.2 (C-2"), 170.7 (C-1). HRMS (ESI): calc (found) for C₂₂H₂₆N₂O₆S ([M+Na]+): 469.1404 (469.1403).

GP4: Reduction via lithium aluminium hydride

The amino alcohols were prepared according to the literature. ^[6] A round bottom flask was charged with a solution of the methyl ester (4.00 mmol) in tetrahydrofuran (18 mL) under nitrogen atmosphere. Upon cooling to 0 °C a solution of lithium aluminium hydride (0.17 g, 4.40 mmol, 0.5 M in THF) was added dropwise. The rection mixture was stirred for 30 min at 0 °C. Afterwards the reaction was quenched with water (1.0 mL) and dichloromethane (35 mL) was added. The organic phase was washed with hydrochloric acid (1 × 15 mL, 1 M in Wasser) and brine (2 × 15 mL) and dried over magnesium sulfate. The solvents were evaporated and the crude product was purified by column chromatography. The products were isolated as oils.

(S)-N-(1-Hydroxy-3-methylbutan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzene sulfonamide (28a)



According to GP4 **28a** was prepared from methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-L-valinate **27a** (0.98 g, 2.45 mmol) and lithium aluminium hydride (0.10 g, 2.70 mmol) as a yellow oil (0.66 g, 1.77 mmol, 72 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1). [α]_D²⁰ + 59 (*c* 1.0 in CHCl₃).


 $R_{\rm f}=0.35$ (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v}=3556$ (w), 3097 (w), 2968 (m), 2929 (m), 2879 (w), 1590 (w), 1544 (vs), 1469 (w), 1440 (w), 1373 (s), 1341 (s), 1295 (w), 1249 (w), 1202 (w), 1160 (s), 1125 (m), 1089 (w), 1065 (m), 1000 (w), 956 (w), 923 (w), 852 (w), 774 (w), 745 (w), 653 (w), 594 (m), 528 (w) cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ 0.80 (d, J=6.6 Hz, 3H, 4-H/5-H), 0.96 (d, J=6.6 Hz, 3H, 5-H/4-H), 1.65 (s, 3H, 5"-H/6"-H), 1.70 (s, 3H, 6"-H/5"-H), 1.73 – 1.87 (m, 1H, 3-H), 1.87 – 2.29 (m, 1H, OH), 2.32 – 2.56 (m, 2H, 2"-H), 3.12 (ddd, J=15.2 Hz, 11.4 Hz, 5.4 Hz, 1H, 1"-H_a), 3.34 (ddd, J=15.2 Hz, 11.4 Hz, 5.4 Hz, 1H, 1"-H_b), 3.51 – 3.66 (m, 2H, 1-H_a, 2-H), 3.81 – 3.96 (m, 1H, 1-H_b), 5.07 (t, J=7.3 Hz, 1H, 3"-H), 7.51 – 7.60 (m, 1H, 3'-H), 7.62 – 7.72 (m, 2H, 4'-H, 5'-H), 8.03 – 8.14 (m, 1H, 6'-H). ¹³C-NMR (101 MHz, CDCl₃) δ 17.9 (C-5"/C-6"), 20.2 (C-4/C-5), 20.3 (C-5/C-4), 25.7 (C-6"/C-5"), 28.9 (C-3), 30.1 (C-2"), 44.4 (C-1"), 62.1 (C-1), 66.1 (C-2), 120.0 (C-3"), 123.8 (C-3'), 131.3 (C-6'), 131.4 (C-5'), 133.3 (C-4'), 134.0 (C-1'), 134.9 (C-4"), 147.9 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₅S ([M+Na]⁺): 393.1455 (393.1465). The spectral data are in accordance with previous reported literature. ^[6]

(*R*)-*N*-(1-Hydroxy-3-methylbutan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (28b)

According to GP4 **28b** was prepared from methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-D-valinate **27b** (2.00 g, 5.02 mmol) and lithium aluminium hydride (0.21 g, 5.52 mmol) as a yellow oil (1.33 g, 3.60 mmol, 72 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1). $\lceil \alpha \rceil_D^{20}$ - 65 (*c* 1.0 in CHCl₃).

 $R_{\rm f}=0.30$ (hexanes/EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v}=3551$ (w), 2967 (w), 2254 (w), 1543 (s), 1470 (w), 1440 (w), 1372 (m), 1340 (m), 1202 (w), 1156 (m), 1125 (m), 1088 (w), 1064 (m), 999 (w), 956 (w), 907 (vs), 852 (m), 771 (w), 726 (vs), 650 (m), 592 (s), 450 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.78 (d, J=6.5 Hz, 3H, 4-H/5-H), 0.95 (d, J=6.5 Hz, 3H, 5-H/4-H), 1.64 (s, 3H, 5"-H/6"-H), 1.69 (s, 3H, 6"-H/5"-H), 1.74 – 1.88 (m, 1H, 3-H), 2.25 (s, br, 1H, OH), 2.33 – 2.54 (m, 2H, 2"-H), 3.12 (ddd, J=15.1 Hz, 11.5 Hz, 5.4 Hz, 1H, 1"-H_a), 3.34 (ddd, J=15.1 Hz, 11.5 Hz, 5.4 Hz, 1H, 1"-H_b), 3.52 – 3.66 (m, 2H, 1-H_a, 2-H), 3.82 – 3.93 (m, 1H, 1-H_b), 5.03 – 5.11 (m, 1H, 3"-H), 7.52 – 7.58 (m, 1H, 3'-H), 7.64 – 7.71 (m, 2H, 4'-H, 5'-H), 8.04 – 8.12 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5"/C-6"), 20.2 (C-4/C-5), 20.3 (C-5/C-4), 25.7 (C-6"/C-5"), 28.8 (C-3), 30.1 (C-2"), 44.4 (C-1"), 62.1 (C-1), 66.0 (C-2), 120.0 (C-3"), 123.8 (C-3'), 131.2 (C-6'), 131.5 (C-5'), 133.4 (C-4'), 133.8 (C-1'), 134.8 (C-4"), 147.8 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₅S ([M+Na]⁺): 393.1455 (393.1459).

(S)-N-(1-Hydroxy-4-methylpentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (28c)




According to GP4 **28c** was prepared from methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-L-leucinate **27c** (2.42 g, 5.87 mmol) and lithium aluminium hydride (0.25 g, 6.46 mmol) as a yellow oil (1.69 g, 4.39 mmol, 75 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1 \rightarrow 1:1). [α]²⁰_D + 15 (*c* 1.0 in

CHCl₃). R_f = 0.24 (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3543 (w), 2958 (m), 1545 (vs), 1468 (w), 1440 (w), 1372 (s), 1341 (m), 1202 (w), 1158 (s), 1125 (m), 1064 (w), 949 (w), 852 (w), 745 (w), 653 (w), 590 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.82 (d, J = 6.6 Hz, 3H, 5-H/6-H), 0.84 (d, J = 6.6 Hz, 3H, 6-H/5-H), 1.30 (ddd, J = 14.1 Hz, 7.1 Hz,

7.1 Hz, 1H, 3-H_a), 1.39 (ddd, J = 14.1 Hz, 7.1 Hz, 7.1 Hz, 1H, 3-H_b), 1.55 – 1.63 (m, 1H, 4-H), 1.64 (s, 3H, 5"-H/6"-H), 1.71 (s, 3H, 6"-H/5"-H), 2.13 (s, br, 1H, OH), 2.28 – 2.37 (m, 1H, 2"-H_a), 2.39 – 2.50 (m, 1H, 2"-H_b), 3.22 (t, J = 8.3 Hz, 2H, 1"-H), 3.52 – 3.63 (m, 2H, 1-H), 3.84 – 3.92 (m, 1H, 2-H), 5.05 – 5.12 (m, 1H, 3"-H), 7.57 – 7.63 (m, 1H, 3'-H), 7.65 – 7.72 (m, 2H, 4'-H, 5'-H), 8.08 – 8.14 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5"/C-6"), 22.5 (C-5, C-6), 24.6 (C-4), 25.7 (C-6"/C-5"), 30.6 (C-8), 39.3 (C-3), 43.8 (C-1"), 58.3 (C-2), 63.3 (C-1), 119.9 (C-3"), 124.1 (C-3'), 131.6 (C-5', C-6'), 133.5 (C-4'), 133.7 (C-1'), 134.9 (C-4"), 147.9 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₈N₂O₅S ([M+Na]⁺): 407.1611 (407.1618).

(R)-N-(1-Hydroxy-4-methylpentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (28d)



According to GP4 **28d** was prepared from methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-D-leucinate **27d** (2.02 g, 4.88 mmol) and lithium aluminium hydride (0.20 g, 5.37 mmol) as a yellow oil (1.26 g, 3.25 mmol, 67 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1 \rightarrow 1:1). [α]²⁰ - 18 (*c* 1.0 in

CHCl₃). R_f = 0.60 (hexanes/EtOAc, 1 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3552 (w), 2958 (m), 2929 (m), 2873 (w), 1545 (vs), 1467 (w), 1373 (s), 1342 (s), 1201 (w), 1159 (s), 1125 (m), 1063 (w), 949 (w), 852 (w), 777 (w), 745 (w), 653 (w), 591 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.82 (d, J = 6.6 Hz, 3H, 5-H/6-H), 0.84 (d, J = 6.6 Hz, 3H, 6-H/5-H), 1.30 (ddd, J = 14.1 Hz, 7.1 Hz, 7.1 Hz, 1H, 3-H_a), 1.37 (ddd, J = 14.1 Hz, 7.1 Hz, 7.1 Hz, 1H, 3-H_b), 1.53 – 1.62 (m, 1H, 4-H), 1.64 (s, 3H, 5"-H/6"-H), 1.70 (s, 3H, 6"-H/5"-H), 2.27 –2.38 (m, 1H, 2"-H_a), 2.39 – 2.50 (m, 1H, 2"-H_b), 3.22 (t, J = 8.3 Hz, 2H, 1"-H), 3.51 – 3.63 (m, 2H, 1-H), 3.83 – 3.92 (m, 1H, 2-H), 5.03 – 5.12 (m, 1H, 3"-H), 7.55 – 7.63 (m, 1H, 3'-H), 7.63 – 7.74 (m, 2H, 4'-H, 5'-H), 8.04 – 8.18 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5"/C-6"), 22.5 (C-5, C-6), 24.7 (C-4), 25.7 (C-6"/C-5"), 30.6 (C-8), 39.3 (C-3), 43.9 (C-1"), 58.3 (C-2), 63.3 (C-1), 119.9 (C-3"), 124.1 (C-3'), 131.6 (C-5', C-6'), 133.5 (C-4'), 133.7 (C-1'), 134.9 (C-4"), 148.0 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₈N₂O₅S ([M+H][†]): 385.1792 (385.1795).


N-((2S,3S)-1-Hydroxy-3-methylpentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide (28e)

28e

According to GP4 **28e** was prepared from methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-L-leucinate **27e** (1.96 g, 4.75 mmol) and lithium aluminium hydride (0.20 g, 5.22 mmol) as a yellow oil (0.76 g, 1.97 mmol, 42 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1). $[\alpha]_D^{20} + 42$ (*c* 2.0 in CHCl₃).

 $R_{\rm f}=0.23$ (hexanes/EtOAc, 4 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v}=3544$ (w, br), 2966 (m), 2931 (m), 2877 (m), 1591 (w), 1543 (vs), 1457 (m), 1440 (m), 1372 (s), 1340 (s), 1202 (w), 1155 (s), 1125 (s), 1080 (m), 1066 (m), 995 (m), 959 (m), 913 (w), 852 (m), 773 (m), 744 (m), 653 (m), 580 (s), 451 (w) cm⁻¹. H-NMR (500 MHz, CDCl₃) δ 0.80 (t, J=6.9 Hz, 3H, 5-H), 0.82 – 0.89 (m, 1H, 4-H_a), 0.91 (d, J=6.6 Hz, 3H, 6-H), 1.46 – 1.63 (m, 2H, 3-H, 4-H_b), 1.65 (s, 3H, 5"-H/6"-H), 1.70 (s, 3H, 6"-H/5"-H), 1.90 – 2.13 (m, 1H, OH), 2.26 – 2.40 (m, 1H, 2"-H_a), 2.44 – 2.58 (m, 1H, 2"-H_b), 3.17 (ddd, J=15.1 Hz, 11.5 Hz, 5.4 Hz, 1H, 1"-H_a), 3.25 (ddd, J=15.1 Hz, 11.5 Hz, 5.4 Hz, 1H, 1"-H_b), 3.57 – 3.66 (m, 2H, 1-H_a, 2-H), 3.81 – 3.88 (m, 1H, 1-H_b), 5.07 (t, J=7.2 Hz, 1H, 3"-H), 7.53 – 7.56 (m, 1H, 3'-H), 7.64 – 7.69 (m, 2H, 4'-H, 5'-H), 8.05 – 8.09 (m, 1H, 6'-H). 13 C-NMR (126 MHz, CDCl₃) δ 11.2 (C-5), 15.9 (C-6), 17.9 (C-5"/C-6"), 25.7 (C-4/(C-6"/C-5")), 25.8 ((C-5"/C-6")/C-4), 30.1 (C-2"), 35.6 (C-3), 44.5 (C-1"), 62.1 (C-1), 64.9 (C-2), 120.0 (C-3"), 123.8 (C-3'), 131.3 (C-6'), 131.5 (C-5'), 133.3 (C-4'), 133.9 (C-1'), 134.9 (C-4"), 147.8 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₈N₂O₅S ([M+Na]⁺): 407.1611 (407.1618).

(S)-N-(1-Hydroxy-3-phenylpropan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (28f)




According to GP4 **28f** was prepared from methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-L-phenyl-alaninate **27f** (5.37 g, 12.0 mmol) and lithium aluminium hydride (0.50 g, 13.2 mmol) as a yellow oil (2.85 g, 6.80 mmol, 57 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1 \rightarrow 1:1). $\lceil \alpha \rceil_D^{20} + 6$ (*c* 1.0 in CHCl₃). $R_f = 0.37$ (hexanes/EtOAc, 2:1,

anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 3538$ (w), 2923 (w), 1543 (vs),1496 (w), 1455 (m), 1372 (s), 1339 (s), 1160 (s), 1126 (m), 1034 (m), 983 (m), 939 (m), 853 (m), 743 (m), 701 (m),

653 (w), 579 (m) cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ 1.65 (s, 3H, 5"'-H/6"'-H), 1.71 (s, 3H, 6"'-H/5"'-H), 1.94 – 2.16 (s, br, 1H, OH), 2.41 (q, J = 7.9 Hz, 2H, 2"'-H), 2.78 (dd, J = 13.6 Hz, 9.2 Hz, 1H, 3-H_a), 2.94 (dd, J = 13.6 Hz, 5.6 Hz, 1H, 3-H_b), 3.26 – 3.47 (m, 2H, 1"'-H), 3.59 – 3.70 (m, 2H, 1-H), 4.05 – 4.16 (m, 1H, 2-H), 5.05 – 5.16 (m, 1H, 3"'-H), 7.05 – 7.12 (m, 2H, 2'-H, 6'-H), 7.12 – 7.23 (m, 3H, 3'-H, 4'-H, 5'-H), 7.53 – 7.68 (m, 3H, 3"-H, 4"-H, 5"-H), 7.91 – 8.01 (m, 1H, 6"-H). ¹³C-NMR (101 MHz, CDCl₃) δ 17.9 (C-5"'/C-6"'), 25.7 (C-6"'/C-5"'), 30.4 (C-2"'), 37.2 (C-3), 44.4 (C-1"'), 61.9 (C-2), 62.3 (C-1), 119.9 (C-3"'), 124.2 (C-5"), 126.8 (C-4'), 128.6 (C-3', C-5'), 129.0 (C-2', C-6'), 131.3 (C-6"), 131.7 (C-3"), 133.5 (C-4"), 133.6 (C-1"), 135.0 (C-4"'), 137.4 (C-1'), 147.9 (C-2"'). HRMS (ESI): calc (found) for C₂₁H₂₆N₂O₅S ([M+Na]⁺): 441.1455 (441.1456).

(*R*)-*N*-(1-Hydroxy-3-phenylpropan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (28g)




According to GP4 **28g** was prepared from methyl-*N*-(4-methylpent-3-en-1-yl)-*N*-((2-nitrophenyl)sulfonyl)-D-phenylalaninate **27g** (3.03 g, 6.77 mmol) and lithium aluminium hydride (0.28 g, 7.45 mmol) as a yellow oil (2.14 g, 5.11 mmol, 75 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2:1 \rightarrow 1:1). [α]_D²⁰ - 7 (c 1.0 in CHCl₃). R_f = 0.37 (hexanes/EtOAc, 2:1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3557 (w), 2923 (w),

1543 (vs),1496 (w), 1454 (m), 1372 (s), 1340 (s), 1160 (s), 1125 (m), 1033 (w), 982 (w), 939 (w), 853 (w), 742 (m), 701 (m), 653 (w), 578 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.65 (s, 3H, 5"'-H/6"'-H), 1.72 (s, 3H, 6"'-H/5"'-H), 2.42 (q, J = 7.9 Hz, 2H, 2"'-H), 2.78 (dd, J = 13.6 Hz, 9.2 Hz, 1H, 3-H_a), 2.95 (dd, J = 13.6 Hz, 5.6 Hz, 1H, 3-H_b), 3.29 – 3.44 (m, 2H, 1"'-H), 3.60 – 3.70 (m, 2H, 1-H), 4.05 – 4.15 (m, 1H, 2-H), 5.07 – 5.15 (m, 1H, 3"'-H), 7.07 – 7.12 (m, 2H, 2'-H, 6'-H), 7.12 – 7.23 (m, 3H, 3'-H, 4'-H, 5'-H), 7.55 – 7.69 (m, 3H, 3"-H, 4"-H, 5"-H), 7.96 – 8.02 (m, 1H, 6"-H). ¹³C-NMR (126 MHz, CDCl₃) δ 18.0 (C-5"'/C-6"'), 25.7 (C-6"'/C-5"'), 30.4 (C-2"'), 37.2 (C-3), 44.3 (C-1"'), 61.9 (C-2), 62.2 (C-1), 119.9 (C-3"'), 124.3 (C-5"), 126.8 (C-4'), 128.6 (C-3', C-5'), 129.0 (C-2', C-6'), 131.4 (C-6"), 131.7 (C-3"), 133.5 (C-4"), 133.7 (C-1"), 135.1 (C-4"'), 137.4 (C-1'), 148.0 (C-2"). HRMS (ESI): calc (found) for C₂₁H₂₆N₂O₅S ([M+Na]⁺): 441.1455 (441.1458).

GP5: Oxidation with Dess-Martin-Periodinane (DMP)

The aldehydes or ketones were prepared according to the literature. A round bottom flask was charged with a solution of the primary or secondary alcohol (3.00 mmol) in dichloromethane (50 mL). DMP (3.18 g, 7.50 mmol) was added at room temperature and the mixture was stirred for 40 min at room temperature. Diethyl ether (130 mL) and a mixture (25 mL, 1:1) of saturated solutions of sodium thiosulfate and sodium bicarbonate were added and stirring continued for 15 min at room temperature until a clear solution was obtained. The phases were separated and the aqueous phase was extracted with diethyl ether (1×45 mL). The organic phases were washed with saturated sodium bicarbonate solution, water and brine (each 2×45 mL) and dried over magnesium sulfate. The solvents were evaporated and the crude product was purified by column chromatography. The products were isolated as oils.


(S)-N-(3-Methyl-1-oxobutan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide (29a)



According to GP5 **29a** was prepared from (*S*)-*N*-(1-Hydroxy-3-methylbutan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide **28a** (0.62 g, 1.68 mmol) and DMP (1.78 g, 4.20 mmol) as a yellow oil (0.41 g, 1.10 mmol, 65 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1). $[\alpha]_D^{20}$ + 37 (*c* 1.0 in CHCl₃).

 $R_{\rm f}=0.73$ (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v}=3095$ (w), 2968 (m), 2932 (w), 2877 (w), 2729 (w), 1732 (m), 1590 (w), 1544 (vs), 1470 (w), 1440 (w), 1372 (s), 1348 (s), 1297 (w), 1249 (w), 1203 (w), 1162 (s), 1126 (m), 1104 (w), 1070 (w), 1002 (w), 975 (w), 960 (w), 852 (m), 778 (m), 745 (m), 676 (w), 653 (w), 588 (m) cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ 0.97 (d, J=6.6 Hz, 3H, 4-H/5-H), 1.16 (d, J=6.6 Hz, 3H, 5-H/4-H), 1.60 (s, 3H, 5"-H/6"-H), 1.67 (s, 3H, 6"-H/5"-H), 2.12 – 2.31 (m, 2H, 3-H, 2"-H_a), 2.31 – 2.44 (m, 1H, 2"-H_b), 3.16 (ddd, J=15.2 Hz, 11.2 Hz, 5.4 Hz, 1H, 1"-H_a), 3.27 (ddd, J=15.2 Hz, 11.2 Hz, 5.7 Hz, 1H, 1"-H_b), 4.20 (d, J=10.1 Hz, 1H, 2-H), 4.98 (t, J=7.0 Hz, 1H, 3"-H), 7.57 – 7.63 (m, 1H, 3'-H), 7.66 – 7.74 (m, 2H, 4'-H, 5'-H), 8.06 – 8.12 (m, 1H, 6'-H), 9.73 (s, 1H, 1-H). ¹³C-NMR (176 MHz, CDCl₃) δ 17.8 (C-5"/C-6"), 20.1 (C-4/C-5), 20.2 (C-5/C-4), 25.7 (C-6"/C-5"), 27.3 (C-3), 29.6 (C-2"), 46.7 (C-1"), 71.5 (C-2), 119.3 (C-3"), 124.2 (C-3"), 131.1 (C-6'), 131.7 (C-5'), 133.5 (C-1'), 133.6 (C-4'), 135.2 (C-4"), 147.9 (C-2'), 199.0 (C-1). HRMS (ESI): calc (found) for C₁₇H₂₄N₂O₅S ([M+H]⁺): 369.1479 (369.1479). The spectral data are in accordance with previous reported literature. ^[6]


(R)-N-(3-Methyl-1-oxobutan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (29b)



According to GP5 **29b** was prepared from (*R*)-*N*-(1-hydroxy-3-methylbutan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide **28b** (0.55 g, 1.48 mmol) and DMP (1.57 g, 3.70 mmol) as a yellow oil (0.41 g, 1.12 mmol, 76 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2 : 1). $[\alpha]_D^{20}$ - 36 (*c* 1.0 in CHCl₃).

 $R_{\rm f}=0.48$ (hexanes/EtOAc, 2: 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v}=3560$ (w), 3092 (w), 2969 (m), 2929 (w), 2880 (w), 2858 (w), 1733 (m), 1591 (w), 1544 (vs), 1470 (w), 1440 (w), 1373 (s), 1346 (m), 1161 (s), 1126 (m), 1072 (w), 976 (w), 914 (w), 852 (w), 776 (w), 752 (m), 672 (w), 653 (w), 580 (m), 563 (w) cm⁻¹. ¹H-NMR (700 MHz, CDCl₃) δ 0.96 (d, J=6.6 Hz, 3H, 4-H/5-H), 1.15 (d, J=6.6 Hz, 3H, 5-H/4-H), 1.59 (s, 3H, 5"-H/6"-H), 1.66 (s, 3H, 6"-H/5"-H), 2.18 (dqq, J=10.1 Hz, 6.6 Hz,

(S)-N-(4-Methyl-1-oxopentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (29c)




According to GP5 **29c** was prepared from (*S*)-*N*-(1-hydroxy-4-methylpentan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **28c** (0.18 g, 0.48 mmol) and DMP (0.41 g, 0.96 mmol) as a yellow oil (0.12 g, 0.32 mmol, 67 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2 : 1). $[\alpha]_D^{20} + 30$ (*c* 1.0 in CHCl₃).

 $R_{\rm f} = 0.63$ (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 2960$ (m), 1736 (m), 1545 (vs), 1440 (w), 1372 (s), 1161 (s), 1126 (m), 1069 (w), 948 (w), 852 (w), 777 (m), 746 (m), 653 (w), 588 (m), 573 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.90 (d, J = 5.8 Hz,

3H, 5-H/6-H), 0.95 (d, J = 5.8 Hz, 3H, 6-H/5-H), 1.47 – 1.56 (m, 1H, 3-H_a), 1.61 (s, 3H, 5"-H/6"-H), 1.67 (s, 3H, 6"-H/5"-H), 1.72 – 1.82 (m, 2H, 3-H_b, 4-H), 2.14 – 2.24 (m, 1H, 2"-H_a), 2.35 – 2.45 (m, 1H, 2"-H_b), 3.09 – 3.18 (m, 1H, 1"-H_a), 3.25 – 3.34 (m, 1H, 1"-H_b), 4.53 (dd, J = 10.0 Hz, 4.0 Hz, 1H, 2-H), 4.98 – 5.04 (m, 1H, 3"-H), 7.60 – 7.64 (m, 1H, 3'-H), 7.68 – 7.75 (m, 2H, 4'-H, 5'-H), 8.06 – 8.12 (m, 1H, 6'-H), 9.56 (s, 1H, 1-H). ¹³C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5/C-6), 21.3 (C-5"/C-6"), 23.1 (C-6"/C-5"), 24.3 (C-4), 25.7 (C-6/C-5), 29.8 (C-2"), 35.7 (C-3), 46.3 (C-1), 64.7 (C-2), 119.3 (C-3"), 124.3 (C-3'), 131.2 (C-6'), 131.7 (C-5'), 133.1 (C-1'), 133.7 (C-4'), 135.3 (C-4"), 148.1 (C-2'), 199.9 (C-1). HRMS (ESI): calc (found) for C₁₈H₂₆N₂O₅S ([M+Na]⁺): 405.1455 (405.1455).

(R)-N-(4-Methyl-1-oxopentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (29d)



According to GP5 **29d** was prepared from (*R*)-*N*-(1-hydroxy-4-methylpentan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide **28d** (1.01 g, 2.64 mmol) and DMP (2.24 g, 5.28 mmol) as a yellow oil (0.79 g, 2.07 mmol, 78 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2 : 1). $[\alpha]_D^{20}$ - 15 (*c* 1.0 in CHCl₃).

 $R_{\rm f} = 0.62$ (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 2958$ (m), 2871 (w), 1735 (m),1675 (w), 1589 (w), 1545 (vs), 1467 (m), 1440 (w), 1372 (s), 1347 (s), 1161 (vs), 1126 (m), 1069 (m), 949 (m), 852 (m), 776 (m), 746 (m), 653 (w), 587 (m), 575 (m) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 0.90 (d, J = 5.8 Hz, 3H, 5-H/6-H), 0.95 (d, J = 5.8 Hz, 3H, 6-H/5-H), 1.47 – 1.56 (m, 1H, 3-H_a), 1.61 (s, 3H, 5"-H/6"-H), 1.68 (s, 3H, 6"-H/5"-H), 1.72 – 1.82 (m, 2H, 3-H_b, 4-H), 2.14 – 2.23 (m, 1H, 2"-H_a), 2.35 – 2.45 (m, 1H, 2"-H_b), 3.13 (ddd, J = 15.1 Hz, 11.0 Hz, 5.7 Hz, 1H, 1"-H_a), 3.29 (ddd, J = 15.1 Hz, 11.0 Hz, 5.1 Hz, 1H, 1"-H_b), 4.53 (dd, J = 10.0 Hz, 4.0 Hz, 1H, 2-H), 4.97 – 5.04 (m, 1H, 3"-H), 7.58 – 7.64 (m, 1H, 3'-H), 7.67 – 7.75 (m, 2H, 4'-H, 5'-H), 8.06 – 8.12 (m, 1H, 6'-H), 9.56 (s, 1H, 1-H). 13 C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5/C-6), 21.3 (C-5"/C-6"), 23.0 (C-6"/C-5"), 24.3 (C-4), 25.7 (C-6/C-5), 29.8 (C-2), 35.7 (C-3), 46.3 (C-1), 64.7 (C-2), 119.3 (C-3"), 124.3 (C-3'), 131.2 (C-6'), 131.7 (C-5'), 133.1 (C-1'), 133.7 (C-4'), 135.3 (C-4"), 148.1 (C-2'), 199.9 (C-1). HRMS (ESI): calc (found) for C₁₈H₂₆N₂O₅S ([M+Na]⁺): 405.1455 (405.1461).

N-((2S,3S)-3-Methyl-1-oxopentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide (29e)

According to GP5 **29e** was prepared from N-((2S,3S)-1-hydroxy-3-methylpentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **28e** (0.76 g, 1.98 mmol) and DMP (2.10 g, 4.95 mmol) as a yellow oil (0.72 g, 1.88 mmol, 95 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (5:1 \rightarrow 4:1 \rightarrow 3:1). $[\alpha]_D^{20}$ +23

(c 2.6 in CHCl₃). $R_{\rm f}=0.40$ (hexanes/EtOAc, 4 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}=2966$ (m), 2928 (m), 2878 (w), 1731 (m), 1673 (w), 1590 (w), 1545 (vs), 1462 (m), 1440 (w), 1373 (s), 1349 (s), 1203 (w), 1161 (s), 1126 (m), 1069 (w), 1007 (w), 962 (w), 852 (w), 777 (m), 746 (m), 691 (w), 653 (w), 586 (m), 456 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.91 (t, J=7.4 Hz, 3H, 5-H), 1.09 – 1.16 (m, 1H, 4-H_a), 1.13 (d, J=6.7 Hz, 3H, 6-H), 1.62 (s, 3H, 5"-H/6"-H), 1.64 – 1.70 (m, 1H, 4-H_b), 1.68 (s, 3H, 6"-H/5"-H), 1.85 – 1.97 (m, 1H, 3-H), 2.16 – 2.26 (m, 1H, 2"-H_a), 2.38 – 2.50 (m, 1H, 2"-H_b), 3.17 (ddd, J=15.1 Hz, 11.5 Hz, 5.7 Hz, 1H, 1"-H_a), 3.28 (ddd, J=15.1 Hz, 11.5 Hz, 5.7 Hz, 1H, 1"-H_b), 4.30 (d, J=9.8 Hz, 1H, 2-H), 4.96 – 5.03 (m, 1H, 3"-H), 7.54 – 7.64 (m, 1H, 3'-H), 7.65 – 7.75 (m, 2H, 4'-H, 5'-H), 8.01 – 8.12 (m, 1H, 6'-H), 9.72 (s, 1H, 1-H). ¹³C-NMR (126 MHz, CDCl₃) δ 10.7 (C-5), 16.1 (C-6), 17.9 (C-5"/C-6"), 25.7 (C-6"/C-5"), 26.0 (C-4), 29.8 (C-2"), 34.0 (C-3), 46.9 (C-1"), 70.6 (C-2), 119.4 (C-3"), 124.2 (C-3"), 131.1 (C-6'), 131.7 (C-1'), 133.2 (C-5'), 133.7 (C-4'), 135.2 (C-4"), 147.9 (C-2'), 199.2 (C-1). HRMS (ESI): calc (found) for C₁₈H₂₆N₂O₅S ([M+Na]⁺): 405.1455 (405.1448).

(S)-N-(4-Methylpent-3-en-1-yl)-2-nitro-N-(1-oxo-3-phenylpropan-2-yl)benzene-sulfonamide (29f)



According to GP5 **29f** was prepared from (*S*)-*N*-(1-hydroxy-3-phenylpropan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **28f** (0.45 g, 1.08 mmol) and DMP (1.15 g, 2.70 mmol) as a yellow oil (0.44 g, 1.07 mmol, 99 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (4:1 \Rightarrow 2:1). [α]_D²⁰ - 20 (*c* 3.9 in CHCl₃). $R_f = 0.44$ (hexanes/EtOAc, 3:1, anisaldehyde 3029 (w), 2915 (w), 1735 (m), 1590 (w), 1542 (vs), 1498 (w),

solution). FT-IR (ATR): $\tilde{v} = 3029$ (w), 2915 (w), 1735 (m), 1590 (w), 1542 (vs), 1498 (w), 1454 (w), 1439 (w), 1371 (s), 1346 (s), 1254 (w), 1204 (w), 1162 (s), 1126 (m), 1096 (w), 1076

(w), 1031 (w), 961 (m), 912 (w), 852 (m), 740 (s), 700 (m), 653 (w), 576 (m), 541 (w), 494 (w) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 1.60 (s, 3H, 5"'-H/6"'-H), 1.68 (s, 3H, 6"'-H/5"'-H), 2.19 – 2.30 (m, 2H, 2"'-H), 2.89 (dd, J = 14.4 Hz, 8.4 Hz, 1H, 3-H_a), 3.26 – 3.35 (m, 1H, 1"'-H_a), 3.35 – 3.45 (m, 2H, 1"'-H_b, 3-H_b), 4.73 (dd, J = 8.4 Hz, 6.4 Hz, 1H, 2-H), 4.99 – 5.05 (m, 1H, 3"'-H), 7.10 – 7.20 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H), 7.51 – 7.60 (m, 2H, 3"-H, 5"-H), 7.62 – 7.68 (m, 1H, 4"-H), 7.78 – 7.84 (m, 1H, 6"-H), 9.70 (s, 1H, 1-H). 13 C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5"'/C-6"'), 25.7 (C-6"'/C-5"'), 29.3 (C-2"'), 33.0 (C-3), 46.0 (C-1"'), 67.1 (C-2), 119.1 (C-3"'), 124.4 (C-3"), 126.9 (C-4'), 128.6 (C-3', C-5'), 129.0 (C-2', C-6'), 130.9 (C-6"), 131.8 (C-5"), 133.3 (C-1"), 133.6 (C-4"'), 135.6 (C-4"), 136.2 (C-1'), 147.8 (C-2"), 199.3 (C-1). HRMS (ESI): calc (found) for C₂₁H₂₄N₂O₅S ([M+H]⁺): 417.1479 (417.1480).

(R)-N-(4-Methylpent-3-en-1-yl)-2-nitro-N-(1-oxo-3-phenylpropan-2-yl)benzene-sulfonamide (29g)

According to GP5 **29g** was prepared from (*R*)-*N*-(1-hydroxy-3-phenylpropan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzene-sulfonamide **28g** (1.34 g, 3.20 mmol) and DMP (2.71 g, 6.40 mmol) as a yellow oil (1.03 g, 2.46 mmol, 77 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (4:1 \rightarrow 2:1). [α]_D²⁰ + 35 (*c* 1.0 in CHCl₃). $R_f = 0.42$ (hexanes/EtOAc, 3:1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu} = 3066$ (w), 3029 (w), 2926 (w), 1736 (m), 1673

(w), 1590 (w), 1542 (vs), 1497 (w), 1455 (m), 1440 (m), 1371 (s), 1345 (s), 1203 (w), 1161 (vs), 1126 (s), 1094 (m), 1030 (w), 959 (m), 852 (m), 741 (s), 700 (m), 653 (w), 579 (m) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 1.60 (s, 3H, 5"'-H/6"'-H), 1.68 (s, 3H, 6"'-H/5"'-H), 2.19 – 2.29 (m, 2H, 2"'-H), 2.88 (dd, J = 14.4 Hz, 8.4 Hz, 1H, 3-H_a), 3.26 – 3.35 (ddd, J = 14.4 Hz, 8.6 Hz, 7.1 Hz, 1H, 1"'-H_a), 3.35 – 3.45 (m, 2H, 1"'-H_b, 3-H_b), 4.73 (dd, J = 8.4 Hz, 6.4 Hz, 1H, 2-H), 4.98 – 5.07 (m, 1H, 3"'-H), 7.10 – 7.20 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H), 7.52 – 7.60 (m, 2H, 3"-H, 5"-H), 7.62 – 7.68 (m, 1H, 4"-H), 7.78 – 7.83 (m, 1H, 6"-H), 9.70 (s, 1H, 1-H). 13 C-NMR (126 MHz, CDCl₃) δ 17.9 (C-5"'/C-6"'), 25.7 (C-6"'/C-5"'), 29.3 (C-2"'), 33.1 (C-3), 46.0 (C-1"'), 67.1 (C-2), 119.1 (C-3"'), 124.4 (C-3"), 127.0 (C-4'), 128.6 (C-3', C-5'), 129.0 (C-2', C-6'), 131.0 (C-6"), 131.8 (C-5"), 133.3 (C-1"), 133.6 (C-4"'), 135.6 (C-4"), 136.2 (C-1'), 148.6 (C-2"), 199.4 (C-1). HRMS (ESI): calc (found) for C₂₁H₂₄N₂O₅S ([M+H]⁺): 417.1479 (417.1481).

GP6: Cyclisation of amino aldehydes

Method A: Using Iron(III)chloride

The reaction was performed according to the literature. $^{[11]}$ A round bottom flask was charged with a solution of the amino aldehyde (1.50 mmol) in dichloromethane (50 mL) under nitrogen atmosphere. Upon cooling to 0 °C a solution of iron(III)chloride (3.0 mL, 3.00 mmol, 1 M in diethyl ether) was added dropwise. The mixture was stirred for 24 h at room temperature. Afterwards sodium hydroxide solution (50 mL, 2 M in water) was added and stirring continued for 5 min. The phases were separated and the aqueous phase was extracted with dichloromethane (3 × 75 mL). The organic phases were dried over magnesium sulfate and the solvents were evaporated. The crude product was purified by column chromatography or HPLC.

Method B: Using SmI₂

The reaction was performed according to the literature.^[12] A round bottom flask was charged with a solution of the amino aldehyde (1.92 mmol) in dichloromethane (25 mL) under nitrogen atmosphere. A solution of samarium diiodide (21 mL, 2.10 mmol, 0.1 M in tetrahydrofuran) was added dropwise at room temperature and stirred for 24 h at room temperature. The solvents were evaporated and the crude product was purified by column chromatography.

Method C: Using MeAlCl₂

The reaction was performed according to the literature. A round bottom flask was charged with a solution of the amino aldehyde (1.96 mmol) in chloroform (75 mL) under nitrogen atmosphere. A solution of methyl aluminium dichloride (2.0 mL, 2.00 mmol, 1.0 M in hexane) was added dropwise and the reaction was stirred for 24 h at reflux temperature. After cooling to room temperature the reaction was quenched with water (25 mL) and extracted with dichloromethane (2×40 mL). The organic phases were washed with brine (20 mL), dried over magnesium sulfate and the solvents were evaporated. The crude product was purified by column chromatography.

$(2S,3R,4S)-2-Isopropyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-ol\\ ((R,S)-30a) \quad and \quad (2S,3R,4R)-4-(2-Hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)-piperidin-3-ol\\ ((R,R)-31a)$


According to GP6A (R,S)-30a was prepared from (S)-N-(3-methyl-1-oxobutan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **29a** (0.72 g, 1.95 mmol) and iron(III)-chloride solution $(3.9 \text{ mL}, 3.90 \text{ mmol}, 1 \text{ M} \text{ in Et}_2\text{O})$ as a colorless solid (0.47 g, 1.28 mmol, 66 %). Diol (R,R)-31a was isolated as well as a colorless solid (0.18 g, 0.46 mmol, 24 %).

Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2 : 1 \rightarrow 1 : 1 \rightarrow 1 : 2).

Alkene (*R*,*S*)-**30a** was also prepared according to GP6B from (*S*)-*N*-(3-methyl-1-oxobutan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **29a** (0.71 g, 1.92 mmol) and samarium diiodide solution (21.0 mL, 2.10 mmol, 1 M in THF) as a colorless solid (0.32 g, 0.87 mmol, 45 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3:1).

(R,S)-30a, mp 138 °C. [α]_D²⁰ + 112 (c 1.0 in CHCl₃). R_f = 0.75 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3547 (w), 3088 (w), 2966 (m), 2932 (w), 2877 (w), 1736 (w), 1646 (w), 1590 (w), 1542 (vs), 1470 (w), 1440 (w), 1373 (s), 1339 (s), 1280 (w), 1207 (w), 1158 (s), 1126 (m), 1096 (w), 1065 (m), 1046 (w), 976 (m), 914 (m), 853 (w), 824 (w), 777 (w), 752 (s), 735 (m),

670 (w), 651 (w), 623 (w), 580 (s), 562 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.86 (d, J = 6.7 Hz, 3H, 7-H/8-H), 1.03 (d, J = 6.7 Hz, 3H, 8-H/7-H), 1.38 – 1.45 (m, 1H, 2-H_a), 1.77 (s, 3H, 10-H), 1.84 (dddd, J = 13.1 Hz, 13.1 Hz, 13.1 Hz, 4.7 Hz, 1H, 2-H_b), 1.98 (s, br, 1H, OH), 2.00 – 2.11 (m, 1H, 6-H), 2.26 (d, J = 12.7 Hz, 1H, 3-H), 3.10 (dt, J = 13.9 Hz, 2.6 Hz, 1H, 1-H_a), 3.69 (d, J = 10.7 Hz, 1H, 5-H), 4.02 – 4.12 (m, 2H, 1-H_b, 4-H), 4.68 (s, 1H, 11-H_a), 4.90 – 4.97 (m, 1H, 11-H_b), 7.50 – 7.56 (m, 1H, 3'-H), 7.58 – 7.67 (m, 2H, 4'-H, 5'-H), 8.10 – 8.17 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 19.9 (C-7/C-8), 20.4 (C-8/C-7), 22.0 (C-10), 22.6 (C-2), 26.5 (C-6), 41.4 (C-1), 41.6 (C-3), 65.2 (C-4), 66.0 (C-5), 112.2 (C-11), 123.5 (C-3'), 131.2 (C-6'), 131.3 (C-5'), 133.1 (C-4'), 134.8 (C-1'), 145.1 (C-9), 148.0 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₄N₂O₅S ([M+Na]⁺): 391.1298 (391.1306); calc (found) for C₁₇H₂₄N₂O₅S ([M+Na]⁺): 369.1479 (369.1476).



(R,R)-31a, mp 185 °C. [α]_D²⁰ + 148 (c 1.0 in CHCl₃). R_f = 0.44 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3362 (w, br), 2969 (m), 1543 (vs), 1470 (m), 1440 (w), 1371 (s), 1340 (s), 1278 (m), 1216 (w), 1157 (vs), 1125 (s), 1092 (m), 1064 (m), 1048 (m), 988 (w), 970 (s), 911 (m), 853 (m), 806 (w), 751 (s), 733 (s), 686 (w), 653 (m), 637 (w), 580 (s), 562 (m) cm⁻¹.

¹H-NMR (500 MHz, CDCl₃) δ 0.77 (d, J = 6.7 Hz, 3H, 1-H), 0.98 (d, J = 6.7 Hz, 3H, 2-H), 1.17 (s, 3H, 10-H/11-H), 1.32 (s, 3H, 11-H/10-H), 1.43 – 1.49 (m, 1H, 3-H), 1.53 – 1.60 (m, 1H, 2-H_a), 1.84 – 2.00 (m, 2H, 2-H_b, 6-H), 3.06 (s, br, 2H, 2 × OH), 3.11 (dt, J = 3.0 Hz,

14.1 Hz, 1H, 1-H_a), 3.52 (d, J = 10.7 Hz, 1H, 5-H), 4.09 – 4.17 (m, 1H, 1-H_b), 4.36 – 4.43 (m, 1H, 4-H), 7.53 – 7.58 (m, 1H, 3'-H), 7.63 – 7.69 (m, 2H, 4'-H, 5'-H), 8.07 – 8.13 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 19.4 (C-2), 19.8 (C-7/C-8), 20.3 (C-8/C-7), 26.4 (C-6), 28.0 (C-10/C-11), 28.6 (C-11/C-10), 41.8 (C-1), 42.0 (C-3), 66.4 (C-4), 66.8 (C-5), 72.1 (C-9), 123.7 (C-3'), 130.9 (C-6'), 131.6 (C-5'), 133.2 (C-4'), 134.7 (C-1'), 147.7 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₆S ([M+H]⁺): 387.1584 (387.1582).

(2S,3S,4S)-2-Isopropyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-ol ((S,S)-30a)

According to GP6C (S,S)-**30a** was prepared from (S)-N-(3-methyl-1-oxobutan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **29a** (0.72 g, 1.96 mmol) and methyl aluminium dichloride solution (2.0 mL, 1.96 mmol, 1 M in hexane) as a colorless solid (0.16 g, 0.44 mmol, 23 %). Alkene (R,S)-**30a** was isolated as well as colorless solid (0.09 g, 0.23 mmol, 12 %). Purification was accomplished by HPLC (OD, n-heptane/isopropanol (95:5), 15 mL/min, R_t ((S,S)-**30a**) = 32.5 min, R_t ((S,S)-**30a**) = 40 min).

(S,S)-30a, mp 43 °C. [α]_D²⁰ + 115 (c 1.0 in CHCl₃). R_f = 0.77 (hexanes/EtOAc, 1 : 1, anisaldehyde solution), FT-IR (ATR): $\tilde{\nu}$ = 3544 (w), 3077 (w), 2962 (w), 1646 (w), 1591 (w), 1541 (vs), 1471 (w), 1440 (m), 1369 (s), 1333 (s), 1295 (m), 1256 (m), 1200 (w), 1157 (vs), 1125 (s), 1082 (s), 1001 (s), 966 (m), 901 (s), 852 (m), 799 (m), 778 (m), 763 (s), 729 (s), 653 (m), 598 (vs), 573 (s) cm⁻¹.

¹H-NMR (500 MHz, CDCl₃) δ 0.64 (d, J = 6.7 Hz, 3H, 7-H/8-H), 1.13 (d, J = 6.7 Hz, 3H, 8-H/7-H), 1.58 (dddd, J = 13.0 Hz, 13.0 Hz, 13.0 Hz, 5.0 Hz, 1H, 2-H_a), 1.63 (s, 3H, 10-H), 1.63 – 1.73 (m, 1H, 2-H_b), 1.86 (s, 1H, OH), 2.15 (dqq, J = 9.5 Hz, 6.7 Hz, 6.7 Hz, 1H, 6-H), 2.45 (ddd, J = 13.0 Hz, 10.8 Hz, 3.9 Hz, 1H, 3-H), 2.94 – 3.05 (m, 1H, 1-H_a), 3.80 (dd, J = 9.5 Hz, 5.2 Hz, 1H, 5-H), 3.85 (dd, J = 10.8 Hz, 5.2 Hz, 1H, 4-H), 3.90 – 4.00 (m, 1H, 1-H_b), 4.87 (s, 1H, 11-H_a), 4.94 (s, 1H, 11-H_b), 7.59 – 7.65 (m, 1H, 3'-H), 7.65 – 7.72 (m, 2H, 4'-H, 5'-H), 8.04 – 8.10 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 18.8 (C-10), 20.4 (C-7/C-8), 22.3 (C-8/C-7), 25.7 (C-6), 30.3 (C-2), 41.4 (C-1), 46.4 (C-3), 62.7 (C-5), 71.7 (C-4), 114.5 (C-11), 124.2 (C-3'), 130.8 (C-6'), 131.7 (C-5'), 133.3 (C-4'), 134.6 (C-1'), 144.6 (C-9), 147.5 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₄N₂O₅S ([M+H]⁺): 369.1479 (369.1481).

(2R,3S,4R)-2-Isopropyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-ol ((S,R)-30b) and (2R,3S,4S)-4-(2-Hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)-piperidin-3-ol ((S,S)-31b)

According to GP6A (S,R)-30b was prepared from (R)-N-(3-methyl-1-oxobutan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **29b** (0.41 g, 1.11 mmol) and iron(III)-chloride solution (2.2 mL, 2.22 mmol, 1 M) in diethyl ether) as a colorless solid (0.28 g, 0.76 mmol, 68 %). Diol (S,S)-31b was isolated as well as a colorless solid (0.05 g, 0.13 mmol, 12 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc $(3:1 \rightarrow 2:1 \rightarrow 1:1)$.

(S,R)-30b, mp 146 °C. $[\alpha]_D^{20}$ – 110 (c 1.0 in CHCl₃). R_f = 0.46 (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3549 (w), 3091 (w), 2966 (m), 2931 (w), 2876 (w), 1646 (w), 1590 (w), 1542 (vs), 1470 (m), 1439 (m), 1372 (s), 1338 (s), 1294 (m), 1280 (m), 1207 (w), 1157 (vs), 1125 (s), 1095 (m), 1065 (m), 1045 (m), 975 (s), 913 (s), 852 (m), 776 (m), 752 (s), 733 (s), 670 (m),

650 (w), 623 (w), 579 (vs), 562 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.86 (d, J = 6.5 Hz, 3H, 7-H/8-H), 1.03 (d, J = 6.5 Hz, 3H, 8-H/7-H), 1.41 (d, J = 13.1 Hz, 1H, 2-H_a), 1.77 (s, 3H, 10-H), 1.83 (ddt, J = 13.1 Hz, 13.1 Hz, 4.7 Hz, 1H, 2-H_b), 1.99 (s, br, 1H, OH), 2.05 (dqq, J = 10.8 Hz, 6.5 Hz, 6.5 Hz, 1H, 6-H), 2.26 (d, J = 12.5 Hz, 1H, 3-H), 3.10 (t, J = 13.7 Hz, 1H, 1-H_a), 3.69 (d, J = 10.8 Hz, 1H, 5-H), 4.02 – 4.12 (m, 2H, 1-H_b, 4-H), 4.68 (s, 1H, 11-H_a), 4.93 (s, 1H, 11-H_b), 7.50 – 7.56 (m, 1H, 3'-H), 7.58 – 7.67 (m, 2H, 4'-H, 5'-H), 8.10 – 8.17 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 19.9 (C-7/C-8), 20.4 (C-8/C-7), 21.9 (C-10), 22.6 (C-2), 26.5 (C-6), 41.4 (C-1), 41.6 (C-3), 65.2 (C-4), 66.0 (C-5), 112.2 (C-11), 123.5 (C-3'), 131.2 (C-6'), 131.3 (C-5'), 133.1 (C-4'), 134.7 (C-1'), 145.1 (C-9), 147.9 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₄N₂O₅S ([M+Na]⁺): 391.1298 (391.1299).



(S,S)-31b, mp 180 °C. [α]_D²⁰ - 135 (c 1.0 in CHCl₃). R_f = 0.22 (hexanes/EtOAc, 1 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3365 (w, br), 2970 (m), 2939 (m), 2877 (w), 1732 (w), 1591 (w), 1543 (vs), 1470 (m), 1440 (w), 1372 (s), 1341 (s), 1278 (m), 1216 (w), 1158 (s), 1126 (m), 1092 (w), 1065 (m), 1048 (w), 970 (m), 911 (m), 853 (w), 806 (w), 776 (w), 751 (m), 734 (s), 685 (w), 653

(w), 637 (w), 581 (s), 562 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.77 (d, J = 6.8 Hz, 3H, 1-H), 0.98 (d, J = 6.8 Hz, 3H, 2-H), 1.17 (s, 3H, 10-H/11-H), 1.32 (s, 3H, 11-H/10-H), 1.46

(ddd, J = 13.3 Hz, 3.7 Hz, 2.1 Hz, 1H, 3-H), 1.58 – 1.62 (m, 1H, 2-H_a), 1.89 (ddt, J = 13.3 Hz, 13.3 Hz, 5.0 Hz, 1H, 2-H_b), 1.95 (dqq, J = 10.8 Hz, 6.8 Hz, 6.8 Hz, 1H, 6-H), 3.01 (s, br, 2H, 2 × OH), 3.11 (ddd, J = 13.3 Hz, 13.3 Hz, 3.0 Hz, 1H, 1-H_a), 3.52 (d, J = 10.8 Hz, 1H, 5-H), 4.09 – 4.16 (m, 1H, 1-H_b), 4.36 – 4.42 (m, 1H, 4-H), 7.53 – 7.58 (m, 1H, 3'-H), 7.63 – 7.69 (m, 2H, 4'-H/5'-H), 8.07 – 8.13 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 19.4 (C-2), 19.8 (C-7/C-8), 20.3 (C-8/C-7), 26.4 (C-6), 28.0 (C-10/C-11), 28.6 (C-11/C-10), 41.7 (C-1), 42.0 (C-3), 66.4 (C-4), 66.8 (C-5), 72.1 (C-9), 123.7 (C-3'), 130.9 (C-6'), 131.6 (C-5'), 133.2 (C-4'), 134.7 (C-1'), 147.7 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₆S ([M+Na]⁺): 409.1404 (409.1407).

 $(2S,3R,4S)\text{-}2\text{-}Isobutyl\text{-}1\text{-}((2\text{-}nitrophenyl)sulfonyl)\text{-}4\text{-}(prop\text{-}1\text{-}en\text{-}2\text{-}yl)piperidin\text{-}3\text{-}ol}\\ ((R,S)\text{-}30c), (2S,3S,4S)\text{-}2\text{-}Isobutyl\text{-}1\text{-}((2\text{-}nitrophenyl)sulfonyl)\text{-}4\text{-}(prop\text{-}1\text{-}en\text{-}2\text{-}yl)piperidin\text{-}3\text{-}ol}\\ ((S,S)\text{-}30c), (2S,3S,4R)\text{-}4\text{-}(2\text{-}Hydroxypropan\text{-}2\text{-}yl)\text{-}2\text{-}isobutyl\text{-}1\text{-}((2\text{-}nitrophenyl)sulfonyl)piperidin\text{-}3\text{-}ol}\\ ((S,R)\text{-}31c) \text{ and } (2S,3R,4R)\text{-}4\text{-}(2\text{-}Hydroxypropan\text{-}2\text{-}yl)\text{-}2\text{-}isobutyl\text{-}1\text{-}((2\text{-}nitrophenyl)\text{-}sulfonyl)\text{-}piperidin\text{-}3\text{-}ol}\\ ((R,R)\text{-}31c)$

According to GP6A (R,S)-30 \mathbf{c} was prepared from (S)-N-(4-methyl-1-oxopentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **29\mathbf{c}** (1.08 g, 2.82 mmol) and iron(III)-chloride solution (5.6 mL, 5.64 mmol, 1 M in diethyl ether) as a colorless solid (63.0 mg, 0.17 mmol, 52 %). Alkene (S,S)-30 \mathbf{c} was isolated as well as a colorless solid (4.00 mg, 0.01 mmol, 3 %). Purification was accomplished by HPLC (Orbit, hexane/isopropanol (97 : 3), 12 mL / min, R_t ((R,S)-30 \mathbf{c}) = 19 min, R_t ((R,S)-31 \mathbf{c} and (R,R)-31 \mathbf{c} were isolated as colorless solids ((R,S)-31 \mathbf{c} 3.00 mg, 7.49 μ mol, 2 %; (R,S)-31 \mathbf{c} 12.0 mg, 0.03 mmol, 9 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (90 : 10), 15 mL / min, R_t ((R,S)-31 \mathbf{c}) = 19 min, R_t ((R,S)-31 \mathbf{c}) = 21 min). Mixtures of alkenes and diols were separated beforehand via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1 \rightarrow 2 : 1 \rightarrow 1 : 1).

Alkene (*R*,*S*)-**30c** was also prepared according to GP6B from (*S*)-*N*-(4-methyl-1-oxopentan-2-yl)-*N*-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **29c** (0.63 g, 1.65 mmol) and samarium diiodide solution (18.2 mL, 1.82 mmol, 0.1 M in THF) as a colorless solid (0.33 g, 0.87 mmol, 53 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1).

(R,S)-30c

(R,S)-30c, mp 141 °C. $[\alpha]_D^{20}$ + 71 (c 0.5 in CHCl₃). R_f = 0.49 (hexanes/ EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3542 (w), 3089 (w), 2956 (m), 2923 (m), 2853 (m), 1725 (w), 1646 (w), 1608 (w), 1591 (w), 1541 (vs), 1467 (m), 1439 (m), 1371 (s), 1340 (s), 1272 (m), 1206 (w), 1160 (vs), 1130 (s), 1067 (m), 1049 (w), 991 (m), 940 (m), 928 (m), 852 (m), 829 (w), 777 (m), 747


(m), 732 (m), 671 (m), 615 (m), 578 (s), 451 (w), 418 (w) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 0.92 (d, J = 6.6 Hz, 3H, 8-H/9-H), 0.93 (d, J = 6.6 Hz, 3H, 9-H/8-H), 1.38 – 1.47 (m, 2H, 2-H_a, 6-H_a), 1.57 (ddd, J = 13.8 Hz, 7.0 Hz, 7.0 Hz, 1H, 6-H_b), 1.64 (ddqq, J = 7.0 Hz, 7.0 Hz, 6.6 Hz, 6.6 Hz, 1H, 7-H), 1.77 (s, 3H, 11-H), 1.88 (ddt, J = 13.4 Hz, 12.9 Hz, 4.5 Hz, 1H, 2-H_b), 2.28 (d, J = 12.9 Hz, 1H, 3-H), 3.20 (ddd, J = 13.6 Hz, 13.4 Hz, 2.5 Hz, 1H, 1-H_a), 3.76 – 3.79 (m, 1H, 4-H), 3.92 – 4.00 (m, 1H, 1-H_b), 4.11 – 4.16 (m, 1H, 5-H), 4.71 (s, 1H, 12-H_a), 4.95 (s, 1H, 12-H_b), 7.56 – 7.61 (m, 1H, 3'-H), 7.63 – 7.68 (m, 2H, 4'-H, 5'-H), 8.13 – 8.18 (m, 1H, 6'-H). 13 C-NMR (126 MHz, CDCl₃) δ 22.0 (C-11), 22.7 (C-8, C-9), 22.7 (C-2), 24.9 (C-7), 38.1 (C-6), 41.0 (C-1), 41.2 (C-3), 57.8 (C-5), 67.3 (C-4), 112.4 (C-12), 123.9 (C-3'), 131.3 (C-6'), 131.4 (C-4'/C-5'), 133.2 (C-5'/C-4'), 134.3 (C-1'), 145.0 (C-10), 147.9 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₆N₂O₅S ([M+Na]⁺): 405.1455 (405.1459).

(S,S)-30c, mp 37 °C. $[\alpha]_D^{20}$ + 50 (*c* 0.2 in CHCl₃). R_f = 0.49 (hexanes/ EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 35475 (w), 3077 (w), 2954 (m), 2925 (m), 2870 (w), 1646 (w), 1590 (w), 1543 (vs), 1467 (m), 1439 (m), 1369 (s), 1334 (s), 1294 (m), 1263 (m), 1160 (vs), 1127 (s), 1080 (s), 1060 (m), 1016 (m), 966 (m), 941 (m), 906 (s), 852 (m), 828 (w), 812 (w), 778 (m), 747

(s), 732 (s), 702 (w), 652 (m), 594 (vs), 567 (s), 447 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.72 (d, J = 6.4 Hz, 3H, 8-H/9-H), 0.85 (d, J = 6.4 Hz, 3H, 9-H/8-H), 1.40 – 1.59 (m, 4H, 2-H_a, 6-H, 7-H), 1.59 – 1.65 (m, 1H, 2-H_b), 1.61 (s, 3H, 11-H), 1.81 (d, J = 2.3 Hz, 1H, OH), 2.32 (dt, J = 11.7 Hz, 4.2 Hz, 1H, 3-H), 3.07 – 3.19 (m, 1H, 1-H_a), 3.71 (ddd, J = 10.6 Hz, 5.3 Hz, 2.3 Hz, 1H, 4-H), 3.84 – 3.92 (m, 1H, 1-H_b), 4.16 – 4.23 (m, 1H, 5-H), 4.85 (s, 1H, 12-H_a), 4.92 (s, 1H, 12-H_b), 7.62 – 7.67 (m, 1H, 3'-H), 7.67 – 7.73 (m, 2H, 4'-H, 5'-H), 8.09 – 8.15 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 18.7 (C-11), 21.4 (C-8/C-9), 23.9 (C-9/C-8), 24.2 (C-7), 29.7 (C-2), 32.8 (C-6), 40.0 (C-1), 45.9 (C-3), 55.6 (C-5), 69.1 (C-4), 114.3 (C-12), 124.3 (C-3'), 131.0 (C-6'), 131.7 (C-5'), 133.5 (C-4'), 134.3 (C-1'), 144.5 (C-10), 147.8 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₆N₂O₅S ([M+Na]⁺): 405.1455 (405.1456).

(S,R)-31c, mp 195 °C. $[\alpha]_D^{20}$ + 63 (c 0.1 in CHCl₃). R_f = 0.11 (hexanes/ EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3323 (w, br), 2958 (m), 2930 (m), 2871 (m), 1545 (vs), 1468 (m), 1439 (m), 1370 (s), 1341 (s), 1279 (m), 1216 (w), 1157 (s), 1126 (s), 1078 (m), 1059 (m), 1015 (m), 964 (m), 943 (w), 900 (m), 853 (m), 778 (m), 748 (m), 732 (s), 652 (w), 595 (vs), 567 (m) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 0.74 (d, J = 6.6 Hz, 3H, 8-H/9-H), 0.85 (d, J =

6.6 Hz, 3H, 9-H/8-H), 1.12 (s, 3H, 11-H/12-H), 1.10 - 1.20 (m, 1H, 2-H_a), 1.20 (s, 3H, 12-H/11-H), 1.40 - 1.50 (m, 1H, 7-H), 1.52 - 1.64 (m, 3H, 2-H_b, 6-H), 1.75 - 1.84 (m, 1H, 3-H), 2.60 (s, br, 1H, OH), 3.06 - 3.18 (m, 1H, 1-H_a), 3.83 - 3.89 (m, 1H, 1-H_b), 3.90 (dd, J = 11.0 Hz, 5.3 Hz, 1H, 4-H), 4.05 (ddd, J = 8.3 Hz, 5.3 Hz, 5.3 Hz, 1H, 5-H), 4.24 (s, br, 1H, OH), 7.60 - 7.66 (m, 1H, 3'-H), 7.66 - 7.72 (m, 2H, 4'-H, 5'-H), 8.07 - 8.15 (m, 1H, 6'-H). 13 C-NMR (126 MHz, CDCl₃) δ 21.4 (C-8/C-9), 23.1 (C-11/C-12), 23.9 (C-9/C-8), 24.3 (C-7), 27.3 (C-2), 30.0 (C-12/C-11), 33.0 (C-6), 40.1 (C-1), 45.0 (C-3), 56.1 (C-5), 71.8 (C-4), 74.9 (C-10), 124.3 (C-3'), 131.0 (C-6'), 131.7 (C-5'), 133.4 (C-4'), 134.4 (C-1'), 147.8 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₈N₂O₆S ([M+Na]⁺): 423.1560 (423.1563).



(R,R)-31c

(R,R)-31c, mp 54 °C. [α]_D²⁰ + 210 (c 0.1 in CHCl₃). R_f = 0.11 (hexanes/ EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3373 (w, br), 2960 (m), 2925 (m), 2872 (m), 1544 (vs), 1469 (m), 1372 (s), 1341 (s), 1261 (m), 1159 (s), 1126 (s), 1094 (m), 1067 (m), 946 (m), 852 (m), 801 (m), 746 (m), 684 (w), 652 (m), 580 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.86 (d, J = 6.6 Hz, 3H, 8-H/9-

H), 0.89 (d, J = 6.6 Hz, 3H, 9-H/8-H), 1.18 (s, 3H, 11-H/12-H), 1.23 – 1.32 (m, 1H, 6-H_a), 1.30 (s, 3H, 12-H/11-H), 1.42 – 1.62 (m, 4H, 2-H_a, 3-H, 6-H_b, 7-H), 1.90 (dddd, J = 13.4 Hz, 13.4 Hz, 13.4 Hz, 4.9 Hz, 1H, 2-H_b), 2.79 (s, br, 1H, OH), 3.15 – 3.24 (m, 1H, 1-H_a), 3.23 (s, br, 1H, OH), 3.97 – 4.04 (m, 2H, 1-H_b, 5-H), 4.07 – 4.12 (m, 1H, 4-H), 7.55 – 7.61 (m, 1H, 3'-H), 7.63 – 7.70 (m, 2H, 4'-H, 5'-H), 8.10 – 8.17 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) 8 19.4 (C-2), 22.5 (C-8/C-9), 22.8 (C-9/C-8), 24.8 (C-7), 28.1 (C-11/C-12), 28.6 (C-12/C-11), 37.9 (C-6), 41.1 (C-1), 41.8 (C-3), 58.7 (C-5), 68.8 (C-4), 72.3 (C-10), 123.9 (C-3'), 131.0 (C-6'), 131.7 (C-5'), 133.3 (C-4'), 134.3 (C-1'), 147.8 (C-2'). HRMS (ESI): calc (found) for $C_{18}H_{28}N_2O_6S$ ([M+Na]⁺): 423.1560 (423.1563).

(2S,3R,4S)-2-((S)-sec-Butyl)-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol ((R,S)-30e) and (2S,3R,4R)-2-((S)-sec-Butyl)-4-(2-hydroxypropan-2-yl)-1-((2-nitrophenyl)-sulfonyl)piperidin-3-ol ((R,R)-31e)

According to GP6A (R,S)-30e was prepared from N-((2S,3S)-3-methyl-1-oxopentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **29e** (0.72 mg, 1.87 mmol) and iron(III)chloride solution (3.74 mL, 3.74 mmol, 1 M in diethyl ether) as a colorless solid (0.42 g, 1.09 mmol, 58 %). Diol (R,R)-31e was isolated as well as a colorless solid (79.0 mg, 0.20 mmol, 11 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2:1 \rightarrow 1:1 \rightarrow 1:2).

Alkene (R,S)-30e was also prepared according to GP6B from N-((2S,3S)-3-methyl-1-oxopentan-2-yl)-N-(4-methylpent-3-en-1-yl)-2-nitrobenzenesulfonamide **29e** (0.13 g, 0.34 mmol) and samarium diiodide solution (3.7 mL, 0.37 mmol, 0.1 M in THF) as a colorless solid (0.07 g, 0.19 mmol, 57 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1).

(R,S)-30e, mp 124 °C. [α]_D²⁰ + 24 (c 0.9 in CHCl₃). R_f = 0.37 (hexanes/EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3551 (w, br), 3089 (w), 2965 (m), 2930 (m), 2877 (w), 1646 (w), 1590 (w), 1542 (vs), 1464 (m), 1440 (m), 1372 (s), 1338 (s), 1280 (m), 1206 (w), 1159 (s), 1126 (m), 1098 (w), 1065 (m), 1047 (w), 988 (m), 974 (m), 952 (m), 907 (m), 853 (m), 824 (w), 776 (m),

751 (s), 734 (m), 671 (m), 651 (w), 622 (w), 580 (s), 531 (w) cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ 0.80 (t, J = 7.1 Hz, 3H, 8-H), 0.84 – 0.93 (m, 1H, 7-H_a), 0.94 (d, J = 6.6 Hz, 3H, 9-H), 1.30 – 1.40 (m, 1H, 2-H_a), 1.47 – 1.60 (m, 1H, 7-H_b), 1.72 (s, 3H, 11-H), 1.72 – 1.84 (m, 2H, 2-H_b, 3-H), 1.93 (d, J = 2.8 Hz, 1H, OH), 2.18 – 2.30 (m, 1H, 6-H), 2.99 – 3.13 (m, 1H, 1-H_a), 3.70 – 3.78 (m, 1H, 4-H), 3.95 – 4.07 (m, 2H, 1-H_b, 5-H), 4.62 (s, 1H, 12-H_a), 4.87 (s, 1H, 12-H_b), 7.43 – 7.52 (m, 1H, 3'-H), 7.55 – 7.65 (m, 2H, 4'-H, 5'-H), 8.05 – 8.15 (m, 1H, 6'-H). ¹³C-NMR (101 MHz, CDCl₃) δ 11.3 (C-8), 16.2 (C-9), 21.9 (C-11), 22.4 (C-2), 25.2 (C-7), 32.7 (C-3), 41.2 (C-6), 41.6 (C-1), 65.0 (C-4), 65.3 (C-5), 112.1 (C-12), 123.4 (C-3'), 131.2 (C-5'), 131.3 (C-6'), 133.2 (C-4'), 134.4 (C-1'), 145.1 (C-10), 148.0 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₆N₂O₅S ([M+Na]⁺): 405.1455 (405.1463).

(R,R)-31e, mp 166 °C. $[\alpha]_D^{20}$ + 13 (c 1.0 in CHCl₃). R_f = 0.08 (hexanes/EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3362 (w, br), 2966 (m), 2930 (m), 2877 (m), 1732 (w), 1591 (w), 1543 (vs), 1464 (m), 1440 (m), 1372 (s), 1341 (s), 1277 (m), 1241 (w), 1213 (w), 1158 (s), 1126 (s), 1094 (w), 1065 (m), 958 (m), 908 (m), 852 (m), 806 (w), 776 (m), 751 (m), 734 (m), 686 (w), 653

(w), 637 (w), 581 (s) cm⁻¹. ¹H-NMR (700 MHz, CDCl₃) δ 0.76 – 0.80 (m, 3H, 8-H), 0.80 – 0.85 (m, 1H, 7-H_a), 0.92 (d, J = 6.5 Hz, 3H, 9-H), 1.15 (s, 3H, 11-H/12-H), 1.30 (s, 3H, 12-H/11-H), 1.41 – 1.47 (m, 1H, 3-H), 1.47 – 1.55 (m, 2H, 2-H_a, 7-H_b), 1.60 – 1.70 (m, 1H, 6-H), 1.81 – 1.90 (dddd, J = 13.3 Hz, 13.3 Hz, 13.3 Hz, 5.0 Hz, 1H, 2-H_b), 2.93 (s, br, 2H, 2xOH), 3.04 – 3.12 (m, 1H, 1-H_a), 3.59 (d, J = 10.9 Hz, 1H, 5-H), 4.05 – 4.13 (m, 1H, 1-H_b), 4.38 – 4.41 (m, 1H, 4-H), 7.50 – 7.55 (m, 1H, 3'-H), 7.60 – 7.67 (m, 2H, 4'-H, 5'-H), 8.06 – 8.12 (m, 1H, 6'-H). ¹³C-NMR (176 MHz, CDCl₃) δ 11.2 (C-8), 16.1 (C-9), 19.2 (C-2), 25.1 (C-7), 28.0 (C-11/C-12), 28.6 (C-12/C-11), 32.5 (C-6), 41.8 (C-1),41.8 (C-3), 65.7 (C-5), 66.5 (C-4), 72.2 (C-10), 123.5 (C-3'), 130.9 (C-6'), 131.5 (C-5'), 133.2 (C-4'), 134.6 (C-1'), 147.8 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₈N₂O₆S ([M+Na]⁺): 423.1560 (423.1560).

 $(2S,3R,4S)-2-\text{Benzyl-1-}((2-\text{nitrophenyl})\text{sulfonyl})-4-(\text{prop-1-en-2-yl})\text{piperidin-3-ol}\ ((R,S)-30f),\ (2S,3S,4S)-2-\text{Benzyl-1-}((2-\text{nitrophenyl})\text{sulfonyl})-4-(\text{prop-1-en-2-yl})\text{piperidin-3-ol}\ ((S,S)-30f)\ \text{and}\ (2S,3R,4R)-2-\text{Benzyl-4-}(2-\text{hydroxypropan-2-yl})-1-((2-\text{nitrophenyl})-\text{sulfonyl})-\text{piperidin-3-ol}\ ((R,R)-31f)$


According to GP6A (R,S)-30 \mathbf{f} was prepared from (S)-N-(4-methylpent-3-en-1-yl)-2-nitro-N-(1-oxo-3-phenylpropan-2-yl)benzenesulfonamide **29\mathbf{f}** (0.44 g, 1.06 mmol) and iron(III)chloride solution (2.1 mL, 2.12 mmol, 1 M in diethyl ether) as a colorless solid (0.10 g, 0.24 mmol, 23 %). Alkene (S,S)-30 \mathbf{f} and diol (R,R)-31 \mathbf{f} were isolated as colorless solids as well ((S,S)-30 \mathbf{f} 0.12 g, 0.30 mmol, 28 % and (R,R)-31 \mathbf{f} 6.00 mg, 0.01 mmol, 3 %). Diol (R,R)-31 \mathbf{f} was isolated via column chromatography on SiO₂ with hexanes/EtOAc (S : S + S + S : S + S : 2). Purification of the mixture of alkenes was accomplished by HPLC (OD, S -hexane/isopropanol (90 : 10), 15 mL/min, S + ((S,S)-30 \mathbf{f}) = 44 min, S + ((S,S)-30 \mathbf{f}) = 51 min).

Alkene (R,S)-**30f** was also prepared according to GP6B from (S)-N-(4-methylpent-3-en-1-yl)-2-nitro-N-(1-oxo-3-phenylpropan-2-yl)benzenesulfonamide **29f** (0.32 g, 0.78 mmol) and samarium diiodide solution (8.6 mL, 0.86 mmol, 0.1 M in THF) as a colorless solid (0.21 g, 0.51 mmol, 65 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (3 : 1).

Alkenes (R,S)-30f and (S,S)-30f were also prepared according to GP6C from (S)-N-(4-methylpent-3-en-1-yl)-2-nitro-N-(1-oxo-3-phenylpropan-2-yl)benzenesulfonamide **29f** (0.17 g, 0.40 mmol) and methyl aluminium dichloride solution (0.4 mL, 0.40 mmol), 1 M in hexane) as a brown oil (crude yield: 0.18 g, 0.42 mmol, quant, ratio: 21 % (R,S)-30f, 79 % (S,S)-30f). The mixture wasn't purified. The ratio was taken from 1 H-NMR spectrum.

(R,S)-30f, mp 110 °C. [α]_D²⁰ + 196 (c 1.0 in CHCl₃). R_f = 0.27 (hexanes/ EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3545 (w, br), 3087 (w), 3028 (w), 2946 (w), 2854 (w), 1646 (w), 1541 (vs), 1497 (w), 1440 (w), 1369 (s), 1331 (m), 1159 (s), 1126 (m), 1079 (m), 1016 (w), 954 (m), 906 (w), 853 (w), 777 (w), 756 (m), 741 (m), 700 (m), 652 (w), 593 (s), 576 (m), 505 (w) cm⁻¹. ¹H NMR (500 MHz, CDCl₃) δ 1.70 – 1.82 (m, 2H, 2-H), 1.75 (s,


3H, 8-H), 2.05 (s, br, 1H, OH), 2.47 (ddd, J = 10.9 Hz, 10.9 Hz, 5.2 Hz, 1H, 3-H), 2.78 (dd, J = 14.1 Hz, 11.4 Hz, 1H, 6-H_a), 3.12 (dd, J = 14.1 Hz, 3.1 Hz, 1H, 6-H_b), 3.37 (ddd, J = 14.9 Hz, 11.9 Hz, 3.9 Hz, 1H, 1-H_a), 3.95 (dd, J = 10.9 Hz, 5.5 Hz, 1H, 4-H), 4.01 – 4.08 (m, 1H, 1-H_b), 4.39 (ddd, J = 11.4 Hz, 5.5 Hz, 3.1 Hz, 1H, 5-H), 4.96 (s, 1H, 9-H_a), 5.01 (s, 1H, 9-H_b), 6.83 – 6.92 (m, 3H, 3'-H, 4'-H, 5'-H), 6.96 – 7.04 (m, 2H, 2'-H, 6'-H), 7.24 – 7.30 (m, 1H, 5"-H), 7.37 – 7.42 (m, 1H, 6"-H), 7.43 – 7.50 (m, 2H, 3"-H, 4"-H). 13 C-NMR (126 MHz, CDCl₃) δ 18.8 (C-8), 29.8 (C-6), 30.7 (C-2), 40.5 (C-1), 46.4 (C-3), 60.6 (C-5), 69.8 (C-4), 114.6 (C-9), 124.2 (C-3"), 126.3 (C-4'), 128.0 (C-3', C-5'), 129.2 (C-2', C-6'), 130.7 (C-6"), 131.9 (C-5"), 132.6 (C-4"), 134.1 (C-1"), 138.4 (C-1'), 144.4 (C-7), 147.0 (C-2"). HRMS (ESI): calc (found) for $C_{21}H_{24}N_{2}O_{5}S$ ([M+Na]⁺): 439.1298 (439.1297).



(S,S)-30f, mp 54 °C. [α]_D²⁰ + 58 (c 0.38 in CHCl₃). R_f = 0.27 (hexanes/ EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3546 (w, br), 3087 (w), 3026 (w), 2923 (m), 2854 (w), 1646 (w), 1591 (w), 1540 (vs), 1495 (w), 1455 (m), 1440 (m), 1371 (s), 1336 (s), 1272 (m), 1159 (vs), 1126 (s), 1094 (w), 1072 (m), 989 (s), 974 (m), 949 (m), 930 (m), 908 (s), 852 (m), 823 (w), 778 (m), 758 (m), 730 (vs), 702 (s), 672 (w), 660 (m), 650 (m), 611 (m), 573 (s), 546

(m), 522 (m), 461 (w), 414 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.50 – 1.57 (m, 1H, 2-H_a), 1.73 (s, 3H, 8-H), 1.78 (s, br, 1H, OH), 2.00 (ddt, J = 13.2 Hz, 13.2 Hz, 4.8 Hz, 1H, 2-H_b), 2.42 – 2.50 (m, 1H, 3-H), 2.96 (dd, J = 13.6 Hz, 9.7 Hz, 1H, 6-H_a), 3.05 (dd, J = 13.6 Hz, 6.2 Hz, 1H, 6-H_b), 3.28 – 3.37 (m, 1H, 1-H_a), 3.72 (s, 1H, 4-H), 3.98 – 4.06 (m, 1H, 1-H_b), 4.27 – 4.34

(m, 1H, 5-H), 4.75 (s, 1H, 9-H_a), 4.92 – 4.99 (s, 1H, 9-H_b), 7.13 – 7.20 (m, 3H, 2'-H, 4'-H, 6'-H), 7.20 – 7.26 (m, 2H, 3'-H, 5'-H), 7.53 – 7.66 (m, 3H, 3"-H, 4"-H, 5"-H), 7.95 – 7.99 (m, 1H, 6"-H). 13 C-NMR (126 MHz, CDCl₃) δ 22.0 (C-8), 22.9 (C-2), 35.9 (C-6), 41.2 (C-3), 41.4 (C-1), 61.0 (C-5), 65.3 (C-4), 112.5 (C-9), 124.1 (C-3"), 126.9 (C-4"), 128.7 ((C-2", C-6")/(C-3", C-5")), 129.0 ((C-3", C-5")/(C-2", C-6")), 131.1 (C-6"), 131.7 (C-5"), 133.1 (C-4"), 134.1 (C-1"), 137.3 (C-1"), 144.8 (C-7), 147.7 (C-2"). HRMS (ESI): calc (found) for $C_{21}H_{24}N_2O_5S$ ([M+Na]⁺): 439.1298 (439.1297).



(R,R)-31f, mp 73 °C. $[\alpha]_D^{20}$ + 118 (c 2.5 in CHCl₃). R_f = 0.51 (hexanes/ EtOAc, 1 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3346 (w, br), 3090 (w), 3027 (w), 2969 (w), 2929 (w), 1736 (w), 1592 (w), 1541 (vs), 1496 (w), 1455 (m), 1440 (m), 1369 (s), 1337 (s), 1272 (m), 1225 (w), 1158 (vs), 1126 (s), 1092 (m), 1072 (m), 1046 (m), 989 (m), 956 (m), 937 (m), 910 (s), 866 (w), 852 (m), 800 (w), 779 (m), 757 (m), 731 (vs), 701 (s), 684 (m), 652 (m), 621

(m), 576 (s), 537 (m) cm⁻¹. ¹H-NMR (700 MHz, CDCl₃) δ 1.23 (s, 3H, 8-H/9-H), 1.27 (s, 3H, 9-H/8-H), 1.67 – 1.73 (m, 2H, 2-H_a, 3-H), 1.98 – 2.08 (m, 1H, 2-H_b), 2.75 (s, br, 1H, OH), 2.85 (dd, J = 13.6 Hz, 9.2 Hz, 1H, 6-H_a), 2.98 (dd, J = 13.6 Hz, 6.5 Hz, 1H, 6-H_b), 3.07 (d, J = 3.9 Hz, 1H, OH), 3.31 – 3.38 (m, 1H, 1-H_a), 4.04 – 4.10 (m, 2H, 1-H_b, 4-H), 4.16 – 4.20 (m, 1H, 5-H), 7.09 – 7.21 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H), 7.55 – 7.65 (m, 3H, 3"-H, 4"-H, 5"-H), 7.94 – 7.98 (m, 1H, 6"-H). ¹³C-NMR (176 MHz, CDCl₃) δ 19.8 (C-2), 28.2 (C-8/C-9), 28.6 (C-9/C-8), 35.7 (C-6), 41.5 (C-1), 41.9 (C-3), 62.2 (C-4), 66.9 (C-5), 72.3 (C-7), 124.3 (C-3"), 127.0 (C-4"), 128.7 (C-3', C-5'), 129.0 (C-2', C-6'), 131.1 (C-6"), 131.9 (C-5"), 133.3 (C-4"), 134.0 (C-1"), 137.1 (C-1'). The signal of quatary C-2" wasn't observed due to low intensity. HRMS (ESI): calc (found) for C₂₁H₂₆N₂O₆S ([M+Na]⁺): 457.1404 (457.1396).


GP7: Deprotection of the amino group

Method A: The reaction was performed according to the literature. $^{[14]}$ A round bottom flask was charged with a solution of the *N*-protected derivative (1.00 mmol) in dimethylformamide (13.0 mL) under nitrogen atmosphere. Potassium carbonate (0.28 g, 2.00 mmol) and thiophenol (0.11 mL, 0.12 g, 1.10 mmol) were added and the mixture was stirred for 20 h at room temperature. Afterwards methyl-*tert*-butyl ether (15 mL) was added and the organic phase was extracted with hydrochloric acid (2 × 12 mL, 1 M in water). The aqueous phase was washed with MTBE (3 × 12 mL) and neutralized with sodium hydroxide solution (2 M). The solvents were evaporated and the crude product was taken up in dichloromethane (5 mL) and filtered

through a short cotton pad to remove remaining salts. The filtrate was evaporated and then purified by column chromatography. The product was once again taken up in dichloromethane (5 mL) and filtered over a short cotton pad to remove eluted silica. The filtrate was evaporated to yield the unprotected product.

Method B: The reaction was performed according to the literature. [15] A round bottom flask was charged with a solution of the *N*-protected derivative (0.13 mmol) in dimethylformamide (2.0 mL) under nitrogen atmosphere. Upon cooling to 0 °C diisopropylethylamine (88.0 μ L, 67.0 mg, 0.52 mmol) and thiophenol (67.0 mL, 72.0 mg, 0.65 mmol) were added and the mixture was stirred for 7 d at room temperature till TLC showed a complete conversion of the starting material. Afterwards methyl-*tert*-butyl ether (9 mL) was added and the organic phase was extracted with hydrochloric acid (2 × 1 mL, 1 M in water). The aqueous phase was washed with MTBE (3 × 3 mL) and neutralized with sodium hydroxide solution (2 M). The solvents were evaporated and the crude product was taken up in dichloromethane (5 mL) and filtered through a short cotton pad to remove remaining salts. The filtrate was evaporated and then purified by column chromatography. The product was once again taken up in dichloromethane (5 mL) and filtered over a short cotton pad to remove eluted silica. The filtrate was evaporated to yield the unprotected product.

(2S,3R,4S)-2-Isopropyl-4-(prop-1-en-2-yl)piperidin-3-ol ((R,S)-32a)




According to GP7A (R,S)-32a was prepared from (2S,3R,4S)-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (R,S)-30a (0.13 g, 0.34 mmol), potassium carbonate (0.09 g, 0.68 mmol) and thiophenol (0.04 g, 0.37 mmol) as a colorless oil (0.05 g, 0.25 mmol, 74 %). Purification was accomplished via column

chromatography on SiO₂ with dichloromethane/methanol (10 : 1 \Rightarrow 5 : 1). [α]_D²⁰ + 45 (c 1.0 in CHCl₃). R_f = 0.75 (dichloromethane/methanol, 5 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3335 (m, br), 3086 (m), 2958 (vs), 2870 (s), 1645 (m), 1469 (s), 1384 (m), 1304 (m), 1259 (m), 1201 (m), 1147 (m), 1119 (m), 1089 (m), 1065 (m), 988 (s), 946 (w), 886 (s), 807 (w), 772 (m), 624 (w), 522 (w), 485 (w), 420 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.94 (d, J = 6.7 Hz, 3H, 7-H/8-H), 1.00 (d, J = 6.7 Hz, 3H, 8-H/7-H), 1.38 – 1.47 (m, 1H, 2-H_a), 1.81 (s, 3H, 10-H), 1.84 (dddd, J = 12.6 Hz, 12.6 Hz, 12.6 Hz, 5.6 Hz, 1H, 2-H_b), 2.00 – 2.14 (m, 1H, 6-H), 2.19 (d, J = 12.6 Hz, 1H, 3H), 2.36 (s, br, 2H, OH, NH), 2.48 (dd, J = 10.7 Hz, 2.5 Hz, 1H, 5-H), 2.71 – 2.84 (m, 2H, 1-H), 3.93 (s, 1H, 4-H), 4.78 (s, 1H, 11-H_a), 4.92 – 4.98 (m, 1H, 11-H_b). 13 C-NMR (126 MHz, CDCl₃) δ 19.7 (C-7/C-8), 20.1 (C-8/C-7), 22.1 (C-10), 24.1 (C-2), 24.8

(C-6), 39.3 (C-1), 41.8 (C-3), 64.8 (C-5), 66.0 (C-4), 111.3 (C-11), 146.6 (C-9). HRMS (ESI): calc (found) for $C_{11}H_{21}NO$ ([M+H]⁺): 184.1696 (184.1692).


(2R,3S,4R)-2-Isopropyl-4-(prop-1-en-2-yl)piperidin-3-ol ((S,R)-32b)



According to GP7A (S,R)-32b was prepared from (2R,3S,4R)-2-Isopropyl-1-((2-nitrophenyl)-sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (S,R)-30b (52.0 mg, 141 µmol), potassium carbonate (39.0 mg, 282 µmol) and thiophenol (17.0 mg, 155 µmol) as a colorless oil (25.0 mg, 136 µmol, 96 %). Purification was accomplished via column

chromatography on SiO₂ with dichloromethane/methanol (10 : 1 → 5 : 1). $[\alpha]_D^{20}$ - 14 (*c* 1.0 in CHCl₃). R_f = 0.16 (dichloromethane/methanol, 10 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3328 (br, s), 2966 (vs), 2875 (s), 2502 (w), 1733 (m), 1646 (m), 1586 (vs), 1440 (vs), 1396 (s), 1375 (s), 1307 (s), 1265 (m), 1221 (m), 1197 (m), 1168 (m), 1143 (m), 1082 (m), 1063 (m), 1043 (m), 1016 (m), 989 (vs), 946 (w), 887 (s), 848 (w), 834 (m), 718 (w), 625 (m), 579 (m), 529 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.04 (d, J = 6.6 Hz, 3H, 7-H/8-H), 1.24 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.59 − 1.68 (m, 1H, 2-Ha), 1.78 (s, 3H, 10-H), 2.05 (dqq, J = 10.8 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 2.18 − 2.28 (m, 1H, 3-H), 2.36 (dddd, J = 13.2 Hz, 13.2 Hz, 13.2 Hz, 5.0 Hz, 1H, 2-Hb), 2.91 (ddd, J = 13.2 Hz, 13.2 Hz, 3.5 Hz, 1H, 1-Ha), 3.30 − 3.42 (m, 1H, 5-H), 3.45 − 3.59 (m, 1H, 1-Hb), 4.13 − 4.24 (m, 1H, 4-H), 4.79 (s, 1H, 11-Ha), 4.92 (s, 1H, 11-Hb). I C-NMR (176 MHz, CDCl₃) δ 19.5 (C-7/C-8), 20.6 (C-8/C-7), 20.8 (C-2), 21.8 (C-10), 25.1 (C-6), 39.1 (C-1), 39.7 (C-3), 65.2 (C-5), 65.3 (C-4), 112.3 (C-11), 144.4 (C-9). HRMS (ESI): calc (found) for C₁₁H₂₁NO ([M+H]⁺): 184.1696 (184.1696).

(2S,3R,4S)-2-((S)-sec-Butyl)-4-(prop-1-en-2-yl)piperidin-3-ol ((R,S)-32e)



According to GP7A (R,S)-32e was prepared from (2S,3R,4S)-2-((S)-sec-butyl)-1-((2-nitrophenyl)-sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (R,S)-30e (65.0 g, 0.17 mmol), potassium carbonate (47.0 mg, 0.34 mmol) and thiophenol (21.0 mg, 0.19 mmol) as a colorless solid (21.0 mg, 0.11 mmol, 62 %). Purification was

accomplished via column chromatography on SiO₂ with dichloromethane/methanol (10 : 1 \rightarrow 5 : 1). mp 55 °C. [α]_D²⁰ + 11 (c 0.46 in CHCl₃). R_f = 0.50 (dichloromethane/methanol, 5 : 1, ninhydrin solution). FT-IR (ATR): \tilde{v} = 3296 (br, w), 2966 (s), 2935 (s), 2878 (m), 1732 (w), 1647 (w), 1580 (m), 1454 (m), 1377 (m), 1307 (m), 1261 (m), 1218 (w), 1193 (w), 1141 (w), 1084 (m), 1067 (m), 1044 (m), 1018 (m), 985 (s), 957 (w), 802 (m), 728 (vs), 643 (m), 624 (m), 552 (w), 519 (w), 491 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.93 (t, J = 7.2 Hz, 3H, 8-H),

1.00 (d, J = 6.7 Hz, 3H, 9-H), 1.31 – 1.43 (m, 1H, 7-H_a), 1.59 – 1.69 (m, 1H, 2-H_a), 1.80 (s, 3H, 11-H), 1.82 – 1.95 (m, 2H, 6-H, 7-H_b), 2.21 – 2.29 (m, 1H, 3-H), 2.35 (dddd, J = 13.4 Hz, 13.4 Hz, 13.4 Hz, 4.7 Hz, 1H, 2-H_b), 2.93 (ddd, J = 13.4 Hz, 13.4 Hz, 3.3 Hz, 1H, 1-H_a), 3.35 –3.43 (m, 1H, 5-H), 3.43 – 3.52 (m, 1H, 1-H_b), 4.13 – 4.23 (m, 1H, 4-H), 4.81 (s, 1H, 12-H_a), 4.95 (s, 1H, 12-H_b). ¹³C-NMR (126 MHz, CDCl₃) δ 10.2 (C-8), 15.1 (C-9), 20.9 (C-2), 21.9 (C-11), 25.4 (C-7), 30.8 (C-6), 39.2 (C-1), 39.9 (C-3), 63.0 (C-5), 65.5 (C-4), 112.4 (C-12), 144.4 (C-10). HRMS (ESI): calc (found) for C₁₂H₂₃NO ([M+H]⁺): 198.1852 (198.1850).

(2S,3R,4S)-2-Benzyl-4-(prop-1-en-2-yl)piperidin-3-ol ((R,S)-32f)

According to GP7A (R,S)-32 \mathbf{f} was prepared from (2S,3R,4S)-2-benzyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (R,S)-30 \mathbf{f} (32.0 mg, 0.08 mmol), potassium carbonate (22.0 mg, 0.16 mmol) and thiophenol ($8.0 \, \mu L$, 9.00 mg, 0.08 mmol) as a colorless solid (19.0 mg, 0.08 mmol, quant). Purification was

accomplished via column chromatography on SiO₂ with dichloromethane/methanol (10 : 1 \Rightarrow 5 : 1). mp 147 °C. [α]_D²⁰ - 25 (c 0.2 in CHCl₃). R_f = 0.19 (dichloromethane /methanol, 10 : 1, ninhydrin solution). FT-IR (ATR): \tilde{v} = 3311 (w, br), 2932 (m), 2854 (m), 2476 (w), 1647 (w), 1580 (m), 1496 (m), 1454 (s), 1376 (m), 1312 (m), 1246 (m), 1179 (m), 1099 (m), 1057 (m), 1019 (m), 993 (m), 959 (w), 908 (s), 832 (w), 729 (vs), 645 (m), 625 (m), 585 (m), 543 (m), 489 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.61 – 1.70 (m, 1H, 2-H_a), 1.71 (s, 3H, 8-H), 2.23 – 2.35 (m, 1H, 2-H_b), 2.42 – 2.53 (m, 1H, 3-H), 2.88 – 2.98 (m, 1H, 6-H_a), 3.09 – 3.20 (m, 1H, 1-H_a), 3.37 – 3.50 (m, 2H, 1-H_b, 6-H), 3.76 – 3.84 (m, 1H, 4-H), 3.95 – 4.05 (m, 1H, 5-H), 4.77 (s, 1H, 9-H_a), 4.95 (s, 1H, 9-H_b), 7.22 – 7.34 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 21.1 (C-2), 21.8 (C-8), 33.6 (C-6), 39.1 (C-1), 39.8 (C-3), 59.3 (C-5), 64.6 (C-4), 112.6 (C-9), 127.3 (C-4'), 129.0 (C-3', C-5'), 129.1 (C-2', C-6'), 135.8 (C-1'), 144.2 (C-7). HRMS (ESI): calc (found) for C₁₅H₂₁NO ([M+H]⁺): 232.1696 (232.1703).


(2S,3S,4S)-2-Benzyl-4-(prop-1-en-2-yl)piperidin-3-ol ((S,S)-32f)

According to GP7A (S,S)-**32f** was prepared from (2S,3S,4S)-2-benzyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (S,S)-**30f** (58.0 mg, 0.14 mmol), potassium carbonate (39.0 mg, 0.28 mmol) and thiophenol (16.0μ L, 17.0 mg, 0.15 mmol) as a colorless solid (27.0 mg, 0.12 mmol, 86 %). Purification was

accomplished via column chromatography on SiO₂ with dichloromethane/methanol (10 : 1 \rightarrow 5 : 1). mp 213 °C. [α]_D²⁰ - 32 (c 1.0 in CHCl₃). $R_f = 0.20$ (dichloromethane/methanol, 10 : 1,

ninhydrin solution). FT-IR (ATR): $\tilde{v} = 3324$ (br, s), 3083 (s), 3061 (s), 3027 (s), 2939 (vs), 2849 (s), 2815 (vs), 2713 (s), 2570 (m), 2553 (m), 2486 (m), 1725 (w), 1642 (m), 1604 (m), 1583 (m), 1495 (m), 1445 (vs), 1409 (s), 1381 (s), 1315 (m), 1266 (m), 1199 (m), 1114 (m), 1092 (m), 1075 (m), 1053 (s), 1032 (s), 1018 (s), 1004 (s), 980 (m), 954 (m), 896 (s), 781 (w), 746 (s), 702 (vs), 637 (m), 586 (m), 543 (m), 526 (m), 467 (m), 419 (w) cm⁻¹. ¹H-NMR (700 MHz, CDCl₃) δ 1.51 (s, 3H, 8-H), 1.90 – 1.98 (m, 1H, 2-H_a), 2.41 –2.51 (m, 1H, 2-H_b), 2.54 – 2.60 (m, 1H, 3-H), 3.14 (ddd, J = 12.8 Hz, 12.8 Hz, 3.4 Hz, 1H, 1-H_a), 3.20 (dd, J = 13.0 Hz, 10.8 Hz, 1H, 6-H_a), 3.27 (dd, J = 13.0 Hz, 4.9 Hz, 1H, 6-H_b), 3.32 – 3.40 (m, 2H, 1-H_b, 5-H), 3.95 – 4.01 (m, 1H, 4-H), 4.59 (s, 1H, 9-H_a), 4.91 (s, 1H, 9-H_b), 7.20 – 7.25 (m, 1H, 4'-H), 7.27 – 7.31 (m, 2H, 3'-H, 5'-H), 7.31 – 7.35 (m, 2H, 2'-H, 6'-H). ¹³C-NMR (176 MHz, CDCl₃) δ 20.0 (C-2), 22.0 (C-8), 34.5 (C-6), 41.1 (C-1), 43.4 (C-3), 57.5 (C-5), 64.4 (C-4), 113.1 (C-9), 127.2 (C-4'), 128.9 (C-3', C-5'), 129.5 (C-2', C-6'), 135.5 (C-1'), 142.1 (C-7). HRMS (ESI): calc (found) for C₁₅H₂₁NO ([M+H]⁺): 232.1696 (232.1692).


(2S,3R,4R)-4-(2-Hydroxypropan-2-yl)-2-isopropylpiperidin-3-ol ((R,R)-33a)



According to GP7B (R,R)-33a was prepared from (2S,3R,4R)-4-(2-hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)piperidin-3-ol (R,R)-31a (89 mg, 0.23 mmol), diisopropylethylamine (59 mg, 0.46 mmol) and thiophenol (63 mg, 0.58 mmol) as a colorless solid (22 mg, 0.11 mmol, 48 %). Purification was accomplished via column

chromatography on SiO₂ with dichloromethane/methanol (5 : 1). mp 71 °C. $[\alpha]_D^{20} + 6$ (c 1.0 in CHCl₃). $R_f = 0.26$ (dichloromethane/methanol, 5 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 3288$ (br, s), 2970 (vs), 1738 (w), 1585 (s), 1465 (m), 1396 (m), 1377 (m), 1278 (w), 1171 (m), 1097 (w), 1063 (w), 989 (m), 912 (w), 849 (w), 808 (w), 730 (m), 644 (w), 572 (w), 525 (w), 426 (w), 415 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.01 (d, J = 6.4 Hz, 3H, 7-H/8-H), 1.21 (s, 3H, 10-H/11-H), 1.24 (d, J = 6.4 Hz, 3H, 8-H/7-H), 1.34 (s, 3H, 11-H/10-H), 1.42 – 1.50 (m, 1H, 3-H), 1.76 (d, J = 13.8 Hz, 1H, 2-H_a), 1.96 (dqq, J = 10.8 Hz, 6.4 Hz, 6.4 Hz, 1H, 6-H), 2.39 (dddd, J = 13.5 Hz, 13.5 Hz, 13.5 Hz, 4.5 Hz, 1H, 2-H_b), 2.90 (ddd, J = 13.5 Hz, 13.3 Hz, 3.3 Hz, 1H, 1-H_a), 3.31 (d, J = 10.8 Hz, 1H, 5-H), 3.49 – 3.59 (m, 1H, 1-H_b), 4.43 (s, br, 1H, OH), 4.49 (s, 1H, 4-H), 5.73 (s, br, 1H, OH). ¹³C-NMR (126 MHz, CDCl₃) δ 17.6 (C-2), 19.5 (C-7/C-8), 20.6 (C-8/C-7), 24.8 (C-6), 27.9 (C-10/C-11), 28.4 (C-11/C-10), 38.9 (C-1), 40.5 (C-3), 65.0 (C-5), 65.5 (C-4), 72.2 (C-9). HRMS (ESI): calc (found) for C₁₁H₂₃NO₂ ([M+H]⁺): 202.1802 (202.1801).


(2R,3S,4S)-4-(2-Hydroxypropan-2-yl)-2-isopropylpiperidin-3-ol ((S,S)-33b)



According to GP7B (S,S)-33b was prepared from (2R,3S,4S)-4-(2-hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)-piperidin-3-ol (S,S)-31b (50.0 mg, 0.13 mmol), diisopropylethylamine ($88.0 \, \mu L$, $67.0 \, \text{mg}$, $0.52 \, \text{mmol}$) and thiophenol ($67.0 \, \mu L$, $72.0 \, \text{mg}$, $0.65 \, \text{mmol}$) as a colorless solid ($15.0 \, \text{mg}$, $0.07 \, \text{mmol}$, $54 \, \%$).

Purification accomplished via column chromatography SiO_2 dichloromethane/methanol (10:1). mp 75 °C. $[\alpha]_D^{20}$ - 27 (c 0.33 in CHCl₃). $R_f = 0.49$ (dichloromethane/methanol, 5:1, ninhydrin solution). FT-IR (ATR): $\tilde{v} = 3321$ (br, s), 2968 (vs), 1585 (s), 1464 (s), 1395 (s), 1377 (s), 1309 (w), 1263 (m), 1169 (s), 1097 (m), 1076 (m), 1064 (m), 1007 (m), 988 (s), 911 (s), 849 (w), 834 (w), 807 (m), 729 (vs), 643 (s), 577 (m), 524 (s), 455 (m) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 1.03 (d, J = 6.4 Hz, 3H, 7-H/8-H), 1.23 (s, 3H, 10-H/11-H), 1.20 - 1.26 (d, J = 6.4 Hz, 3H, 8-H/7-H), 1.36 (s, 3H, 11-H/10-H), 1.43 - 1.51(m, 1H, 3-H), 1.72 - 1.82 (m, 1H, 2-H_a), 1.97 (dqq, <math>J = 11.0 Hz, 6.4 Hz, 6.4 Hz, 1H, 6-H), 2.34-2.50 (m, 1H, 2-H_b), 2.83 - 2.98 (m, 1H, 1-H_a), 3.38 (d, J = 11.0 Hz, 1H, 5-H), 3.54 - 3.64 (m, 1H, 1-H_b), 4.52 (s, 1H, 4-H), 8.34 (s, 1H, NH/OH), 8.80 (s, 1H, OH/NH). ¹³C-NMR (126 MHz, CDCl₃) δ 17.6 (C-2), 19.5 (C-7/C-8), 20.6 (C-8/C-7), 24.8 (C-6), 27.9 (C-10/C-11), 28.4 (C-11/C-10), 38.9 (C-1), 40.5 (C-3), 64.9 (C-5), 65.6 (C-4), 72.3 (C-9). HRMS (ESI): calc (found) for $C_{11}H_{23}NO_2$ ([M+H]⁺): 202.1802 (202.1802).

(2S,3R,4R)-2-((S)-sec-Butyl)-4-(2-hydroxypropan-2-yl)piperidin-3-ol ((R,R)-33e)



According to GP7B (R,R)-33e was prepared from (2S,3R,4R)-2-((S)-sec-butyl)-4-(2-hydroxypropan-2-yl)-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol (R,R)-31e (47.0 mg, 117 µmol), diisopropylethylamine (80 µL, 60 mg, 468 mmol) and thiophenol (59 µL, 64 mg, 585 mmol) as a colorless solid (16.0 mg, 74.0 µmol, 63 %). Purification was

accomplished via column chromatography on SiO₂ with dichloromethane/methanol (10 : 1 \rightarrow 5 : 1). mp 173 °C. [α]_D²⁰ - 12 (c 0.5 in CHCl₃). R_f = 0.35 (dichloromethane/methanol, 5 : 1, ninhydrin solution). FT-IR (ATR): \tilde{v} = 3337 (s, br), 2969 (vs), 2880 (s), 1588 (s), 1462 (s), 1382 (vs), 1283 (m), 1197 (m), 1164 (s), 1098 (m), 1066 (m), 983 (s), 953 (w), 912 (m), 838 (w), 809 (m), 785 (w), 730 (s), 643 (m), 557 (m), 499 (m) cm⁻¹. ¹H-NMR (700 MHz, CDCl₃) δ 0.94 (t, J = 7.4 Hz, 3H, 8-H), 0.97 (d, J = 6.7 Hz, 3H, 9-H), 1.22 (s, 3H, 11-H/12-H), 1.34 (s, 3H, 12-H/11-H), 1.34 – 1.40 (m, 1H, 7-H_a), 1.45 – 1.50 (m, 1H, 3-H), 1.72 – 1.82 (m, 2H, 2-H_a, 6-H), 1.82 – 1.91 (m, 1H, 7-H_b), 2.37 (dddd, J = 13.8 Hz, 13.8 Hz, 13.8 Hz, 4.7 Hz, 1H, 2-H_b),

2.85 - 2.97 (m, 1H, 1-H_a), 3.39 (d, J = 11.0 Hz, 1H, 5-H), 3.49 - 3.57 (m, 1H, 1-H_b), 4.45 - 4.55 (m, 1H, 4-H). ¹³C-NMR (176 MHz, CDCl₃) δ 10.2 (C-8), 15.0 (C-9), 17.6 (C-2), 25.3 (C-7), 27.9 (C-11/C-12), 28.3 (C-12/C-11), 30.3 (C-6), 38.9 (C-1), 40.4 (C-3), 63.0 (C-5), 65.5 (C-4), 72.2 (C-10). HRMS (ESI): calc (found) for $C_{12}H_{25}NO_2$ ([M+H]⁺): 216.1958 (216.1968).

(2S,4S)-2-Isopropyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-one

8 0 11 7 0 5 4 3 2 10 6' S, N 2 1' O 1 NO₂ (S)-S2a ((S)-S2a)

According to GP5 (*S*)-**S2a** was prepared from (2*S*,3*R*,4*S*)-2-isopropyl-4-(prop-1-en-2-yl)-piperidin-3-ol (*R*,*S*)-**30a** (0.11 g, 0.30 mmol) and DMP (0.32 g, 0.75 mmol) as a colorless solid (0.118 g, 0.32 mmol, quant) without further purification. mp 112 °C. $[\alpha]_D^{20}$ + 30 (*c* 1.0 in CHCl₃). R_f = 0.50 (hexanes/EtOAc,

3 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 3089$ (w), 2967 (m), 2929 (w), 2874 (w), 1716 (s), 1650 (w), 1590 (w), 1543 (vs), 1467 (m), 1440 (m), 1369 (vs), 1302 (m), 1251 (w), 1195 (w), 1161 (vs), 1126 (m), 1091 (m), 1061 (m), 1040 (w), 999 (m), 981 (s), 905 (s), 852 (m), 778 (s), 761 (m), 739 (m), 729 (m), 675 (w), 655 (m), 585 (s), 535 (w), 466 (w) cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ 0.89 (d, J = 6.7 Hz, 3H, 7-H/8-H), 0.95 (d, J = 6.7 Hz, 3H, 8-H/7-H), 1.54 (s, 3H, 10-H), 1.83 – 2.00 (m, 2H, 2-H), 2.22 (dqq, J = 10.8 Hz, 6.7 Hz, 6.7 Hz, 1H, 6-H), 3.17 (dd, J = 12.5 Hz, 6.4 Hz, 1H, 3-H), 3.52 (ddd, J = 15.3 Hz, 12.3 Hz, 3.4 Hz, 1H, 1-H_a), 3.88 (d, J = 10.8 Hz, 1H, 5-H), 4.11 – 4.19 (m, 1H, 1-H_b), 4.63 (s, 1H, 11-H_a), 4.90 (s, 1H, 11-H_b), 7.56 – 7.64 (m, 1H, 3'-H), 7.64 – 7.73 (m, 2H, 4'-H, 5'-H), 7.95 – 8.02 (m, 1H, 6'-H). ¹³C-NMR (176 MHz, CDCl₃) δ 18.6 (C-7/C-8), 19.4 (C-8/C-7), 20.2 (C-10), 28.0 (C-6), 31.4 (C-2), 40.7 (C-1), 53.6 (C-3), 71.8 (C-5), 114.4 (C-11), 124.0 (C-3'), 130.9 (C-6'), 131.9 (C-5'), 133.5 (C-1'), 133.8 (C-4'), 141.3 (C-9), 147.8 (C-2'), 204.4 (C-4). HRMS (ESI): calc (found) for C₁₇H₂₂N₂O₅S ([M+H]⁺): 367.1322 (367.1324).

(2R,4R)-2-Isopropyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-one ((R)-S2b)




According to GP5 (*R*)-**S2b** was prepared from (2R,3S,4R)-2-isopropyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (*S,R*)-**30b** (0.21 g, 0.56 mmol) and DMP (0.59 g, 1.40 mmol) as a colorless solid (0.17 g, 0.47 mmol, 84 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2:1). mp 124 °C. [α]_D²⁰ - 15 (*c* 1.0 in

CHCl₃). $R_f = 0.51$ (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 3091$ (w),

2927 (m), 2934 (w), 1717 (s), 1650 (w), 1590 (w), 1544 (vs), 1467 (m), 1440 (w), 1371 (vs), 1302 (w), 1195 (w), 1163 (vs), 1126 (m), 1091 (w), 1061 (w), 1040 (w), 981 (m), 905 (m), 852 (w), 778 (m), 761 (m), 740 (m), 728 (m), 675 (w), 655 (w), 585 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.89 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.94 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.53 (s, 3H, 10-H), 1.89 (dddd, J = 12.6 Hz, 12.6 Hz, 12.6 Hz, 4.7 Hz, 1H, 2-H_a), 1.91 – 1.99 (m, 1H, 2-H_b), 2.22 (dqq, J = 10.7 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 3.16 (dd, J = 12.6 Hz, 6.4 Hz, 1H, 3-H), 3.52 (ddd, J = 15.2 Hz, 12.6 Hz, 3.3 Hz, 1H, 1-H_a), 3.87 (d, J = 10.7 Hz, 1H, 5-H), 4.11 – 4.19 (m, 1H, 1-H_b), 4.62 (s, 1H, 11-H_a), 4.90 (s, 1H, 11-H_b), 7.57 – 7.63 (m, 1H, 3'-H), 7.64 – 7.73 (m, 2H, 4'-H, 5'-H), 7.94 –8.02 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 18.6 (C-7/C-8), 19.4 (C-8/C-7), 20.2 (C-10), 28.0 (C-6), 31.5 (C-2), 40.8 (C-1), 53.6 (C-3), 71.8 (C-5), 114.4 (C-11), 124.0 (C-3'), 131.0 (C-6'), 131.9 (C-5'), 133.5 (C-1'), 133.8 (C-4'), 141.2 (C-9), 147.8 (C-2'), 204.4 (C-4). HRMS (ESI): calc (found) for C₁₇H₂₂N₂O₅S ([M+Na]⁺): 389.1142 (389.1143).

$(2S,\!4S)\text{-}2\text{-}Isobutyl\text{-}1\text{-}((2\text{-}nitrophenyl)\text{sulfonyl})\text{-}4\text{-}(prop\text{-}1\text{-}en\text{-}2\text{-}yl)piperidin\text{-}3\text{-}one} \\ ((S)\text{-}S2c)$



According to GP5 (*S*)-**S2c** was prepared from (2*S*,4*S*)-2-isobutyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (*R*,*S*)-**30c** (60.0 mg, 0.16 mmol) and DMP (0.17 mg, 0.39 mmol) as a colorless solid (49.0 mg, 0.13 mmol, 82 %). Purification was accomplished via column chromatography on SiO₂ with hexanes/EtOAc (2:1). mp 136 °C. [α]_D²⁰ + 38 (*c* 1.0 in CHCl₃).

 $R_{\rm f} = 0.32$ (hexanes/EtOAc, 3 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 3091$ (w), 2958 (m), 2929 (w), 2871 (w), 1716 (s), 1650 (w), 1590 (w), 1542 (vs), 1468 (m), 1440 (m), 1369 (vs), 1297 (m), 1194 (w), 1160 (vs), 1126 (s), 1098 (m), 1061 (m), 1019 (m), 998 (w), 968 (s), 911 (s), 852 (m), 836 (w), 777 (m), 749 (s), 733 (s), 654 (m), 621 (w), 587 (vs), 573 (vs), 538 (w), 477 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.87 (d, J = 6.1 Hz, 3H, 8-H/9-H), 0.94 (d, J = 6.1 Hz, 3H, 9-H/8-H), 1.55 (s, 3H, 11-H), 1.56 – 1.64 (m, 2H, 6-H_a, 7-H), 1.66 – 1.76 (m, 1H, 6-H_b), 1.90 –1.98 (m, 2H, 2-H), 3.18 – 3.24 (m, 1H, 3-H), 3.50 – 3.62 (m, 1H, 1-H_a), 4.03 – 4.11 (m, 1H, 1-H_b), 4.34 – 4.41 (m, 1H, 5-H), 4.67 (s, 1H, 12-H_a), 4.91 (s, 1H, 12-H_b), 7.62 – 7.66 (m, 1H, 3-H'), 7.67 – 7.74 (m, 2H, 4-H', 5-H'), 8.03 – 8.06 (m, 1H, 6-H'). ¹³C-NMR (126 MHz, CDCl₃) δ 20.0 (C-11), 22.1 (C-8/C-9), 22.5 (C-9/C-8), 24.4 (C-7), 30.5 (C-2), 39.4 (C-6), 40.3 (C-1), 53.1 (C-3), 63.8 (C-5), 114.8 (C-12), 124.3 (C-3'), 131.1 (C-6'), 132.0 (C-5'), 133.4 (C-1'), 133.9 (C-4'), 141.4 (C-10), 147.9 (C-2'), 204.7 (C-4). HRMS (ESI): calc (found) for C₁₈H₂₄N₂O₅S ([M+H]⁺): 381.1479 (381.1474).

(2S,4S)-2-Benzyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-one ((S)-S2f)

According to GP5 (*S*)-S2f was prepared from a mixture of (2S,3R,4S)-2-benzyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-ol (*R,S*)-30f and (2*S*,3*S*,4*S*)-2-benzyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-ol (*S,S*)-30f (0.10 g, 0.24 mmol) and DMP (0.25 g, 0.60 mmol) as a colorless solid (0.10 g, 0.24 mmol, quant). mp 178 °C. [α]_D²⁰ + 108 (*c* 1.0 in CHCl₃). $R_f = 0.24$ (hexanes/EtOAc, 3 : 1, anisaldehyde solution).

FT-IR (ATR): $\tilde{v} = 3087$ (w), 3028 (w), 2930 (w), 2865 (w), 1717 (s), 1650 (w), 1590 (w), 1541 (vs), 1496 (w), 1455 (m), 1440 (m), 1368 (s), 1303 (m), 1251 (w), 1161 (vs), 1126 (s), 1100 (m), 1061 (m), 1030 (w), 1012 (w), 967 (s), 909 (m), 852 (m), 756 (s), 734 (s), 700 (s), 654 (m), 596 (s), 573 (s), 506 (w), 465 (w) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 1.64 (s, 3H, 8-H), 1.98 (ddt, J = 13.4 Hz, 6.1 Hz, 2.7 Hz, 1H, 2-H_a), 2.08 (ddt, J = 13.4 Hz, 12.6 Hz, 4.5 Hz, 1H, 2-H_b), 3.05 (dd, J = 13.9 Hz, 6.2 Hz, 1H, 6-H_a), 3.15 (dd, J = 13.9 Hz, 8.8 Hz, 1H, 6-H_b), 3.19 (dd, J = 12.6 Hz, 6.1 Hz, 1H, 3-H), 3.57 (ddd, J = 14.6 Hz, 12.5 Hz, 12.6 Hz, 11H, 1-H_a), 11H, 11H,

GP8: Conversion to diols with terminal alcohol

The reaction was performed according to the literature. A round bottom flask was charged with a solution of the alkene (0.15 mmol) in tetrahydrofuran (2 mL) under nitrogen atmosphere. Upon cooling to 0 °C a solution of borane (1 M in THF) was added dropwise and the mixture was stirred for 20 h at room temperature. Potassium hydroxide solution (200 μL, 0.60 mmol, 3 M in water) and hydrogen peroxide (2.0 mL, 0.60 mmol, 30 %) were added and stirring was continued for 10 min. Dichloromethane (17 mL) was added and the phases were separated. The aqueous phase was extracted with dichloromethane (3 × 8 mL) and the organic phases were dried over sodium sulfate. The crude product was purified by HPLC.

(2S,3S,4S)-4-((R)-1-Hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol ((S,S,R)-34a) and (2S,3S,4S)-4-((S)-1-Hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((S,S,S)-34a)

GP8 According (S,S,R)-34a to was prepared from (2S,4S)-2-isopropyl-1-((2nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)piperidin-3-one (S)-S2a (33.0 mg,90.0 µmol), borane-THF-solution (0.12 mL, 0.12 mmol, 1 M in THF), hydrogen peroxide (1.2 mL, 0.36 mmol, 30 %) and potassium hydroxide (20.0 mg, 0.36 mmol) as a colorless solid (6.00 mg, 16.0 µmol, 17 %). Diol (S,S,S)-34a was isolated as well as a colorless solid (8.00 mg, 21.0 µmol, 23 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (95:5), 15 mL / min, $R_t((S,S,R)-34a) = 56.5$ min, $R_t((S,S,S)-34a) = 93$ min).

(S,S,R)-34a, mp 58 °C. $[\alpha]_D^{20}$ + 96 (c 0.39 in CHCl₃). R_f = 0.34 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3277 (w, br), 2961 (m), 2930 (m), 2877 (m), 1590 (w), 1542 (vs), 1470 (m), 1440 (w), 1370 (s), 1344 (s), 1264 (w), 1204 (w), 1159 (vs), 1125 (m), 1079 (m), 1061 (m), 1017 (m), 993 (m), 953 (w), 911 (m), 884 (m), 852 (m), 778 (m), 764 (m), 730 (vs), 653 (m), 599 (vs), 571 (s), 530 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.63 (d,

J = 6.6 Hz, 3H, 7-H/8-H), 0.87 (d, J = 7.3 Hz, 3H, 10-H), 1.13 (d, J = 6.6 Hz, 3H, 8-H, 7-H), 1.41 (dddd, J = 13.0 Hz, 13.0 Hz, 13.0 Hz, 5.1 Hz 1H, 2-H_a), 1.52 – 1.63 (m, 1H, 2-H_b), 1.87 – 2.00 (m, 2H, 3-H, 9-H), 2.16 (dqq, J = 9.8 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 2.98 (ddd, J = 13.0 Hz, 13.0 Hz, 2.8 Hz, 1H, 1-H_a), 3.54 (dd, J = 10.6 Hz, 2.8 Hz, 1H, 11-H_a), 3.63 (dd, J = 10.6 Hz, 6.3 Hz, 1H, 11-H_b), 3.71 (dd, J = 9.8 Hz, 4.9 Hz, 1H, 5-H), 3.83 (dd, J = 10.9 Hz, 4.9 Hz, 1H, 4-H), 3.88 – 3.97 (m, 1H, 1-H_b), 7.59 – 7.65 (m, 1H, 3'-H), 7.65 – 7.72 (m, 2H, 4'-H, 5'-H), 8.04 – 8.12 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 12.2 (C-10), 20.5 (C-7/C-8), 22.1 (C-8/C-7), 25.7 (C-6), 28.8 (C-2), 37.0 (C-3), 40.4 (C-9), 41.4 (C-1), 63.7 (C-5), 66.1 (C-11), 72.4 (C-4), 124.1 (C-3'), 130.8 (C-6'), 131.8 (C-5'), 133.3 (C-4'), 134.6 (C-1'), 147.4 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₆S ([M+Na]⁺): 409.1404 (409.1404).


(S,S,S)-34a

(S,S,S)-34a, mp 165 °C. $[\alpha]_D^{20}$ + 130 (c 0.24 in CHCl₃). R_f = 0.25 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3366 (w, br), 2961 (m), 2878 (m), 1590 (w), 1544 (vs), 1471 (m), 1440 (w), 1372 (s), 1345 (s), 1267 (m), 1160 (s), 1125 (m), 1080 (m), 1024 (m), 985 (m), 946 (w), 912 (m), 891 (w), 852 (w), 764 (m), 736 (m), 653 (m), 600 (vs), 571 (m) cm⁻¹. ¹H-NMR (500 MHz,

CDCl₃) δ 0.66 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.77 (d, J = 6.9 Hz, 3H, 10-H), 1.14 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.29 (dddd, J = 13.0 Hz, 13.0 Hz, 13.0 Hz, 5.2 Hz, 1H, 2-H_a), 1.54 – 1.62 (m, 1H, 2-H_b), 1.95 – 2.13 (m, 4H, 3-H, 9-H, 2xOH), 2.19 (dqq, J = 9.8 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 2.98 (ddd, J = 13.0 Hz, 13.0 Hz, 2.9 Hz, 1H, 1-H_a), 3.47 (dd, J = 10.5 Hz, 7.8 Hz, 1H, 11-H_a), 3.60 (dd, J = 10.5 Hz, 5.2 Hz, 1H, 11-H_b), 3.70 (dd, J = 9.8 Hz, 4.9 Hz, 1H, 5-H), 3.85 (dd, J = 11.1 Hz, 4.9 Hz, 1H, 4-H), 3.87 – 3.95 (m, 1H, 1-H_b), 7.58 – 7.64 (m, 1H, 3'-H), 7.64 – 7.73 (m, 2H, 4'-H, 5'-H), 8.02 – 8.10 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 11.9 (C-10), 20.5 (C-7/C-8), 22.3 (C-8/C-7), 25.7 (C-6), 26.1 (C-2), 34.8 (C-9), 37.3 (C-3), 41.4 (C-1), 63.8 (C-5), 66.0 (C-11), 73.0 (C-4), 124.1 (C-3'), 130.7 (C-6'), 131.7 (C-5'), 133.2 (C-4'), 134.7 (C-1'), 147.5 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₆S ([M+Na]⁺): 409.1404 (409.1406).

(2S,3R,4S)-4-((S)-1-Hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol ((R,S,S)-34a und (2S,3R,4S)-4-((R)-1-Hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((R,S,R)-34a)

According to GP8 (R,S,S)-34a was prepared from (2S,3R,4S)-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (R,S)-30a (55.0 mg, 150 µmol), borane-THF-solution (0.2 mL, 0.20 mmol, 1 M in THF), hydrogen peroxide (2.0 mL, 0.60 mmol, 30 %) and potassium hydroxide (34.0 mg, 0.60 mmol) as a colorless solid (18.0 mg, 47.0 µmol, 31 %). Diol (R,S,R)-34a was isolated as well as a colorless solid (6.00 mg, 16.0 µmol, 11 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (95 : 5), 15 mL / min, Rt ((R,S,S)-34a) = 122 min, Rt ((R,S,R)-34a) = 134 min).




(R,S,S)-34a

(R,S,S)-34a, mp 138 °C. $[\alpha]_D^{20}$ + 154 (c 1.0 in CHCl₃). R_f = 0.24 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3539 (w), 3355 (w), 2964 (m), 2929 (m), 2877 (m), 1542 (vs), 1470 (m), 1439 (w), 1372 (s), 1335 (s), 1281 (w), 1207 (w), 1158 (s), 1125 (m), 1066 (m), 1044 (m), 970 (s), 913 (s), 853 (m), 778 (w), 751 (s), 734 (s), 685 (w), 663 (w), 651 (w), 620 (w), 578 (s), 560 (m) cm⁻¹.

¹H-NMR (500 MHz, CDCl₃) δ 0.72 (d, J = 6.8 Hz, 3H, 7-H/8-H), 0.93 – 1.00 (m, 6H, 8-H/7-H, 10-H), 1.36 – 1.45 (m, 1H, 2-H_a), 1.54 – 1.61 (m, 1H, 3-H), 1.61 – 1.69 (m, 1H, 9-H), 1.69 (dddd, J = 12.7 Hz, 12.7 Hz, 12.7 Hz, 4.9 Hz, 1H, 2-H_b), 2.01 (dqq, J = 11.0 Hz, 6.8 Hz, 6.8 Hz, 1H, 6-H), 2.84 (br, s, 2H, 2xOH), 3.10 (ddd, J = 15.3 Hz, 12.7 Hz, 2.7 Hz, 1H, 1-H_a), 3.50 (dd, J = 11.2 Hz, 5.2 Hz, 1H, 11-H_a), 3.55 (d, J = 11.0 Hz, 1H, 5-H), 3.65 (dd, J = 11.2 Hz, 3.0 Hz, 1H, 11-H_b), 4.00 – 4.08 (m, 1H, 1-H_b), 4.12 – 4.18 (m, 1H, 4-H), 7.52 – 7.59 (m, 1H, 3'-H), 7.61 – 7.70 (m, 2H, 4'-H, 5'-H), 8.08 – 8.16 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 15.4

(C-10), 19.9 (C-7/C-8), 20.2 (C-8/C-7), 24.3 (C-2), 26.7 (C-6), 37.3 (C-9), 38.3 (C-3), 42.2 (C-1), 64.6 (C-11), 64.8 (C-4), 66.9 (C-5), 123.8 (C-3'), 131.0 (C-6'), 131.6 (C-5'), 133.3 (C-4'), 134.7 (C-1'), 147.7 (C-2'). HRMS (ESI): calc (found) for $C_{17}H_{26}N_2O_6S$ ([M+H]⁺): 387.1584 (387.1586).




(R,S,R)-34a, mp 41 °C. $[\alpha]_D^{20}$ + 129 (c 1.0 in CHCl₃). R_f = 0.24 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3547 (w), 3345 (w), 2963 (m), 2927 (m), 2876 (m), 1543 (vs), 1469 (m), 1440 (w), 1372 (s), 1336 (s), 1281 (w), 1159 (s), 1125 (m), 1076 (m), 1046 (m), 995 (w), 967 (m), 912 (m), 853 (w), 778 (w), 751 (m), 734 (m), 652 (w), 581 (m), 560 (m) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃)

 δ 0.71 (d, J = 6.8 Hz, 3H, 7-H/8-H), 0.96 (d, J = 6.8 Hz, 3H, 8-H/7-H), 0.97 (d, J = 6.6 Hz, 3H, 10-H), 1.43 – 1.54 (m, 1H, 2-H_a), 1.63 (dddd, J = 12.7 Hz, 12.7 Hz, 12.7 Hz, 4.4 Hz, 1H, 2-H_b), 1.62 – 1.70 (m, 1H, 3-H), 1.70 – 1.80 (m, 1H, 9-H), 2.02 (dqq, J = 10.7 Hz, 6.8 Hz, 6.8 Hz, 1H, 6-H), 2.94 (s, br, 2H, 2xOH), 3.05 – 3.18 (m, 1H, 1-H_a), 3.45 (dd, J = 11.1 Hz, 4.2 Hz, 1H, 11-H_a), 3.49 (dd, J = 11.1 Hz, 6.4 Hz, 1H, 11-H_b), 3.53 (d, J = 10.7 Hz, 1H, 5-H), 4.01 (s, 1H, 4-H), 4.04 – 4.13 (m, 1H, 1-H_b), 7.53 – 7.60 (m, 1H, 3'-H), 7.60 – 7.70 (m, 2H, 4'-H, 5'-H), 8.05 – 8.15 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 16.3 (C-10), 19.8 (C-7/C-8), 20.3 (C-8/C-7), 21.4 (C-2), 26.7 (C-6), 37.6 (C-9), 38.1 (C-3), 42.3 (C-1), 64.5 (C-11), 67.1 (C-5), 67.1 (C-4), 123.8 (C-3'), 130.9 (C-6'), 131.6 (C-5'), 133.3 (C-4'), 134.7 (C-1'), 147.7 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₆S ([M+H]⁺): 387.1584 (387.1583).

(2R,3R,4S)-4-((S)-1-Hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((R,R,S)-34b), (2R,3R,4R)-4-((R)-1-Hydroxypropan-2-yl)-2-isopropyl-1-((2-R)-1-Hydroxypropyl-1-((2-R)-1-Hydroxypropyl-1-((2-R)-1-Hydroxypropyl-1-((2-R)-1-Hydroxypropyl-1-((2-R)-1-Hydroxypropyl-1-((2-R)-1-Hydroxypropyl-1-((2-R)-1-Hydroxypropyl-1-((2-R)-1nitrophenyl)sulfonyl)-piperidin-3-ol (2R,3S,4R)-4-((S)-1-((R,R,R)-34b)and Hydroxypropan-2-yl)-2-isopropyl-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((S,R,S)-34b) According to GP8 (R,R,S)-34b was prepared from (2R,4R)-2-isopropyl-1-((2nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-one (R)-**S2b** (0.15 g, 0.40 mmol), borane solution (0.54 mL, 0.54 mmol, 1 M in THF), potassium hydroxide (91 mg, 1.62 mmol) and hydrogen peroxide (5.4 mL, 1.62 mmol, 30 %) as a colorless oil (59.0 mg, 0.15 mmol, 38 %). Diol (R,R,R)-34b was isolated as a colorless solid (56.0 mg, 0.15 mmol, 36 %) and Diol (S,R,S)-34b was isolated as a colorless oil (12.0 mg, 31 µmol, 8 %). Purification was accomplished by HPLC (Orbit, hexanes/EtOAc (40 : 60), 15 mL/min, R_t ((R,R,S)-34b) = 26 min, R_t ((R,R,R)-**34b**) = 32 min, R_t ((S,R,S)-**34b**) = 39.5 min).

(R,R,S)-34b, $[\alpha]_D^{20}$ - 119 (*c* 1.0 in CHCl₃). R_f = 0.38 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3276 (br, w), 2961 (m), 2877 (m), 1591 (w), 1542 (vs), 1470 (m), 1440 (w), 1370 (s), 1343 (s), 1262 (m), 1204 (w), 1158 (s), 1125 (m), 1079 (s), 1060 (m), 1017 (m), 992 (s), 953 (m), 910 (s), 884 (m), 852 (m), 778 (m), 764 (s), 728 (vs), 653 (m), 598 (vs), 570 (s),

530 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.62 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.86 (d, J = 7.2 Hz, 3H, 10-H), 1.12 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.40 (dddd, J = 13.0 Hz, 13.0 Hz, 13.0 Hz, 5.2 Hz, 1H, 2-H_a), 1.52 – 1.61 (m, 1H, 2-H_b), 1.85 (br, s, 1H, OH), 1.88 – 1.97 (m, 2H, 3-H, 9-H), 2.15 (dqq, J = 9.8 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 2.98 (ddd, J = 14.6 Hz, 13.0 Hz, 3.1 Hz, 1H, 1-H_a), 3.53 (dd, J = 10.6 Hz, 3.2 Hz, 1H, 11-H_a), 3.61 (dd, J = 10.6 Hz, 6.0 Hz, 1H, 11-H_b), 3.70 (dd, J = 9.8 Hz, 5.0 Hz, 1H, 5-H), 3.82 (dd, J = 11.1 Hz, 5.0 Hz, 1H, 4-H), 3.86 – 3.95 (m, 1H, 1-H_b), 7.58 – 7.64 (m, 1H, 3'-H), 7.64 – 7.71 (m, 2H, 4'-H, 5'-H), 8.03 – 8.10 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 12.2 (C-10), 20.5 (C-7/C-8), 22.1 (C-8/C-7), 25.7 (C-6), 28.8 (C-2), 37.1 (C-3), 40.4 (C-9), 41.4 (C-1), 63.7 (C-5), 66.1 (C-11), 72.3 (C-4), 124.1 (C-3'), 130.8 (C-6'), 131.8 (C-5'), 133.3 (C-4'), 134.6 (C-1'), 147.4 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₆S ([M+H]⁺): 387.1584 (387.1585).



(R,R,R)-34b

(R,R,R)-34b, mp 167 °C. $[\alpha]_D^{20}$ - 107 (c 1.0 in CHCl₃). R_f = 0.27 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3366 (br, w), 2961 (m), 2878 (m), 1590 (w), 1543 (vs), 1471 (w), 1440 (w), 1372 (s), 1345 (s), 1268 (w), 1159 (s), 1125 (m), 1080 (m), 1024 (m), 1002 (m), 985 (m), 947 (w), 912 (m), 891 (w), 853 (w), 764 (m), 736 (m), 653 (m), 600 (vs), 571 (m) cm⁻¹. 1 H-NMR

(500 MHz, CDCl₃) δ 0.65 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.76 (d, J = 7.0 Hz, 3H, 10-H), 1.13 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.28 (dddd, J = 13.1 Hz, 13.1 Hz, 13.1 Hz, 5.0 Hz, 1H, 2-H_a), 1.53 – 1.60 (m, 1H, 2-H_b), 1.64 (s, 1H, OH), 1.95 – 2.11 (m, 2H, 3-H, 9-H), 2.18 (dqq, J = 9.9 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 2.98 (ddd, J = 14.5 Hz, 13.1 Hz, 3.0 Hz, 1H, 1-H_a), 3.47 (dd, J = 10.5 Hz, 7.7 Hz, 1H, 11-H_a), 3.59 (dd, J = 10.5 Hz, 5.3 Hz, 1H, 11-H_b), 3.69 (dd, J = 9.9 Hz, 5.0 Hz, 1H, 5-H), 3.84 (dd, J = 11.1 Hz, 5.0 Hz, 1H, 4-H), 3.87 – 3.95 (m, 1H, 1-H_b), 7.57 – 7.64 (m, 1H, 3'-H), 7.64 – 7.71 (m, 2H, 4'-H, 5'-H), 8.00 – 8.10 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 11.9 (C-10), 20.5 (C-7/C-8), 22.3 (C-8/C-7), 25.7 (C-2), 26.1 (C-6), 34.8 (C-9), 37.3 (C-3), 41.4 (C-1), 63.9 (C-5), 66.0 (C-11), 73.0 (C-4), 124.1 (C-3'), 130.7 (C-6'),

131.7 (C-5'), 133.2 (C-4'), 134.1 (C-1'), 147.5 (C-2'). HRMS (ESI): calc (found) for $C_{17}H_{26}N_2O_6S$ ([M+H]⁺): 387.1584 (387.1589).

(S,R,S)-34b

(S,R,S)-34b, $[\alpha]_D^{20}$ - 129 (c 0.62 in CHCl₃). R_f = 0.22 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3335 (br, w), 2961 (m), 2927 (m), 2876 (m), 1591 (w), 1542 (vs), 1468 (m), 1439 (w), 1371 (s), 1334 (s), 1281 (m), 1211 (w), 1157 (s), 1124 (s), 1075 (m), 1063 (m), 1045 (m), 994 (m), 966 (s), 910 (vs), 852 (m), 810 (w), 777 (m), 751 (s), 731 (vs), 687 (w), 651 (m),


628 (w), 580 (vs), 560 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.70 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.95 (d, J = 7.0 Hz, 3H, 10-H), 0.96 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.40 – 1.52 (m, 1H, 2-H_a), 1.62 (dddd, J = 12.6 Hz, 12.6 Hz, 12.6 Hz, 4.5 Hz, 1H, 2-H_b), 1.62 – 1.70 (m, 1H, 3-H), 1.70 – 1.80 (m, 1H, 9-H), 2.02 (dqq, J = 10.8 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 2.90 – 3.30 (m, 2H, 1-H_a, OH), 3.44 (dd, J = 11.1 Hz, 4.4 Hz, 1H, 11-H_a), 3.47 (dd, J = 11.1 Hz, 6.6 Hz, 1H, 11-H_b), 3.51 – 3.57 (m, 1H, 5-H), 4.00 (s, 1H, 4-H), 4.02 – 4.10 (m, 1H, 1-H_b), 7.53 – 7.59 (m, 1H, 3'-H), 7.62 – 7.70 (m, 2H, 4'-H, 5'-H), 8.06 – 8.15 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 16.3 (C-10), 19.8 (C-7/C-8), 20.3 (C-8/C-7), 21.3 (C-2), 26.7 (C-6), 37.6 (C-9), 38.2 (C-3), 42.3 (C-1), 64.4 (C-11), 67.0 (C-5), 67.1 (C-4), 123.8 (C-3'), 130.9 (C-6'), 131.6 (C-5'), 133.3 (C-4'), 134.7 (C-1'), 147.7 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₆S ([M+H]⁺): 387.1584 (387.1583).

(2S,3S,4S)-4-((R)-1-Hydroxypropan-2-yl)-2-isobutyl-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol ((S,S,R)-34c) and (2S,3S,4S)-4-((S)-1-Hydroxypropan-2-yl)-2-isobutyl-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((S,S,S)-34c)

According to GP8 (S,S,R)-34c was prepared from (2S,4S)-2-isobutyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-one (S)-S2c (43.0 mg, 0.11 mmol), borane-THF-solution (0.15 mL, 1 M in THF, 0.15 mmol), potassium hydroxide (25.0 mg, 0.44 mmol) and hydrogen peroxide (1.46 mL, 30 % in water, 0.44 mmol) as a colorless solid (13.0 mg, 0.03 mmol, 20 %). Diol (S,S,S)-34c was isolated as well as a colorless solid (9.00 mg, 0.02 mmol, 29 %). Purification was accomplished by HPLC (Orbit, hexane/isopropanol (90:10), 15 mL / min, R_t ((S,S,S)-34c) = 35 min, R_t ((S,S,S)-34c) = 43 min).

(S,S,R)-34c, mp 48 °C. [α]_D²⁰ + 138 (c 0.1 in CHCl₃). R_f = 0.26 (hexanes/EtOAc, 1 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 2956 (m), 2924 (m), 2872 (m), 1543 (vs), 1467 (m), 1439 (w), 1371 (s), 1339 (s), 1268 (m), 1210 (w), 1161 (s), 1125 (m), 1067 (m), 1038 (m), 996 (m), 939 (m), 926 (m), 852 (m), 779 (w), 747 (m), 733 (m), 680 (w), 652 (w), 619 (w), 577 (m), 526 (w) cm⁻¹. ¹H-

NMR (500 MHz, CDCl₃) δ 0.85 (d, J = 6.2 Hz, 3H, 8-H/9-H), 0.88 (d, J = 6.2 Hz, 3H, 9-H/8-H), 0.96 (d, J = 7.1 Hz, 3H, 11-H), 1.35 – 1.43 (m, 1H, 6-H_a), 1.46 – 1.58 (m, 3H, 2-H_a, 6-H_b, 7-H), 1.60 – 1.69 (m, 2H, 2-H_b, 3-H), 1.70 – 1.80 (m, 1H, 10-H), 3.13 –3.23 (m, 1H, 1-H_a), 3.47 (dd, J = 11.1 Hz, 4.4 Hz, 1H, 12-H_a), 3.50 (dd, J = 11.1 Hz, 6.3 Hz, 1H, 12-H_b), 3.70 – 3.75 (m, 1H, 4-H), 3.92 – 4.03 (m, 2H, 1-H_b, 5-H), 7.57 – 7.64 (m, 1H, 3'-H), 7.64 – 7.71 (m, 2H, 4'-H, 5'-H), 8.10 – 8.16 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 16.3 (C-11), 21.2 (C-2), 22.6 (C-8/C-9), 22.7 (C-9/C-8), 24.9 (C-3), 37.5 (C-10), 37.8 (C-7), 38.0 (C-6), 41.5 (C-1), 58.8 (C-5), 64.5 (C-12), 69.3 (C-4), 124.1 (C-3'), 131.1 (C-6'), 131.7 (C-5'), 133.4 (C-4'), 134.1 (C-1'), 147.8 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₄N₂O₅S ([M+H]⁺): 401.1741 (401.1742).




(S,S,S)-34c

(S,S,S)-34c, mp 172 °C. [α]_D²⁰ + 14 (c 0.2 in CHCl₃). R_f = 0.21 (hexanes/EtOAc, 1 : 1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3346 (m, br), 2956 (s), 2926 (s), 1545 (vs), 1467 (m), 1439 (m), 1372 (s), 1269 (m), 1163 (s), 1125 (m), 1079 (m), 1038 (m), 998 (w), 942 (m), 852 (w), 780 (w), 748 (m), 731 (m), 652 (w), 595 (s), 568 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.74 (d, J = 5.9 Hz,

3H, 8-H/9-H), 0.76 (d, J = 7.1 Hz, 3H, 11-H), 0.85 (d, J = 5.9 Hz, 3H, 9-H/8-H), 1.17 – 1.29 (m, 1H, 2-H_a), 1.39 – 1.50 (m, 2H, 6-H_a, 7-H), 1.52 – 1.61 (m, 2H, 2-H_b, 6-H_b), 1.80 – 1.89 (m, 1H, 3-H), 1.92 – 2.01 (m, 1H, 10-H), 3.05 – 3.15 (m, 1H, 1-H_a), 3.47 (dd, J = 10.4 Hz, 7.8 Hz, 1H, 12-H_a), 3.60 (dd, J = 10.4 Hz, 5.3 Hz, 1H, 12-H_b), 3.72 (dd, J = 11.0 Hz, 5.4 Hz, 1H, 4-H), 3.79 – 3.86 (m, 1H, 1-H_b), 4.05 – 4.13 (m, 1H, 5-H), 7.60 – 7.66 (m, 1H, 3'-H), 7.66 – 7.73 (m, 2H, 4'-H, 5'-H), 8.07 – 8.13 (m, 1H, 6'-H). ¹³C-NMR (176 MHz, CDCl₃) δ 12.1 (C-11), 21.4 (C-8/C-9), 24.0 (C-9/C-8), 24.2 (C-7), 25.8 (C-2), 32.8 (C-6), 35.2 (C-10), 37.3 (C-3), 40.1 (C-1), 56.5 (C-5), 66.1 (C-12), 70.4 (C-4), 124.3 (C-3'), 131.0 (C-6'), 131.7 (C-5'), 133.4 (C-4'), 134.4 (C-1'), 147.8 (C-2'). HRMS (ESI): calc (found) for C₁₈H₂₄N₂O₅S ([M+Na]⁺): 423.1560 (423.1562).

(2S,3S,4S)-2-Benzyl-4-((R)-1-hydroxypropan-2-yl)-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((S,S,R)-34f), (2S,3R,4S)-2-Benzyl-4-((S)-1-hydroxypropan-2-yl)-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol ((R,S,S)-34f), (2S,3S,4S)-2-Benzyl-4-((S)-1-hydroxypropan-2-yl)-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((S,S,S)-34f) and (2S,3R,4S)-2-Benzyl-4-((R)-1-hydroxypropan-2-yl)-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol ((R,S,R)-34f)

According GP8 (S,S,R)-34f prepared from (2S,4S)-2-benzyl-1-((2was nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-one (S)-**S2f** (0.16 g, 0.39 mmol), boranesolution (0.52 mL, 0.52 mmol, 1 M in THF), potassium hydroxide (88.0 mg, 1.56 mmol) and hydrogen peroxide (5.2 mL, 53.0 mg, 1.56 mmol, 30 %) as a colorless solid (35.0 mg, 31.0 µmol, 21 %). Diols (R,S,S)-34f, (S,S,S)-34f and (R,S,R)-34f were isolated as well as colorless solids ((*R*,*S*,*S*)-**34f**, 5.00 mg, 12.0 µmol, 3 %; (*S*,*S*,*S*)-**34f**, 26.0 mg, 60.0 µmol, 15 %; (R,S,R)-34f, 17.0 mg, 39.0 µmol, 10 %). Purification was accomplished by HPLC (Orbit, hexanes/EtOAc (40 : 60), 12 mL/min, R_t ((S,S,R)-34f) = 27 min, R_t ((R,S,S)-34f) = 30.5 min and Orbit, hexanes/isopropanol (90 : 10), 15 mL/min, R_t ((S,S,S)-34f) = 22 min, R_t ((R,S,R)-34f) = 45 min).



(S,S,R)-34f

(S,S,R)-34f, mp 60 °C. $[\alpha]_D^{20}$ + 158 (c 1.0 in CHCl₃). R_f = 0.35 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3279 (br, w), 3029 (w), 2937 (w), 2880 (w), 1592 (w), 1539 (vs), 1497 (w), 1455 (m), 1440 (m), 1366 (s), 1336 (s), 1263 (w), 1199 (w), 1157 (s), 1126 (s), 1067 (m), 1009 (m), 953 (s), 909 (s), 870 (m), 852 (m), 834 (w), 777 (w), 755 (s), 729 (vs), 699 (vs), 650 (m), 590 (vs), 570 (s), 503 (m), 462 (w) cm⁻¹. 1 H-NMR (500 MHz,

CDCl₃) δ 0.99 (d, J = 7.3 Hz, 3H, 8-H), 1.59 (dddd, J = 12.9 Hz, 12.9 Hz, 12.9 Hz, 4.9 Hz, 1H, 2-H_a), 1.64 – 1.71 (m, 1H, 2-H_b), 1.73 (s, br, 1H, OH), 1.90 – 2.02 (m, 2H, 3-H, 7-H), 2.78 (dd, J = 14.3 Hz, 11.5 Hz, 1H, 6-H_a), 3.12 (dd, J = 14.3 Hz, 3.1 Hz, 1H, 6-H_b), 3.29 – 3.38 (m, 1H, 1-H_a), 3.63 (dd, J = 10.5 Hz, 3.1 Hz, 1H, 9-H_a), 3.74 (dd, J = 10.5 Hz, 5.8 Hz, 1H, 9-H_b), 3.92 (dd, J = 11.0 Hz, 5.5 Hz, 1H, 4-H), 3.96 – 4.03 (m, 1H, 1-H_b), 4.30 (ddd, J = 11.5 Hz, 5.5 Hz, 3.1 Hz, 1H, 5-H), 6.82 – 6.92 (m, 3H, 3'-H, 4'-H, 5'-H), 6.96 – 7.03 (m, 2H, 2'-H, 6'-H), 7.21 – 7.28 (m, 1H, 5"-H), 7.31 – 7.38 (m, 1H, 6"-H), 7.40 – 7.50 (m, 2H, 3"-H, 4"-H). ¹³C-NMR (176 MHz, CDCl₃) δ 12.1 (C-8), 29.7 (C-2), 29.9 (C-6), 37.4 (C-7), 40.7 (C-1, C-3), 61.5 (C-5), 66.4 (C-9), 70.3 (C-4), 124.1 (C-3"), 126.2 (C-4'), 128.0 (C-3', C-5'), 129.2 (C-2', C-6'), 130.6 (C-6"), 131.9 (C-5"), 132.6 (C-4"), 134.1 (C-1"), 138.7 (C-1'), 147.0 (C-2"). HRMS (ESI): calc (found) for C₂₁H₂₆N₂O₆S ([M+Na]⁺): 457.1404 (457.1404).

(S,S,S)-34f, mp 183 °C. [α]_D²⁰ + 150 (c 1.0 in CHCl₃). R_f = 0.29 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3530 (w), 3365 (br, w), 3091 (w), 3027 (w), 2957 (m), 2930 (m), 2881 (w), 1591 (w), 1541 (vs), 1497 (w), 1454 (m), 1441 (m), 1371 (s), 1336 (s), 1268 (w), 1159 (vs), 1126 (m), 1074 (m), 1032 (m), 955 (s), 911 (m), 881 (w), 852 (m), 834 (w), 779 (w), 756 (s), 735 (s), 700 (m), 651 (w), 593 (s), 568 (m), 500 (w) cm⁻¹. ¹H-NMR

(500 MHz, CDCl₃) δ 0.91 (d, J = 6.9 Hz, 3H, 8-H), 1.45 (dddd, J = 13.0 Hz, 13.0 Hz, 13.0 Hz, 4.9 Hz, 1H, 2-H_a), 1.56 (s, 1H, OH), 1.70 – 1.77 (m, 1H, 2-H_b), 1.95 – 2.10 (m, 2H, 3-H, 7-H), 2.81 (dd, J = 14.2 Hz, 11.3 Hz, 1H, 6-H_a), 3.11 (dd, J = 14.2 Hz, 3.3 Hz, 1H, 6-H_b), 3.28 – 3.37 (m, 1H, 1-H_a), 3.56 (dd, J = 10.5 Hz, 7.8 Hz, 1H, 9-H_a), 3.70 (dd, J = 10.5 Hz, 4.8 Hz, 1H, 9-H_b), 3.94 (dd, J = 10.9 Hz, 5.4 Hz, 1H, 4-H), 3.96 – 4.02 (m, 1H, 1-H_b), 4.29 (ddd, J = 11.3 Hz, 5.4 Hz, 3.3 Hz, 1H, 5-H), 6.84 – 6.94 (m, 3H, 3'-H, 4'-H, 5'-H), 6.98 – 7.04 (m, 2H, 2'-H, 6'-H), 7.26 – 7.31 (m, 1H, 5"-H), 7.35 – 7.41 (m, 1H, 6"-H), 7.42 – 7.50 (m, 2H, 3"-H, 4"-H). ¹³C-NMR (126 MHz, CDCl₃) δ 12.5 (C-8), 27.1 (C-2), 30.1 (C-6), 35.6 (C-7), 38.0 (C-3), 40.6 (C-1), 61.6 (C-5), 66.1 (C-9), 71.4 (C-4), 124.2 (C-3"), 126.3 (C-4'), 128.1 (C-3', C-5'), 129.2 (C-2', C-6'), 130.6 (C-6"), 131.8 (C-5"), 132.7 (C-4"), 134.1 (C-1"), 138.5 (C-1'), 147.2 (C-2"). HRMS (ESI): calc (found) for C₂₁H₂₆N₂O₆S ([M+H] $^+$): 435.1584 (435.1584).

(R,S,S)-34f, mp 53 °C. $[\alpha]_D^{20}$ + 90 (c 0.26 in CHCl₃). R_f = 0.33 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3326 (br, w), 3087 (w), 3028 (w), 2957 (m), 2927 (m), 1731 (w), 1591 (w), 1542 (vs), 1495 (w), 1455 (m), 1440 (m), 1372 (s), 1338 (s), 1273 (w), 1160 (s), 1126 (m), 1066 (m), 1032 (m), 991 (m), 966 (w), 946 (m), 930 (m), 852 (m), 780 (w), 758 (m), 745 (m), 702 (m), 680 (w), 653 (w), 572 (m), 543 (w), 516 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.00 (d, J = 6.9 Hz, 3H, 8-H), 1.52 – 1.57 (m,

1H, 2-H_a),1.58 (s, br, 1H, OH), 1.66 – 1.75 (m, 1H, 7-H), 1.76 – 1.89 (m, 2H, 2-H_b, 3-H), 2.24 (s, br, 1H, OH), 2.90 (dd, J = 13.5 Hz, 9.2 Hz, 1H, 6-H_a), 2.99 (dd, J = 13.5 Hz, 6.6 Hz, 1H, 6-H_b), 3.28 – 3.37 (m, 1H, 1-H_a), 3.49 (dd, J = 11.0 Hz, 5.1 Hz, 1H, 9-H_a), 3.63 (dd, J = 11.0 Hz, 3.0 Hz, 1H, 9-H_b), 3.80 – 3.86 (m, 1H, 4-H), 3.96 – 4.04 (m, 1H, 1-H_b), 4.17 – 4.24 (m, 1H, 5-H), 7.09 – 7.20 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H, 6'-H), 7.54 – 7.65 (m, 3H, 3"-H, 4"-H, 5"-H), 7.91 – 7.97 (m, 1H, 6"-H). ¹³C-NMR (126 MHz, CDCl₃) δ 15.3 (C-8), 24.3 (C-2), 35.8 (C-6), 37.1 (C-7), 37.9 (C-3), 41.9 (C-1), 62.2 (C-5), 64.6 (C-9), 65.5 (C-4), 124.3 (C-3"), 126.9 (C-1)

4'), 128.6 (C-2', C-6'), 129.1 (C-3', C-5'), 131.1 (C-6"), 131.9 (C-5"), 133.3 (C-4"), 134.0 (C-1"), 137.3 (C-1"), 147.6 (C-2"). HRMS (ESI): calc (found) for $C_{21}H_{26}N_2O_6S$ ([M+Na]⁺): 457.1404 (457.1399).

(R,S,R)-34f, mp 57 °C. $[\alpha]_D^{20}$ + 60 (c 1.0 in CHCl₃). R_f = 0.26 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3540 (w), 3304 (br, w), 3090 (w), 3027 (w), 2958 (m), 2928 (m), 2879 (w), 1591 (w), 1541 (vs), 1495 (w), 1455 (m), 1440 (w), 1371 (s), 1335 (s), 1272 (w), 1159 (vs), 1126 (m), 1066 (m), 1034 (m), 994 (m), 963 (m), 945 (m), 929 (m), 911 (m), 878 (w), 852 (m), 778 (w), 758 (m), 732 (vs), 701 (m), 680 (m), 651 (w), 616 (w), 574 (s), 543 (w) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 0.95 (d, J = 7.0 Hz, 3H,


8-H), 1.52 - 1.64 (m, 1H, $2-H_a$), 1.70 - 1.82 (m, 2H, $2-H_b$, 7-H), 1.82 - 1.90 (m, 1H, 3-H), 2.89 (dd, J = 13.5 Hz, 8.5 Hz, 1H, $6-H_a$), 2.98 (dd, J = 13.5 Hz, 6.8 Hz, 1H, $6-H_b$), 3.26 - 3.36 (m, 1H, $1-H_a$), 3.50 (dd, J = 11.0 Hz, 4.4 Hz, 1H, $9-H_a$), 3.53 (dd, J = 11.0 Hz, 6.3 Hz, 1H, $9-H_b$), 3.68 - 3.74 (m, 1H, 4-H), 3.96 - 4.06 (m, 1H, $1-H_b$), 4.16 - 4.26 (m, 1H, 5-H), 7.07 - 7.13 (m, 3H, 2'-H, 4'-H, 6'-H), 7.13 - 7.20 (m, 2H, 3'-H, 5'-H), 7.50 - 7.56 (m, 1H, 5''-H), 7.56 - 7.64 (m, 2H, 3''-H, 4''-H), 7.83 - 7.91 (m, 1H, 6''-H). 13 C-NMR (126 MHz, CDCl₃) 8 16.2 (C-8), 21.7 (C-2), 35.7 (C-6), 37.3 (C-7), 37.8 (C-3), 41.8 (C-1), 62.3 (C-5), 64.5 (C-9), 67.5 (C-4), 124.3 (C-3"), 126.9 (C-4"), 128.6 (C-2', C-6'), 129.0 (C-3', C-5'), 131.0 (C-6"), 131.9 (C-5"), 133.3 (C-4"), 133.9 (C-1"), 137.3 (C-1'), 147.6 (C-2"). HRMS (ESI): calc (found) for $C_{21}H_{26}N_2O_6S$ ([M+H] $^+$): 435.1584 (435.1585).

GP9: Conversion to epoxides

The reaction was performed according to the literature. A round bottom flask was charged with a solution of the alkene (0.27 mmol) in a mixture of isopropanol and water (20 mL, 4:1). *meta*-Chloroperbenzoic acid (71.0 mg, 0.41 mmol) was added and the mixture was stirred for 24 h at room temperature. Isopropanol was evaporated and the remaining mixture was extracted with ethyl acetate (2×60 mL). The organic phases were washed with saturated sodium thiosulfate solution (2×60 mL), sodium hydroxide solution (2×60 mL, 1 M) and brine (1×60 mL). They were dried over sodium sulfate and the solvents were evaporated. The crude product was purified by HPLC.


(2S,3R,4R)-2-Isopropyl-4-((S)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol ((R,R,S)-35a) and (2S,3R,4R)-2-Isopropyl-4-((R)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((R,R,R)-35a)

According to GP9 (R,R,S)-35a was prepared from (2S,3R,4S)-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (R,S)-30a (0.10 mg, 0.27 mmol) and m-chloroperbenzoic acid (71.0 mg, 0.41 mmol) as a yellow oil (42.0 mg, 0.11 mmol, 41 %). Epoxide (R,R,R)-35a was isolated as well as a yellow oil (55.0 mg, 0.14 mmol, 52 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (90 : 10), 15 mL/min, Rt ((R,R,S)-35) = 21.5 min, Rt ((R,R,R)-35a) = 24.5 min.



(R,R,S)-35a, $[\alpha]_D^{20}$ + 108 (c 1.0 in CHCl₃). R_f = 0.29 (hexanes/EtOAc, 2:1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3532 (br, w), 2966 (m), 2939 (m), 1541 (vs), 1470 (m), 1440 (m), 1372 (s), 1337 (s), 1281 (m), 1258 (m), 1158 (vs), 1125 (s), 1081 (m), 1062 (m), 1046 (m), 969 (s), 909 (s), 852 (m), 778 (m), 751 (s), 731 (vs), 680 (m), 651 (m), 620 (m), 577 (vs), 559 (s) cm⁻¹. ¹H-NMR

(700 MHz, CDCl₃) δ 0.78 (d, J = 6.7 Hz, 3H, 7-H/8-H), 0.98 (d, J = 6.7 Hz, 3H, 8-H/7-H), 1.35 (s, 3H, 10-H) 1.38 – 1.42 (m, 1H, 2-H_a), 1.68 – 1.75 (m, 1H, 3-H), 1.74 (dddd, J = 12.7 Hz, 12.7 Hz, 4.6 Hz, 1H, 2-H_b), 1.94 (dqq, J = 10.8 Hz, 6.7 Hz, 6.7 Hz, 1H, 6-H), 2.52 (d, J = 4.4 Hz, 1H, 11-H_a), 2.71 (d, J = 4.4 Hz, 1H, 11-H_b), 2.74 (d, J = 3.3 Hz, 1H, OH), 3.02 – 3.10 (m, 1H, 1-H_a), 3.57 (d, J = 10.8 Hz, 1H, 5-H), 4.04 – 4.09 (m, 1H, 1-H_b), 4.17 – 4.21 (m, 1H, 4-H), 7.53 – 7.57 (m, 1H, 3'-H), 7.61 – 7.69 (m, 2H, 4'-H, 5'-H), 8.08 – 8.13 (m, 1H, 6'-H). 13 C-NMR (176 MHz, CDCl₃) δ 19.9 (C-7/C-8), 20.2 (C-8/C-7), 20.6 (C-10), 21.1 (C-2), 26.4 (C-6), 39.4 (C-3), 41.4 (C-1), 51.9 (C-11), 59.0 (C-9), 66.2 (C-4), 66.8 (C-5), 123.6 (C-3'), 131.3 (C-5'), 131.4 (C-6'), 133.2 (C-4'), 134.7 (C-1'), 147.9 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₄N₂O₆S ([M+NH₄]⁺): 402.1693 (402.1695).




(R,R,R)-35a, $[\alpha]_D^{20}$ + 94 (c 1.0 in CHCl₃). R_f = 0.23 (hexanes/EtOAc, 2 : 1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3529 (br, w), 2968 (m), 2933 (m), 2876 (w), 1542 (vs), 1470 (w), 1449 (w), 1372 (s), 1340 (s), 1278 (m), 1159 (vs), 1125 (m), 1079 (m), 1063 (m), 1046 (m), 971 (s), 912 (s), 852 (m), 778 (m), 749 (m), 732 (s), 680 (m), 651 (w), 614 (m), 577 (s), 559 (m) cm⁻¹.

¹H-NMR (700 MHz, CDCl₃) δ 0.78 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.98 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.34 (s, 3H, 10-H), 1.47 – 1.53 (m, 1H, 2-H_a), 1.64 (dddd, J = 13.2 Hz, 13.2 Hz,

13.2 Hz, 4.7 Hz, 1H, 2-H_b), 1.86 – 1.91 (m, 1H, 3-H), 1.94 (dqq, J = 10.8 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 2.57 (d, J = 4.3 Hz, 1H, 11-H_a), 2.82 (d, J = 2.6 Hz, 1H, OH), 2.85 (d, J = 4.3 Hz, 1H, 11-H_b), 3.05 (ddd, J = 13.2 Hz, 13.2 Hz, 2.5 Hz, 1H, 1-H_a), 3.55 (d, J = 10.8 Hz, 1H, 5-H), 4.03 – 4.10 (m, 2H, 1-H_b, 4-H), 7.50 – 7.57 (m, 1H, 3'-H), 7.60 – 7.70 (m, 2H, 4'-H, 5'-H), 8.06 – 8.12 (m, 1H, 6'-H). ¹³C-NMR (176 MHz, CDCl₃) δ 19.8 (C-7/C-8), 20.3 (C-8/C-7), 20.4 (C-2), 20.7 (C-10), 26.4 (C-6), 38.5 (C-3), 41.6 (C-1), 52.0 (C-11), 58.7 (C-9), 65.6 (C-4), 66.7 (C-5), 123.6 (C-3'), 131.3 (C-5'), 131.3 (C-6'), 133.2 (C-4'), 134.7 (C-1'), 147.9 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₄N₂O₆S ([M+NH₄]⁺): 402.1693 (402.1693).

(2R,3S,4S)-2-Isopropyl-4-((S)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol ((S,S,S)-35b) and (2R,3S,4S)-2-Isopropyl-4-((R)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((S,S,R)-35b)

According to GP9 (S,S,S)-35**b** was prepared from (2R,3S,4R)-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (S,R)-30**b** (0.22 g, 0.60 mmol) and m-chloroperbenzoic acid (0.16 g, 0.90 mmol) as a colorless solid (0.11 g, 0.28 mmol, 47 %). Epoxide (S,S,R)-35**b** was isolated as well as colorless solid (51.0 mg, 0.14 mmol, 23 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (95 : 5), 15 mL/min, Rt ((S,S,S)-35**b**) = 38 min, Rt ((S,S,R)-35**b**) = 47.5 min).



(S, S, S)-35b

(S,S,S)-35b, mp 120 °C. [α]_D²⁰ - 103 (c 1.0 in CHCl₃). R_f = 0.16 (hexanes/EtOAc, 2:1, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3524 (br, w), 3097 (w), 2968 (m), 2933 (w), 1591 (w), 1543 (vs), 1470 (w), 1440 (w), 1373 (s), 1339 (s), 1281 (w), 1206 (w), 1160 (s), 1126 (m), 1082 (m), 1062 (m), 1046 (w), 970 (m), 911 (m), 852 (m), 816 (w), 779 (w), 751 (m), 733 (m), 680 (w), 652 (w), 620 (w), 578


(s), 560 (m) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.78 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.98 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.35 (s, 3H, 10-H), 1.36 – 1.43 (m, 1H, 2-H_a), 1.67 – 1.75 (m, 1H, 3-H), 1.75 (dddd, J = 13.0 Hz, 13.0 Hz, 13.0 Hz, 4.9 Hz, 1H, 2-H_b), 1.94 (dqq, J = 11.2 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 2.53 (d, J = 4.5 Hz, 1H, 11-H_a), 2.71 (d, J = 4.5 Hz, 1H, 11-H_b), 2.74 (d, J = 3.1 Hz, 1H, OH), 2.99 – 3.13 (m, 1H, 1-H_a), 3.53 – 3.61 (m, 1H, 5-H), 4.02 – 4.10 (m, 1H, 1-H_b), 4.17 – 4.24 (m, 1H, 4-H), 7.51 – 7.58 (m, 1H, 3'-H), 7.60 – 7.69 (m, 2H, 4'-H, 5'-H), 8.06 – 8.14 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 19.9 (C-7/C-8), 20.2 (C-8/C-7), 20.6 (C-10), 21.1 (C-2), 26.4 (C-6), 39.4 (C-3), 41.5 (C-1), 51.9 (C-11), 59.0 (C-9), 66.2 (C-4), 66.8 (C-5), 123.7 (C-3'), 131.3 (C-6'), 131.4 (C-5'), 133.2 (C-4'), 134.7 (C-1'), 147.9 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₄N₂O₆S ([M+Na]⁺): 407.1247 (407.1249).

(S,S,R)-35b, mp 49 °C. $[\alpha]_D^{20}$ - 81 (c 1.0 in CHCl₃). R_f = 0.14 (hexanes/EtOAc, 2:1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3527 (br, w), 2967 (m), 2934 (w), 2877 (w), 1591 (w), 1542 (vs), 1470 (w), 1440 (w), 1372 (s), 1339 (s), 1277 (m), 1210 (w), 1159 (vs), 1125 (m), 1079 (m), 1063 (m), 1046 (m), 971 (s), 911 (s), 852 (m), 816 (w), 778 (m), 749 (s), 731 (s), 680 (m), 651 (m), 613 (m),

577 (s), 559 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 0.78 (d, J = 6.5 Hz, 3H, 7-H/8-H), 0.98 (d, J = 6.5 Hz, 3H, 8-H/7-H), 1.34 (s, 3H, 10-H), 1.45 – 1.53 (m, 1H, 2-H_a), 1.64 (dddd, J = 13.1 Hz, 13.1 Hz, 13.1 Hz, 5.7 Hz, 1H, 2-H_b), 1.85 – 1.92 (m, 1H, 3-H), 1.94 (dqq, J = 10.9 Hz, 6.5 Hz, 6.5 Hz, 1H, 6-H), 2.56 (d, J = 4.1 Hz, 1H, 11-H_a), 2.83 (d, J = 3.1 Hz, 1H, OH), 2.85 (d, J = 4.1 Hz, 1H, 11-H_b), 3.05 (ddd, J = 15.4 Hz, 13.1 Hz, 2.8 Hz, 1H, 1-H_a), 3.52 – 3.59 (m, 1H, 5-H), 4.03 – 4.10 (m, 2H, 1-H_b, 4-H), 7.50 – 7.57 (m, 1H, 3'-H), 7.59 – 7.67 (m, 2H, 4'-H, 5'-H), 8.06 – 8.15 (m, 1H, 6'-H). ¹³C-NMR (126 MHz, CDCl₃) δ 19.8 (C-7/C-8), 20.4 (C-8/C-7), 20.4 (C-10), 20.7 (C-2), 26.4 (C-6), 38.5 (C-3), 41.6 (C-1), 52.0 (C-11), 58.7 (C-9), 65.6 (C-4), 66.7 (C-5), 123.6 (C-3'), 131.3 (C-6'), 131.3 (C-5'), 133.2 (C-4'), 134.6 (C-1'), 147.9 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₄N₂O₆S ([M+NH₄]⁺): 402.1693 (402.1697).

$(2S,3R,4R)-2-Benzyl-4-((S)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol\\ ((R,R,S)-35f) and (2S,3R,4R)-2-Benzyl-4-((R)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)-piperidin-3-ol\\ ((R,R,R)-35f)$

According to GP9 (R,R,S)-35f was prepared from (2S,3R,4S)-2-benzyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (R,S)-30f (0.21 g, 0.51 mmol) and m-chlorperbenzoic acid (0.13 mg, 0.77 mmol) as a colorless solid (0.13 g, 0.29 mmol, 58 %). Epoxide (R,R,R)-35f was also isolated as a colorless solid (0.09 g, 0.20 mmol, 39 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (90:10), 15 mL/min, $R_t((R,R,S)$ -35f) = 21 min, $R_t((R,R,R)$ -35f) = 24 min.



(R,R,S)-35f, mp 173 °C. $[\alpha]_D^{20}$ + 40 (c 0.1 in CHCl₃). R_f = 0.57 (hexanes/EtOAc, 1:1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3546 (w), 2957 (m), 2925 (s), 2854 (m), 1726 (m), 1543 (vs), 1495 (w), 1455 (m), 1374 (s), 1339 (s), 1269 (m), 1162 (s), 1127 (m), 1078 (m), 990 (w), 965 (w), 852 (w), 745 (m), 732 (m), 702 (m), 678 (w), 608 (w), 571 (m) cm⁻¹. 1 H-NMR (700 MHz, CDCl₃) δ 1.33 (s, 3H, 8-H), 1.51 – 1.54 (m, 1H, 2-H_a), 1.86 –1.95 (m, 2H, 2-H_b, 3-H), 2.54

(dd, J = 4.3 Hz, 1H, 9-H_a), 2.56 (d, J = 4.4 Hz, 1H, OH), 2.71 (d, J = 4.3 Hz, 1H, 9-H_b), 2.85

(dd, J = 13.7 Hz, 9.7 Hz, 1H, 6-H_a), 3.01 (dd, J = 13.7 Hz, 6.3 Hz, 1H, 6-H_b), 3.27 – 3.34 (m, 1H, 1-H_a), 3.85 – 3.88 (m, 1H, 4-H), 4.01 – 4.05 (m, 1H, 1-H_b), 4.18 – 4.23 (m, 1H, 5-H), 7.12 – 7.18 (m, 3H, 2'-H, 4'-H, 6'-H), 7.19 – 7.23 (m, 2H, 3'-H, 5'-H), 7.55 – 7.59 (m, 1H, 5"-H), 7.60 – 7.65 (m, 2H, 3"-H, 4"-H), 7.95 – 7.99 (m, 1H, 6"-H). ¹³C-NMR (176 MHz, CDCl₃) δ 20.5 (C-8), 21.3 (C-2), 35.6 (C-6), 39.4 (C-3), 41.2 (C-1), 51.9 (C-9), 59.0 (C-7), 61.0 (C-5), 66.7 (C-4), 124.3 (C-3"), 127.0 (C-4'), 128.8 (C-3', C-5'), 128.9 (C-2', C-6'), 131.2 (C-6"), 131.8 (C-5"), 133.3 (C-4"), 134.0 (C-1"), 137.0 (C-1'), 147.7 (C-2"). HRMS (ESI): calc (found) for $C_{21}H_{24}N_2O_6S$ ([M+Na]⁺): 455.1247 (455.1248).

(R,R,R)-35f, mp 120 °C. [α]_D²⁰ + 30 (c 0.1 in CHCl₃). R_f = 0.51 (hexanes/EtOAc, 1:1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3465 (w), 3026 (w), 2926 (m), 2855 (w), 1722 (w), 1592 (w), 1542 (vs), 1495 (w), 1455 (m), 1372 (s), 1338 (s), 1271 (m), 1161 (vs), 1127 (m), 1078 (m), 1066 (m), 989 (m), 968 (m), 947 (m), 928 (m), 909 (m), 874 (w), 852 (m), 781 (w), 761 (m), 733 (s), 702 (m), 679 (m), 651 (w), 607 (m), 588 (m), 572 (m), 546 (w), 518 (w) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 1.35 (s, 3H, 8-H), 1.58 – 1.65 (m, 1H, 2-

H_a), 1.77 (dddd, J = 13.3 Hz, 4.7 Hz, 1H, 2-H_b), 2.08 – 2.14 (m, 1H, 3-H), 2.56 (d, J = 4.3 Hz, 1H, 9-H_a), 2.60 (d, J = 4.3 Hz, 1H, OH), 2.83 (d, J = 4.3 Hz, 9-H_b), 2.87 (dd, J = 13.8 Hz, 9.2 Hz, 1H, 6-H_a), 2.99 (dd, J = 13.8 Hz, 6.5 Hz, 1H, 6-H_b), 3.25 – 3.34 (m, 1H, 1-H_a), 3.76 – 3.82 (m, 1H, 4-H), 3.99 – 4.07 (m, 1H, 1-H_b), 4.16 – 4.23 (m, 1H, 5-H), 7.10 – 7.17 (m, 3H, 2'-H, 4'-H, 6'-H), 7.17 – 7.24 (m, 2H, 3'-H, 5'-H), 7.52 – 7.58 (m, 1H, 5''-H), 7.58 – 7.66 (m, 2H, 3''-H, 4''-H), 7.90 – 7.95 (m, 1H, 6''-H). ¹³C-NMR (126 MHz, CDCl₃) δ 20.5 (C-8), 20.8 (C-2), 35.7 (C-6), 38.5 (C-3), 41.4 (C-1), 51.8 (C-9), 58.3 (C-7), 62.0 (C-5), 66.1 (C-4), 124.2 (C-3''), 127.0 (C-4'), 128.7 (C-3', C-5'), 129.0 (C-2', C-6'), 131.1 (C-6''), 131.8 (C-5''), 133.3 (C-4''), 134.0 (C-1''), 137.1 (C-1'), 147.8 (C-2''). HRMS (ESI): calc (found) for C₂₁H₂₄N₂O₆S ([M+H]⁺): 433.1428 (433.1438).


(2S,3S,4R)-2-Benzyl-4-((R)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((S,R,R)-35f) and (2S,3S,4R)-2-Benzyl-4-((S)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol ((S,R,S)-35f)

According to GP9 (S,R,R)-35f was prepared from (2S,3S,4S)-2-benzyl-1-((2-nitrophenyl)sulfonyl)-4-(prop-1-en-2-yl)-piperidin-3-ol (S,S)-30f (55.0 mg, 0.13 mmol) and m-chloroperbenzoic acid (34.0 mg, 0.20 mmol) as a colorless solid (25.0 mg, 58.0 mmol, 44 %). Epoxide (S,R,S)-35f was isolated as well as a colorless solid (20.0 mg, 46.0 mmol, 35 %).

Purification was accomplished by HPLC (Orbit, hexanes/EtOAc (60 : 40), 15 mL/min, $R_t((S,R,R)-35\mathbf{f}) = 24.5 \text{ min}, R_t((S,R,S)-35\mathbf{f}) = 27 \text{ min}.$

(S,R,R)-35f, mp 58 °C. $[\alpha]_D^{20} = +203$ (c = 1.0 in CHCl₃). $R_f = 0.43$ (hexanes/EtOAc, 1:1, anisaldehyde solution). FT-IR (ATR): $\tilde{v} = 3448$ (br, w), 3026 (w), 2928 (w), 1592 (w), 1541 (vs), 1497 (w), 1454 (w), 1370 (s), 1333 (s), 1297 (m), 1256 (w), 1205 (w), 1159 (s), 1126 (m), 1086 (m), 1058 (m), 1013 (m), 957 (m), 943 (m), 911 (w), 853 (m), 832 (w), 811 (w), 779 (w), 756 (s), 740 (s), 700 (m), 652 (w), 592 (s), 573 (m), 512 (w) cm⁻¹. ¹H-NMR (700 MHz,

CDCl₃) δ 1.42 (s, 3H, 8-H), 1.52 (dddd, J = 13.3 Hz, 13.3 Hz, 13.3 Hz, 4.9 Hz, 1H, 2-H_a), 1.93 - 1.99 (m, 1H, 2-H_b), 2.08 (ddd, J = 13.3 Hz, 11.0 Hz, 4.0 Hz, 1H, 3-H), 2.71 (d, J = 3.7 Hz, 1H, 9-H_a), 2.72 (dd, J = 14.4 Hz, 11.7 Hz, 1H, 6-H_a), 3.05 (d, J = 3.7 Hz, 1H, 9-H_b), 3.13 (dd, J = 14.4 Hz, 3.2 Hz, 1H, 6-H_b), 3.36 (ddd, J = 14.6 Hz, 13.3 Hz, 2.8 Hz, 1H, 1-H_a), 3.73 (s, 1H, OH), 3.75 (dd, J = 11.0 Hz, 5.7 Hz, 1H, 4-H), 4.02 - 4.08 (m, 1H, 1-H_b), 4.24 (ddd, J = 11.7 Hz, 5.7 Hz, 3.2 Hz, 1H, 5-H), 6.82 - 6.90 (m, 3H, 3'-H, 4'-H, 5'-H), 6.95 - 7.03 (m, 2H, 2'-H, 6'-H), 7.24 - 7.29 (m, 1H, 5"-H), 7.35 - 7.40 (m, 1H, 4"-H), 7.42 - 7.50 (m, 2H, 3"-H, 6"-H). 13 C-NMR (176 MHz, CDCl₃) δ 20.9 (C-8), 29.0 (C-2), 29.8 (C-6), 40.1 (C-1), 41.3 (C-3), 51.7 (C-9), 60.1 (C-7), 60.4 (C-5), 70.0 (C-4), 124.3 (C-3"), 126.3 (C-4'), 128.0 (C-3', C-5'), 129.2 (C-2', C-6'), 130.7 (C-4"), 131.9 (C-5"), 132.7 (C-6"), 133.9 (C-1"), 138.3 (C-1'), 147.0 (C-2"). HRMS (ESI): calc (found) for C₂₁H₂₄N₂O₆S ([M+Na]⁺): 455.1247 (455.1244).



(S,R,S)-35f, mp 142 °C. [α]_D²⁰ + 220 (c 1.0 in CHCl₃). R_f = 0.31 (hexanes/EtOAc, 1:1, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3481 (br, w), 3089 (w), 3028 (w), 2925 (w), 1591 (w), 1541 (vs), 1497 (w), 1441 (w), 1370 (s), 1333 (s), 1294 (w), 1275 (w), 1250 (w), 1159 (s), 1126 (m), 1090 (m), 1073 (m), 1013 (w), 957 (m), 924 (m), 91 (m), 866 (w), 852 (m), 833 (w), 807 (w), 779 (w), 756 (s), 740 (s), 700 (m), 651 (w), 592 (s), 575 (m), 539 (w), 501 (w), 443 (w) cm⁻¹.

¹H-NMR (700 MHz, CDCl₃) δ 1.36 (s, 3H, 8-H), 1.46 (ddd, J = 13.1 Hz, 11.2 Hz, 3.9 Hz, 1H, 3-H), 1.65 (dddd, J = 13.1 Hz, 13.1 Hz, 13.1 Hz, 4.9 Hz, 1H, 2-H_a), 1.77 – 1.83 (m, 1H, 2-H_b), 2.60 (d, J = 4.4 Hz, 1H, 9-H_a), 2.65 (dd, J = 14.1 Hz, 11.5 Hz, 1H, 6-H_a), 2.66 (d, J = 4.4 Hz, 1H, 9-H_b), 3.12 (dd, J = 14.1 Hz, 3.0 Hz, 1H, 6-H_b), 3.12 (s, br, 1H, OH), 3.29 – 3.36 (m, 1H, 1-H_a), 4.02 – 4.10 (m, 1H, 1-H_b), 4.19 (ddd, J = 11.2 Hz, 5.5 Hz, 2.3 Hz, 1H, 4-H), 4.32 (ddd, J = 11.5 Hz, 5.5 Hz, 3.0 Hz, 1H, 5-H), 6.81 – 6.89 (m, 3H, 3'-H, 4'-H, 5'-H), 6.94 – 7.00 (m,

2H, 2'-H, 6'-H), 7.25 - 7.30 (m, 1H, 5"-H), 7.37 - 7.42 (m, 1H, 4"-H), 7.42 - 7.49 (m, 2H, 3"-H, 6"-H). 13 C-NMR (176 MHz, CDCl₃) δ 16.3 (C-8), 28.8 (C-2), 29.6 (C-6), 40.0 (C-1), 44.2 (C-3), 52.6 (C-9), 58.5 (C-7), 60.8 (C-5), 71.1 (C-4), 124.3 (C-3"), 126.3 (C-4"), 128.0 (C-3", C-5"), 129.2 (C-2", C-6"), 130.8 (C-4"), 132.0 (C-5"), 132.7 (C-6"), 134.0 (C-1"), 138.2 (C-1"), 146.9 (C-2"). HRMS (ESI): calc (found) for $C_{21}H_{24}N_{2}O_{6}S$ ([M+Na]*): 455.1247 (455.1245).

GP10: Conversion to triols

The reaction was performed according to the literature. A round bottom flask was charged with a solution of the alkene (0.09 mmol) in a mixture of tetrahydrofuran and water (8 mL, 4:1) under nitrogen atmosphere. Upon cooling to 0 °C perchloric acid solution (1.25 mL, 7 %) was added and the mixture was stirred for 24 h at room temperature. Afterwards the mixture was neutralized using sodium hydroxide solution (1 M) and extracted with ethyl acetate (3 × 14 mL). The organic phases were washed with brine (2 × 9 mL) and dried over sodium sulfate. The solvents were evaporated and the crude product was purified by HPLC.

(R)-2-((2S,3R,4R)-3-Hydroxy-2-isopropyl-1-((2-nitrophenyl)sulfonyl)piperidin-4-yl)-propane-1,2-diol ((R,R,R)-36a) und (S)-2-((2S,3R,4R)-3-Hydroxy-2-isopropyl-1-((2-nitrophenyl)-sulfonyl)piperidin-4-yl)propane-1,2-diol ((R,R,S)-36a)

According to GP10 (R,R,R)-36a was prepared from (2S,3R,4R)-2-isopropyl-4-((S)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)-sulfonyl)piperidin-3-ol (R,R,S)-35a (33.0 mg, 90.0 µmol) and perchloric acid (1.3 mL, 1.54 mmol, 7 % in water) as a colorless solid (1.00 mg, 2.48 µmol, 3 %). Triol (R,R,S)-36a was isolated as well as a colorless solid (15.0 mg, 37.0 µmol, 41 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (85 : 15), 15 mL / min, R_t ((R,R,R)-36a) = 47 min, R_t ((R,R,S)-36a) = 51 min).

Both triols were also obtained according to GP9 starting from (2S,3R,4R)-2-isopropyl-4-((R)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)-sulfonyl)piperidin-3-ol (R,R,R)-35a (49.0 mg, 0.13 mmol) and perchloric acid (1.8 mL, 2.22 mmol, 7 % in water): Triol (R,R,R)-36a (11.0 mg, 27.0 μ mol, 21 %), triol (R,R,S)-36a (2.00 mg, 4.97 μ mol, 4 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (85 : 15), 15 mL/min).

(R,R,R)-36a, mp 50 °C. $[\alpha]_D^{20}$ + 141 (c 1.0 in CHCl₃). R_f = 0.12 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3382 (br, w), 2967 (m), 2933 (m), 1542 (vs), 1469 (m), 1440 (m), 1371 (s), 1332 (s), 1279 (m), 1158 (vs), 1125 (s), 1085 (m), 1064 (s), 1045 (s), 997 (w), 970 (s), 911 (s), 852 (m), 806 (w), 776 (m), 751 (s), 732 (vs), 688 (w), 652 (m), 580 (s), 560 (m) cm⁻¹. 1 H-NMR

(700 MHz, CDCl₃) δ 0.65 (d, J = 6.7 Hz, 3H, 7-H/8-H), 0.97 (d, J = 6.7 Hz, 3H, 8-H/7-H), 1.22 (s, 3H, 10-H), 1.45 – 1.50 (m, 1H, 2-H_a), 1.62 (s, br, 1H, OH), 1.67 – 1.72 (m, 1H, 3-H), 1.82 (dddd, J = 13.0 Hz, 13.0 Hz, 13.0 Hz, 4.9 Hz, 1H, 2-H_b), 1.99 (dqq, J = 10.8 Hz, 6.7 Hz, 6.7 Hz, 1H, 6-H), 3.08 – 3.15 (m, 1H, 1-H_a), 3.26 (d, J = 11.5 Hz, 1H, 11-H_a), 3.36 (s, br, 1H, OH), 3.51 (d, J = 10.8 Hz, 1H, 5-H), 3.55 (d, J = 11.5 Hz, 1H, 11-H_b), 4.08 – 4.15 (m, 1H, 1-H_b), 4.37 (s, 1H, 4-H), 7.56 – 7.63 (m, 1H, 3'-H), 7.64 – 7.73 (m, 2H, 4'-H, 5'-H), 8.04 – 8.12 (m, 1H, 6'-H). 13 C-NMR (176 MHz, CDCl₃) δ 19.7 (C-7/C-8), 20.1 (C-8/C-7), 20.9 (C-2), 24.8 (C-10), 26.7 (C-6), 41.9 (C-1), 42.1 (C-3), 65.2 (C-4), 66.5 (C-11), 67.0 (C-5), 73.0 (C-9), 124.0 (C-3'), 130.8 (C-6'), 131.8 (C-5'), 133.5 (C-4'), 134.5 (C-1') 147.6 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₇S ([M+H]⁺): 403.1533 (403.1543).

(R,R,S)-36a

(R,R,S)-36a, mp 50 °C. $[\alpha]_D^{20} = +132$ (c = 1.0 in CHCl₃). $R_f = 0.09$ (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu} = 3382$ (br, w), 2967 (m), 2929 (m), 1542 (vs), 1466 (m), 1440 (m), 1371 (s), 1334 (s), 1277 (m), 1156 (s), 1124 (s), 1092 (m), 1063 (m), 1047 (s), 995 (w), 973 (s), 910 (vs), 853 (m), 807 (w), 776 (m), 751 (s), 731 (vs), 685 (m), 652 (m), 579 (s), 560 (s) cm⁻¹. 1 H-NMR


(700 MHz, CDCl₃) δ 0.69 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.97 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.17 (s, 3H, 10-H), 1.52 – 1.59 (m, 1H, 2-H_a), 1.71 – 1.78 (m, 1H, 3-H), 1.92 (dddd, J = 13.4 Hz, 13.4 Hz, 13.4 Hz, 4.9 Hz, 1H, 2-H_b), 1.98 (dqq, J = 10.7 Hz, 10.7 Hz, 6.6 Hz, 1H, 6-H), 2.07 (s, br, 1H, OH), 3.08 – 3.18 (m, 1H, 1-H_a), 3.34 (s, br, 2H, 2xOH), 3.47 (d, J = 10.7 Hz, 1H, 5-H), 3.57 (s, 2H, 11-H), 4.11 – 4.18 (m, 1H, 1-H_b), 4.40 (s, 1H, 4-H), 7.53 – 7.62 (m, 1H, 3'-H), 7.62 – 7.73 (m, 2H, 4'-H, 5'-H), 8.03 – 8.10 (m, 1H, 6'-H). ¹³C-NMR (176 MHz, CDCl₃) δ 19.5 (C-2), 19.7 (C-7/C-8), 20.2 (C-8/C-7), 23.1 (C-10), 26.5 (C-6), 38.9 (C-3), 42.0 (C-1), 66.2 (C-4), 66.8 (C-5), 68.8 (C-11), 74.0 (C-9), 123.9 (C-3'), 130.7 (C-6'), 131.7 (C-5'), 133.4 (C-4'), 134.6 (C-1'), 147.6 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₇S ([M+H]⁺): 403.1533 (403.1535).

(R)-2-((2R,3S,4S)-3-Hydroxy-2-isopropyl-1-((2-nitrophenyl)sulfonyl)piperidin-4-yl)-propan-1,2-diol ((S,S,R)-36b) and (S)-2-((2R,3S,4S)-3-Hydroxy-2-isopropyl-1-((2-nitrophenyl)sulfonyl)piperidin-4-yl)propan-1,2-diol ((S,S,S)-36b)

According to GP10 (S,S,R)-36**b** was prepared from (2R,3S,4S)-2-isopropyl-4-((S)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)sulfonyl)piperidin-3-ol (S,S,S)-35**b** (0.11 g, 0.28 mmol) and perchloric acid (4.0 mL, 4.93 mmol, 7 % in water) as a colorless solid (7.00 mg, 17.4 μ mol, 6 %). Triol (S,S,S)-36**b** was isolated as well as a colorless solid (0.05 g, 124 μ mol, 44 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (90 : 10), 15 mL/min, R_t ((S,S,S)-36**b**) = 109 min, R_t ((S,S,S)-36**b**) = 113 min).

(S,S,R)-36b, mp 51 °C. [α]_D²⁰ - 121 (c 0.4 in CHCl₃). R_f = 0.09 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3372 (br, w), 2967 (m), 2932 (m), 1591 (w), 1543 (vs), 1469 (m), 1440 (m), 1372 (s), 1334 (s), 1279 (m), 1159 (s), 1125 (s), 1085 (m), 1064 (m), 1046 (s), 997 (w), 971 (s), 912 (s), 853 (m), 806 (w), 777 (w), 751 (s), 733 (vs), 688 (w), 652 (m), 581 (s), 560 (m) cm⁻¹.

¹H-NMR (500 MHz, CDCl₃) δ 0.65 (d, J = 6.6 Hz, 3H, 7-H/8-H), 0.97 (d, J = 6.6 Hz, 3H, 8-H/7-H), 1.23 (s, 3H, 10-H), 1.45 – 1.51 (m, 1H, 2-H_a), 1.67 – 1.73 (m, 1H, 3-H), 1.82 (dddd, J = 13.2 Hz, 13.2 Hz, 13.2 Hz, 4.6 Hz, 1H, 2-H_b), 1.99 (dqq, J = 11.2 Hz, 6.6 Hz, 6.6 Hz, 1H, 6-H), 3.07 – 3.16 (m, 1H, 1-H_a), 3.26 (d, J = 11.3 Hz, 1H, 11-H_a), 3.36 (s, br, 1H, OH), 3.48 – 3.53 (m, 1H, 5-H), 3.56 (d, J = 11.3 Hz, 1H, 11-H_b), 4.07 – 4.16 (m, 1H, 1-H_b), 4.34 – 4.40 (m, 1H, 4-H), 7.57 – 7.62 (m, 1H, 3'-H), 7.65 – 7.71 (m, 2H, 4'-H, 5'H), 8.04 – 8.11 (m, 1H, 6'-H). (C-6), 41.9 (C-1), 42.1 (C-3), 65.2 (C-4), 66.5 (C-11), 67.0 (C-5), 73.0 (C-9), 124.0 (C-3'), 130.8 (C-6'), 131.8 (C-5'), 133.5 (C-4'), 134.5 (C-1'), 147.6 (C-2'). HRMS (ESI): calc (found) for C₁₇H₂₆N₂O₇S ([M+H]⁺): 403.1533 (403.1535).




(S,S,S)-36b, mp 51 °C, $[\alpha]_D^{20}$ - 107 (c 0.5 in CHCl₃). R_f = 0.06 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 3388 (br, m), 2967 (m), 2935 (m), 2877 (w), 1591 (w), 1542 (vs), 1469 (m), 1440 (m), 1372 (s), 1335 (s), 1278 (m), 1157 (s), 1124 (s), 1092 (m), 1063 (m), 1047 (s), 973 (s), 912 (s), 853 (m), 807 (w), 777 (w), 751 (s), 733 (vs), 686 (w), 652 (m), 580 (s), 560 (m)

cm⁻¹. 1 H-NMR (700 MHz, CDCl₃) δ 0.68 (d, J = 6.7 Hz, 3H, 7-H/8-H), 0.96 (d, J = 6.7 Hz, 3H, 8-H/7-H), 1.16 (s, 3H, 10-H), 1.52 – 1.62 (m, 1H, 2-H_a), 1.71 – 1.78 (m, 1H, 3-H), 1.91 (dddd, 1.71 – 1.78 (m,

J = 13.2 Hz, 13.2 Hz, 13.2 Hz, 4.8 Hz, 1H, 2-H_b), 1.97 (dqq, J = 10.8 Hz, 6.7 Hz, 6.7 Hz, 1H, 6-H), 2.22 (s, br, 1H, OH), $3.08 - 3.18 \text{ (m, } 1\text{H, } 1\text{-H}_a)$, 3.34 - 3.44 (m, 2H, 2xOH), 3.44 - 3.50 (m, 1H, 5-H), 3.56 (s, 2H, 11-H), $4.08 - 4.18 \text{ (m, } 1\text{H, } 1\text{-H}_b)$, 4.39 (s, 1H, 4-H), 7.52 - 7.62 (m, 1H, 3'-H), 7.62 - 7.71 (m, 2H, 4'-H, 5'-H), 8.04 - 8.15 (m, 1H, 6'-H). $^{13}\text{C-NMR}$ (176 MHz, 176 CDCl_3) 19.5 (C-2), 19.8 (C-7/C-8), 19.1 (C-8/C-7), 19.1 (C-10), 19.1 (C-6), 19.1 (C-6), 19.1 (C-7), 19.1 (C-7),

(S)-2-((2S,3R,4R)-2-Benzyl-3-hydroxy-1-((2-nitrophenyl)sulfonyl)piperidin-4-yl)-propan-1,2-diol ((R,R,S)-36f) and (R)-2-((2S,3R,4R)-2-Benzyl-3-hydroxy-1-((2-nitrophenyl)sulfonyl)piperidin-4-yl)propan-1,2-diol ((R,R,R)-36f)

According to GP10 (R,R,S)-**36f** was prepared from a mixture of (2S,3R,4R)-2-benzyl-4-((S)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)-sulfonyl)-piperidin-3-ol (R,R,S)-**35f** and (2S,3R,4R)-2-benzyl-4-((R)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)-sulfonyl)-piperidin-3-ol (R,R,R)-**35f** (0.15 g, 0.36 mmol) and perchloric acid (5.0 mL, 6.17 mmol, 7 % in water) as a colorless solid (64.0 mg, 0.06 mmol, 39 %). Triol (R,R,R)-**36f** was isolated as well as a colorless solid (64.0 mg, 0.06 mmol, 39 %). Purification was accomplished by HPLC (OD, n-hexane/isopropanol (90: 10), 15 mL/min, R_t ((R,R,S)-**36f**) = 120 min, R_t ((R,R,R)-**36f**) = 136 min.



(R,R,S)-36f, mp 60 °C. $[\alpha]_D^{20}$ + 30 (*c* 0.2 in CHCl₃). R_f = 0.24 (hexanes/EtOAc, 1 : 2, anisaldehyde solution), FT-IR (ATR): \tilde{v} = 3364 (w, br), 2922 (vs), 2852 (s), 1736 (w), 1543 (s), 1465 (m), 1426 (w), 1373 (m), 1338 (m), 1161 (m), 1125 (m), 1045 (w), 995 (w), 932 (w), 852 (w), 732 (w), 652 (w), 573 (w), 418 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.23 (s, 3H, 8-H), 1.60 – 1.66 (m, 1H, 2-H_a), 1.87 – 2.01 (m, 2H, 2-H_b, 3-H), 2.86 (dd, J = 13.8 Hz, 8.4 Hz, 1H, 6-H_a), 2.97 (dd, J = 13.8 Hz, 7.2 Hz, 1H, 6-H_b), 3.12 –

3.29 (m, br, 1H, OH), 3.32 (d, J = 11.2 Hz, 1H, 9-H_a), 3.33 – 3.41 (m, 1H, 1-H_a), 3.61 (d, J = 11.2 Hz, 1H, 9-H_b), 4.04 – 4.12 (m, 2H, 1-H_b, 4-H), 4.16 – 4.21 (m, 1H, 5-H), 7.06 – 7.11 (m, 3H, 2'-H, 4'-H, 6'-H), 7.11 – 7.16 (m, 2H, 3'-H, 5'-H), 7.53 – 7.58 (m, 1H, 5"-H), 7.59 – 7.65 (m, 2H, 3"-H, 4"-H), 7.85 – 7.90 (m, 1H, 6"-H). ¹³C-NMR (176 MHz, CDCl₃) δ 21.0 (C-2), 24.6 (C-8), 35.6 (C-6), 41.6 (C-3), 41.7 (C-1), 62.6 (C-5), 66.2 (C-4), 66.7 (C-9), 73.1 (C-7), 124.5 (C-3"), 127.0 (C-4'), 128.6 (C-3', C-5'), 129.0 (C-2', C-6'), 131.0 (C-6"), 132.0 (C-5"),

133.4 (C-4"), 133.8 (C-1"), 136.9 (C-1'), 147.5 (C-2"). HRMS (ESI): calc (found) for $C_{21}H_{26}N_2O_7S$ ([M+Na]⁺): 473.1353 (473.1352).

(R,R,R)-36f, mp 71 °C. $[\alpha]_D^{20}$ + 70 (c 0.1 in CHCl₃). R_f = 0.22 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3364 (m, br), 2924 (vs), 2853 (s), 1733 (w), 1542 (vs), 1496 (w), 1455 (m), 1372 (s), 1337 (s), 1277 (m), 1160 (s), 1126 (s), 1089 (m), 1047 (m), 975 (m), 934 (m), 853 (w), 733 (m), 703 (m), 652 (w), 576 (m), 422 (w) cm⁻¹. 1 H-NMR (500 MHz, CDCl₃) δ 1.23 (s, 3H, 8-H), 1.66 – 1.73 (m, 1H, 2-H_a), 1.90 – 1.98 (m, 1H, 3-H), 2.05


(dddd, J = 13.2 Hz, 13.2 Hz, 13.2 Hz, 4.9 Hz, 1H, 2-H_b), 2.86 (dd, J = 13.7 Hz, 9.9 Hz, 1H, 6-H_a), 2.97 (dd, J = 13.7 Hz, 6.6 Hz, 1H, 6-H_b), 3.05 (s, br, 1H, OH), 3.18 (s, br, 1H, OH), 3.33 – 3.42 (m, 1H, 1-H_a), 3.49 – 3.55 (m, 2H, 9-H), 4.04 – 4.12 (m, 2H, 1-H_b, 4-H), 4.12 – 4.18 (m, 1H, 5-H), 7.08 – 7.13 (m, 3H, 2'-H, 4'-H, 6'-H), 7.14 – 7.19 (m, 2H, 3'-H, 5'-H), 7.54 – 7.66 (m, 3H, 3"-H, 4"-H, 5"-H), 7.89 – 7.95 (m, 1H, 6"-H). 13 C-NMR (176 MHz, CDCl₃) δ 19.8 (C-2), 23.2 (C-8), 35.6 (C-6), 38.9 (C-3), 41.7 (C-1), 62.3 (C-5), 66.8 (C-4), 68.6 (C-9), 74.1 (C-7), 124.4 (C-3"), 127.0 (C-4'), 128.6 (C-3', C-5'), 129.0 (C-2', C-6'), 131.0 (C-6"), 132.0 (C-5"), 133.4 (C-4"), 133.9 (C-1"), 136.9 (C-1'), 147.7 (C-2"). HRMS (ESI): calc (found) for $C_{21}H_{26}N_{2}O_{7}S$ ([M+Na]*): 473.1353 (473.1354).

 $(R) - 2 - ((2S,3S,4R) - 2 - Benzyl - 3 - hydroxy - 1 - ((2 - nitrophenyl) sulfonyl) piperidin - 4 - yl) - propane - 1,2 - diol \qquad ((S,R,R) - 36f) \qquad \text{and} \qquad (S) - 2 - ((2S,3S,4R) - 2 - Benzyl - 3 - hydroxy - 1 - ((2 - nitrophenyl) sulfonyl) piperidin - 4 - yl) - propane - 1,2 - diol \(((S,R,S) - 36f)\)$

According to GP10 (S,R,R)-36**f** was prepared from (2S,3S,4R)-2-benzyl-4-((S)-2-methyloxiran-2-yl)-1-((2-nitrophenyl)-sulfonyl)piperidin-3-ol (S,R,R)-35**f** (65.0 mg, 0.15 mmol) and perchloric acid (2.0 mL, 2.47 mmol, 7 % in water) as a colorless solid (16.0 mg, 0.04 mmol, 24 %). Triol (S,R,S)-36**f** was isolated as well as a colorless solid (16.0 mg, 11 %). Purification was accomplished by HPLC (Orbit, hexanes/isopropanol (10) 15 mL/min, 100 mg, 101 min, 102 min, 103 min, 103 min, 104 min, 105 min.

(S,R,R)-36f, mp 107 °C. $[\alpha]_D^{20}$ + 246 (c 0.1 in CHCl₃). R_f = 0.27 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): $\tilde{\nu}$ = 2929 (m), 1543 (vs), 1468 (m), 1455 (m), 1440 (m), 1374 (vs), 1340 (vs), 1303 (m), 1281 (s), 1260 (m), 1157 (vs), 1125 (s), 1082 (vs), 1048 (vs), 1017 (m), 982 (w), 956 (s), 941 (m), 909 (s), 871 (s), 853 (m), 793 (m), 778 (m), 757 (vs), 730 (vs), 699 (s), 651 (m), 590 (vs), 569 (s), 558 (m), 541 (m), 508 (w), 492 (w), 460 (w), 421

(w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.21 (s, 3H, 8-H), 1.35 (dddd, J = 12.8 Hz, 12.8 Hz, 12.8 Hz, 12.8 Hz, 4.8 Hz, 1H, 2-H_a), 1.62 (s, br, 2H, 2xOH), 1.70 – 1.80 (m, 1H, 2-H_b), 2.19 –2.28 (m, 1H, 3-H), 2.81 (dd, J = 14.1 Hz, 11.3 Hz, 1H, 6-H_a), 3.19 (dd, J = 14.1 Hz, 2.8 Hz, 1H, 6-H_b), 3.32 – 3.41 (m, 1H, 1-H_a), 3.42 (d, J = 11.1 Hz, 1H, 9-H_a), 3.59 (d, J = 11.1 Hz, 1H, 9-H_b), 3.94 – 4.02 (m, 1H, 1-H_b), 4.21 (dd, J = 10.9 Hz, 5.4 Hz, 1H, 4-H), 4.24 – 4.30 (m, 1H, 5-H), 6.83 – 6.93 (m, 3H, 3'-H, 4'-H, 5'-H), 6.97 – 7.03 (m, 2H, 2'-H, 6'-H), 7.24 – 7.30 (m, 1H, 5"-H), 7.33 – 7.40 (m, 1H, 6"-H), 7.42 – 7.50 (m, 2H, 3"-H, 4"-H). ¹³C-NMR (126 MHz, CDCl₃) δ 18.7 (C-8), 27.7 (C-2), 30.0 (C-6), 40.2 (C-3), 40.3 (C-1), 61.2 (C-5), 68.3 (C-9), 71.9 (C-4), 76.4 (C-7), 124.2 (C-3"), 126.3 (C-4'), 128.1 (C-3', C-5'), 129.2 (C-2', C-6'), 130.6 (C-6"), 131.9 (C-5"), 132.8 (C-4"), 134.0 (C-1"), 138.5 (C-1'), 147.1 (C-2"). HRMS (ESI): calc (found) for C₂₁H₂₆N₂O₇S ([M+H]⁺): 451.1533 (451.1533).



(S,R,S)-36f

(S,R,S)-36f, mp 160 °C. [α]_D²⁰ + 270 (c 0.1 in CHCl₃). R_f = 0.19 (hexanes/EtOAc, 1 : 2, anisaldehyde solution). FT-IR (ATR): \tilde{v} = 3029 (w), 2935 (m), 1541 (vs), 1497 (w), 1454 (m), 1440 (m), 1370 (s), 1335 (s), 1282 (m), 1159 (s), 1124 (s), 1097 (m), 1069 (m), 1014 (w), 957 (m), 912 (w), 865 (m), 853 (m), 778 (w), 756 (s), 739 (m), 700 (m), 652 (w), 591 (s), 570 (m), 508 (w) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 1.26 (s, 3H, 8-H), 1.42 (dddd, J = 13.1 Hz,

13.1 Hz, 13.1 Hz, 4.7 Hz, 1H, 2-H_a), 1.80 – 1.89 (m, 1H, 2-H_b), 2.06 – 2.15 (m, 1H, 3-H), 2.78 (dd, J = 14.2 Hz, 11.2 Hz, 1H, 6-H_a), 3.17 (dd, J = 14.2 Hz, 2.3 Hz, 1H, 6-H_b), 3.29 – 3.40 (m, 1H, 1-H_a), 3.57 (d, J = 10.4 Hz, 1H, 9-H_a), 3.86 (d, J = 10.4 Hz, 1H, 9-H_b), 3.98 – 4.06 (m, 1H, 1-H_b), 4.15 – 4.27 (m, 2H, 4-H, 5-H), 6.83 – 6.93 (m, 3H, 3'-H, 4'-H, 5'-H), 6.97 – 7.03 (m, 2H, 2'-H, 6'-H), 7.24 – 7.30 (m, 1H, 5"-H), 7.35 – 7.40 (m, 1H, 6"-H), 7.42 – 7.52 (m, 2H, 3"-H, 4"-H). ¹³C-NMR (126 MHz, CDCl₃) δ 24.2 (C-8), 27.8 (C-2), 29.8 (C-6), 40.7 (C-1), 44.1 (C-3), 61.5 (C-5), 66.2 (C-9), 72.3 (C-4), 76.1 (C-7), 124.2 (C-3"), 126.3 (C-4'), 128.1 (C-3', C-5'), 129.2 (C-2', C-6'), 130.7 (C-6"), 132.0 (C-5"), 132.8 (C-4"), 133.9 (C-1"), 138.5 (C-1'), 147.0 (C-2"). HRMS (ESI): calc (found) for C₂₁H₂₆N₂O₇S ([M+Na]⁺): 473.1353 (473.1359).

3) Functionalizations of hydroxypiperidines

In addition to the previous efforts a series of functionalizations of hydroxypiperidines was examined (Table S1). We aimed towards iminosugar analogues with different substitution patterns and stereoinformation to create a variety of compounds for the following biological examinations.

Table S1: Functionalization of olefin to diols 34


entry		substrate	R	yield ^a (R,S,X)- 34 [%]	dr ^b	yield ^c (S,S,X)- 34 [%]	dr ^d
1	L-Val	(R,S)-30a	i-Pr	42	74:26	-	-
2	L-Val	(S)-S2a	<i>i</i> -Pr	-	-	40	57:73
3	$\operatorname{D-Val}^e$	(R)-S2b	<i>i</i> -Pr	8	1:99<	74	49:51
4	L-Leu	(S)-S2c	<i>i</i> -Bu	-		49	59:41
5	L-Phe	(S)-S2f	Bn	13	23:77	36	42:58

^a Combined yields of (*R*,*S*,*S*)-**34** and (*R*,*S*,*R*)-**34**; ^b Diastereomeric ratio of (*R*,*S*,*S*)-**34** and (*R*,*S*,*R*)-**34**; ^c Combined yields of (*S*,*S*,*S*)-**34** and (*S*,*S*,*R*)-**34**; ^d Diastereomeric ratio of (*S*,*S*,*S*)-**34** and (*S*,*S*,*R*)-**34**; ^e Starting from D-valine, all stereocenters are inverted. ^{d,e} Diastereomeric ratios were determined by HPLC and/or ¹H-NMR. In case of dr >99: 1 no traces of the minor diastereomer could be detected by ¹H-NMR.

Conversion of L-Val alkene (R,S)-30a to diol (R,S,X)-34a was achieved by hydroboration using borane-THF solution. Two diastereomers (R,S,S)-34a and (R,S,R)-34a (entry 1) were isolated in a combined yield of 42 % with a diastereomeric ration of 74 : 26 after separation via HPLC. Since NOESY-data of our compounds showed no major differences due to the free rotation of the *exo*cyclic group, the newly formed stereocenter was assigned by comparison to similar structures in the literature.^[18]

In an attempt to invert the stereoinformation at C-4 of these diols, the alkenes 30 were first converted to their corresponding ketones (S)-S2 by DMP-oxidation according to the literature [6,16] in good yields (82 % - quant). This gave the additional benefit of using mixtures of alkenes (R,S)-30 and (S,S)-30, which differed at the C-4, without the necessity of prior separation of the alkenes by HPLC. Employing the ketones (S)-S2 in borane-mediated hydroboration under the same conditions as before, led to diols (S,S,S)-34 and (S,S,R)-34 with inverted stereochemistry at C-4 compared to the first attempt (entry 1). For L-valine no additional diols (R,S)-34a were observed with this method. Instead the diols (S,S,S)-34a and (S,S,R)-34a were isolated with the desired inversion with a combined yield of 40 % (dr 57:43) (entry 2). For D-valine diols (R,R,R)-34b and (R,R,S)-34b (all stereocenters are inverted) were isolated with a combined yield of 74 % (dr 49 : 51) (entry 3). In addition diol (S,R,S)-34b was isolated with 8 % yield as a single diastereomer. L-leucine ketone (S)-S2c gave (S,S,S)-34c and (S,S,R)-34c with a combined yield of 49 % (dr 59 : 41) (entry 4). Turning to L-phenylalanine all four diastereomers could be observed and isolated. The diols (R,S,S)-34f and (R,S,R)-34f were isolated with a combined yield of 13 % (dr 23:77) and the diols (S,S,S)-34f and (S,S,R)-**34f** were isolated with a combined yield of 36 % (dr 42:58) (entry 5). While being isolated mostly as solids, none of these diols could be recrystallized from different solvents to obtain crystal structures for assignment of the newly created *exo*cyclic stereocenter. Hence comparison to the literature^[18] as described above was necessary.

To increase the polarity of the products we addressed next the synthesis of the corresponding triols **36** (Scheme S1). Therefore alkenes **30** were converted to their corresponding epoxides **35** by using m-CPBA. The epoxides were isolated as mixtures of diastereomers (R,R,S)-**35** and (R,R,R)-**35** and were separated for analytical purposes. The newly formed stereocenter couldn't be assigned from the measured NOESY-spectra and therefore assignment was done by comparison of the epoxides **35** to similar compounds from the literature^[19] and correlation with the triols **36**. The L-valine based epoxides (R,R,S)-**35a** and (R,R,R)-**35a** were isolated with a combined yield of 93 % (dr 44 : 56) (entry 1), while D-valine gave the epoxides (S,S,R)-**35b** and (S,S,S)-**35b** with a combined yield of 70 % (dr 33 : 67) (entry 2). For L-phenylalanine both diastereomers, (R,S)-**30f** as well as (S,S)-**30f**, could successfully be converted (entries 3,4). First, the epoxides (R,R,S)-**35f** and (R,R,S)-**35f** were isolated with a combined yield of 97 % (dr 60 : 40) (entry 3) and in a following experiment the epoxides (S,R,S)-**35f** and (S,R,S)-**35f** were isolated with a combined yield of 79 % (44 : 56) (entry 4).



Scheme S1 ^a All stereocenters are inverted for D-valine; ^b A mixture of (R,R,S)-35f and (R,R,R)-35f was used; ^c dr of (S,R,S)- and (S,R,R)-derivatives. ^a Diastereomeric ratios were determined by HPLC and/or ¹H-NMR.

Subsequently, the epoxide groups were opened with perchloric acid to yield the corresponding triols as mixtures of diastereomers differing at the newly formed stereocenter (Scheme 7). The assignment of the new stereocenter was done by comparison to the literature^[20] for the same reasons as described above. Also, no crystal structures could be obtained for both species. After separation of the epoxides (R,R,S)-35a and (R,R,R)-35a, the single diastereomer (R,R,S)-35a was converted to triols (R,R,S)-36a and (R,R,R)-36a with a combined yield of 44 % (dr 93: 7) (entry 5), while epoxide (R,R,R)-35a gave the corresponding triols with a combined yield of 25 % (dr 16: 84) (entry 6). D-Valine epoxide (S,S,S)-35b gave the corresponding triols (S,S,R)-36b and (S,S,S)-36b in a combined yield of 50 % (dr 12: 88) (entry 7). For

L-phenylalanine a mixture of both epoxides (R,R,S)-35f and (R,R,R)-35f was used, which gave the triols (R,R,S)-36f and (R,R,R)-36f in a combined yield of 78 % (dr 50 : 50) (entry 8). Switching to epoxide (S,R,R)-35f of L-phenylalanine gave the corresponding triols (S,R,S)-36f and (S,R,R)-36f in a combined yield of 35 % (dr 31 : 69) (entry 9). Using a single diastereomer of the epoxides gave one of their corresponding triols as major product, which resemble the orientation of the starting material. Mixtures of epoxides could be used as well and gave both diastereomers in the same amount.

4) Stereochemical elucidation of the cyclic hydroxypiperidines

All endocyclic stereocenters of the piperidine ring system could be assigned by analyzing the coupling constants between attached hydrogens using standard Karplus relations. The resulting structures were then verified by comparison to NOESY spectra.

One example for this approach is given in Table S2 by comparison of L-valine derivatives (R,S)-30a and (S,S)-30a. This method was applied for all further compounds of this work in an analogous procedure.

Table S2: Comparison of ${}^{3}J$ -coupling constants for stereo elucidation of L-valine derivatives (R,S)-30a and (S,S)-30a. *Equatorial* hydrogens were marked in red, *axial* hydrogens in blue.

Entry	Coupling	(R,S)- 30a	(S,S)-30a		
Liftiy	constant	(H,S) 30 u	(5,5) 504		
(1)	$^3J_{ m 2H(ax)-3H}$	12.7 Hz	13.0 Hz		
(2)	$^3J_{ m 3H\text{-}4H}$	<5 Hz ^a	10.8 Hz		
(3)	$^3J_{ m 4H-5H}$	<5 Hz ^a	5.2 Hz		

^a Coupling constants taken from multiplet.

The Karplus relation was used to distinguish between *axial* and *equatorial* hydrogens in the six-membered ring system (Table S2). The stereocenter at C-5 was given by L-valine as the starting material. Since alkene (*R*,*S*)-30a showed a coupling constant of 12.7 Hz between one hydrogen of C-2 and C-3 (entry 1), these two hydrogens were in an *axial-axial-correlation*. This information led to an *axial* position of the isopropyl side chain at C-5. Both the coupling constants between hydrogens at C-3 and C-4 as well as between hydrogens at C-4 and C-5 were taken from multiplets and showed values of <5 Hz respectively (entries 2 and 3). Coming from an *axial* position of the hydrogen at C-3, this led to both hydrogens at C-4 and C-5 being in an *equatorial* position. A similar approach for alkene (*S*,*S*)-30a gave again an *axial* position for

the hydrogen at C-3 because of a coupling constant of 13.0 Hz between one of the hydrogens at C-2 and C-3 (entry 1). This time however the coupling constant between the hydrogens at C-3 and C-4 showed a value of 10.8 Hz (entry 2), which indicated an *axial-axial* relation. Therefore, the hydrogen at C-4 was assigned to an *axial* position. The coupling constant for the hydrogens at C-4 and C-5 showed a value of 5.2 Hz (entry 3), which was possible for the expected *axial-equatorial* correlation. The resulting structures were compared to NOESY data for the investigated compounds (Table S3). This confirmed the previously assigned structures.

The newly formed exocyclic stereocenter of the functionalized hydroxy piperidines was assigned by comparison to similar structures from the literature (see Table S4-S8, only selected examples were shown). This method was applied for all further compounds of this work in an analogous procedure.

One example is given in Table S4 by comparison of the L-valine derivatives (R,S,X)-34a and the L-phenylalanine derivatives (R,S,X)-34f with compound S3 from the literature. The signals from the 1 H and 13 C NMR-spectra for the exocyclic group containing the newly formed stereocenter were analyzed. The chemical shift values for the 8-H of S3 were more like the values obtained for the first diols (entry 1). Also, the values for the chemical shifts and coupling constants of 9-H_a and 9-H_b were a better fit with these compounds (entries 2 and 3). The values for 10-H (entry 4) were fitting this assignment as well, while the comparison of 13 C NMR signals gave no clear relation to one of these compounds (entries 5 – 7).. However because of the mentioned similarities in the 1 H NMR data the first diols were assigned as (R,S,S)-34a and (R,S,S)-34f, while the second diols were assigned as (R,S,R)-34f. Similar analysis led to assignment of further compounds derived from other amino acids.


Table S3: Comparison of NOESY-signals for L-valine derivatives (*R*,*S*)-**30a** and (*S*,*S*)-**30a**. Color coding: red: no signal observed, green: signal visible, yellow: no information due to overlapping signals, orange: diagonal.

	1-H _{ax}	1-H _{eq}	2-H _{ax}	2-H _{eq}	3-H	4-H	5-H	6-H	7/8-H	8/7-H	10-H	11-H _a	11-H _b	
1-H _{ax}														8 11
1-H _{eq}														6 5 3
2-H _{ax} 2-H _{eq} 3-H 4-H														8 OH 11 7 O-Ns N 1 2
2-H _{eq}														$\frac{\dot{N}}{2}$
3-H														0-1NS
4-H														III
5-H														Na
6-H														HNS
7/8-H														← → → → → → → → → → →
8/7-H														HR OH
10-H														(R,S)-30a
11-H _a														
11-H _b														
1-H _{ax}														
1-H _{eq} 2-H _{ax}														ı OH II
2-H _{ax}														(S)
2-H _{eq}														N = 1
3-H														o-Ns N
2-H _{eq} 3-H 4-H 5-H														OH (S) := O-Ns N
5-H														
6-H														_H Ns
7/8-H														HNS H OH
8/7-H														HR H
10-H														H ' H
11-H _a														(S,S)-30a
11 - H_b														

Table S4: Comparison of NMR data with the literature known compound $S3^{[21]}$ for the assignment of the newly formed stereocenter of diols (R,S,X)-34a,f.

Entry		(R,S,S)-34a	(R,S,R)-34a	(R,S,S)-34f	(R,S,R)- 34f	S3
(1) (2)	8-H 9-H _a	1.61-1.69 (m) 3.50 (dd,	1.70-1.80 (m) 3.45 (dd,	1.66-1.75 (m) 3.49 (dd,	1.70-1.82 (m) 3.50 (dd,	1.62 (m) 3.56 (dd,
(2)	> 11a	J = 11.2, 5.2 Hz	J = 11.1, 4.2 Hz	J = 11.0, 5.1 Hz	J = 11.0, 4.4 Hz	J = 11.0, 6.0 Hz
(3)	$9-H_b$	3.65 (dd,	3.49 (dd,	3.63 (dd,	3.53 (dd,	3.68 (dd,
		J = 11.2, 3.0 Hz	J = 11.1, 6.4 Hz	J = 11.0, 3.0 Hz	J = 11.0, 6.3 Hz	J = 11.0, 3.0 Hz
(4)	10-H	0.93-1.00 (m)	0.97 (d, J = 10.6 Hz)	1.00 (d, J = 6.9 Hz)	0.95 (d, J = 7.0 Hz)	1.00 (m, J = 7.0 Hz)
(5)	C-8	37.3	37.6	37.1	37.3	38.1
(6)	C-9	64.6	64.5	64.6	64.5	65.0
(7)	C-10	15.4	16.3	15.3	16.2	15.9

Table S5: Comparison of NMR data with the literature known compound $S4^{[18]}$ for the assignment of the newly formed stereocenter of diols (S,S,X)-34a,f.



Entry		(S,S,S)-34a	(S,S,R)- 34a	(S,S,S)- 34f	(S,S,R)- 34f	S4
(1)	8-H	1.95-2.13 (m)	1.87-2.00 (m)	1.95-2.10 (m)	1.90-2.02 (m)	1.80-1.88 (m)
(2)	9-H _a	3.47 (dd,	3.54 (dd,	3.56 (dd,	3.63 (dd,	3.56 (dd,
		J = 10.5, 7.8 Hz	J = 10.6, 2.8 Hz	J = 10.5, 7.8 Hz	J = 10.5, 3.1 Hz	J = 10.7, 3.4 Hz
(3)	$9-H_b$	3.60 (dd,	3.63 (dd,	3.70 (dd,	3.74 (dd,	3.65 (dd,
		J = 10.5, 5.2 Hz	J = 10.6, 6.3 Hz	J = 10.5, 4.8 Hz	J = 10.5, 5.8 Hz	J = 10.7, 5.5 Hz
(4)	10-H	0.77 (d, J = 6.9 Hz)	0.87 (d, J = 7.3 Hz)	0.91 (d, J = 6.9 Hz)	0.99 (d, J = 7.3 Hz)	-
(5)	C-8	34.8	40.4	35.6	37.4	_
(6)	C-9	66.0	66.1	66.1	66.4	67.2
(7)	C-10	11.9	12.2			11.9

Table S6: Comparison of NMR data with the literature known compounds **S5** and **S6**^[17] for the assignment of the newly formed stereocenter of triols (R,R,X)-36a,f.





Table S7: Comparison of NMR data with the literature known compounds **S7** and $S8^{[20]}$ for the assignment of the newly formed stereocenter of triols (S,R,X)-36a,f.

Table S8: Comparison of NMR data with the literature known compounds **S9** and **S10**^[19] for the assignment of the newly formed stereocenter of epoxides (S,R,X)-35f.



5) Chitin fiber synthesis assay with Thalassiosira rotula




Figure S1: Nonlinear regression model fit of the single cell measurements. **A**: Interpretation of the calculated parameters. *e* is the halfway point (time where half the maximum length of the chitin is synthesized), *b* is the Hill slope (relative slope at the halfway point), *d* is the achieved length of the synthesized chitin fiber. Black dots are original chitin length measurements of cell 1 from the DMSO control (see Supplementary File 1 - Thalassiosira Measurements). Blue line represents the calculated fit. Light-blue ribbon signifies the 95% confidence interval calculated with the *predict* function in $R^{(22)}$. **B-F**: Three-parameter logistic fit of the single chitin measurements for each individual treatment. **B**: (*S*,*S*)-32f, **C**: (*R*,*S*)-33e, **D**: (*R*,*S*)-33f, and **E**: (*R*,*R*)-33e). For each treatment condition the cells were supplemented with 100 μM (final concentration) iminosugar and were observed for 100 min. All fits were calculated with the *drm* function (LL.3) of the drc package (version 3.0-1) in $R^{(23)}$.





Figure S2: Average of the three-parameter logistic fit of the iminosugar-treated cells (blue line). The original measured datapoints are represented by black dots. In each dataset the cells were treated with 100 μ M iminosugar (final concentration) and were observed for 100 min. **A**: Control with DMSO, **B**: (*S*,*S*)-32f, **C**: (*R*,*S*)-32e, **D**: (*R*,*S*)-32f, and **E**: (*R*,*R*)-33e. All fits were calculated with the *drm* function (LL.3) of the drc package (version 3.0-1) in the R environment^[23].


6) Literature

- [1] L. Fanter, D. Schepmann, B. Wünsch, Archiv der Pharmazie n.d., 351, 1700334.
- [2] J. Tauchman, I. Císařová, P. Štěpnička, European Journal of Organic Chemistry **2010**, 2010, 4276–4287.
- [3] J. Li, Y. Sha, *Molecules* **2008**, *13*, 1111–1119.
- [4] M. Cambiè, P. D'Arrigo, E. Fasoli, S. Servi, D. Tessaro, F. Canevotti, L. Del Corona, *Tetrahedron: Asymmetry* **2003**, *14*, 3189–3196.
- [5] S. G. Davies, H. J. Sanganee, P. Szolcsanyi, *Tetrahedron* **1999**, *55*, 3337–3354.
- [6] Y. Liu, A. Maden, W. V. Murray, Tetrahedron 2002, 58, 3159–3170.
- [7] W. Russell Bowman, D. R. Coghlan, *Tetrahedron* **1997**, *53*, 15787–15798.
- [8] A. Yen, A. H. Pham, E. M. Larin, M. Lautens, *Org. Lett.* **2019**, *21*, 7549–7553.
- [9] E. Biron, H. Kessler, *J. Org. Chem.* **2005**, *70*, 5183–5189.
- [10] F. Salvaggio, J. T. Hodgkinson, L. Carro, S. M. Geddis, W. R. J. D. Galloway, M. Welch, D. R. Spring, Eur. J. Org. Chem. 2016, 2016, 434–437.
- [11] S. Laschat, M. Grehl, Chem. Ber. 1994, 127, 2023–2034.
- [12] T. K. Sarkar, S. K. Nandy, Tetrahedron Letters 1996, 37, 5195–5198.
- [13] C. A. M. Cariou, B. M. Kariuki, J. S. Snaith, Org. Biomol. Chem. 2008, 6, 3337–3348.
- [14] U. Voigtmann, S. Blechert, Org. Lett. 2000, 2, 3971–3974.
- [15] J. J. Turner, N. Wilschut, H. S. Overkleeft, W. Klaffke, G. A. van der Marel, J. H. van Boom, *Tetrahedron Letters* **1999**, *40*, 7039–7042.
- [16] W.-D. Z. Li, Z.-H. Gao, Org. Lett. 2005, 7, 2917–2920.
- [17] F. J. Aladro, F. M. Guerra, F. J. Moreno-Dorado, J. M. Bustamante, Z. D. Jorge, G. M. Massanet, *Tetrahedron* **2001**, *57*, 2171–2178.
- [18] J. A. Moreira, A. G. Corrêa, *Tetrahedron: Asymmetry* **2003**, *14*, 3787–3795.
- [19] J. H. Kim, H. J. Lim, S. H. Cheon, Tetrahedron 2003, 59, 7501–7507.
- [20] T. M. Le, T. Huynh, G. Endre, A. Szekeres, F. Fülöp, Z. Szakonyi, RSC Adv. 2020, 10, 38468–38477.
- [21] J. Casanovas, A. M. Namba, S. León, G. L. B. Aquino, G. V. J. da Silva, C. Alemán, *J. Org. Chem.* **2001**, *66*, 3775–3782.
- [22] R Core Team, R: A Language and Environment for Statistical Computing, Vienna, Austria, 2022.
- [23] C. Ritz, F. Baty, J. C. Streibig, D. Gerhard, *PLOS ONE* **2015**, *10*, e0146021.


7) NMR-spectra




¹H-NMR **S1**




¹³C-NMR **S1**




¹H-NMR **25a**




¹³C-NMR **25a**





¹H-NMR **26a**






¹H-NMR **27a**






¹H-NMR **28a**






Current Data Parameters NAME Jan20-2020 EXPNO 731 PROCNO 1	
F2 - Acquisition Parameters Date	
SF01 100.6152851 MHz NUC1 13C P1 10.00 use	
SF02 400.1016004 MHz NUC2 1H CPDPRG[2 waltz16 PCPD2 90.00 user PLW2 12.0000000 W PLW12 0.27805999 W PLW13 0.22522999 W	
F2 - Processing parameters SI 32768 SF 100.6052250 MHz WDW EM SSB 0	
LB 1.00 Hz GB 0	


1.40





¹H-NMR **29a**





¹³C-NMR **29a**














¹H-NMR (*R*,*S*)-**32a**





¹³C-NMR (*R,S*)-**32a**







¹³C-NMR (*R*,*R*)-**31a**







¹³C-NMR (*R*,*R*)-**31a**












¹³C-NMR (*S,S,R*)-**34a**




¹H-NMR (S,S,S)-**34a**







S108




11VII(11,5,5)-**3-a**





S110





S111


















Current Da	ata Parameters
NAME	May31-2021
EXPNO	51
PROCNO	ī
1100110	*
F2 - Acqui	sition Parameters
Date_	20210531
Time	18.04
INSTRUM	spect
	5 mm CPQCI 1H-
PULPROG	zgpq30
ID	65356
And the state of t	CDC13
SOLVENT	
NS	1024
DS	4
SWH	40760.871 Hz
FIDRES	0.623675 Hz
AQ	0.8017003 sec
RG	182.53
DW	12.267 usec
DE	18.00 usec
TE	298.0 K
D1	2.00000000 sec
D11	0.03000000 sec
TD0	1
	CHANNEL f1 ======
SFO1	176.1232717 MHz
NUC1	13C
P1	12.00 usec
PLW1	105.00000000 W
======= (CHANNEL f2 ======
SFO2	700.3628014 MHz
NUC2	1H
CPDPRG[2	waltz16
PCPD2	65.00 usec
PLW2	9.89999962 W
PLW12	0.15564001 W
PLW13	0.07837200 W
F2 - Proce	essing parameters
SI	131072
SF	176.1056620 MHz
WDW	EM
SSB (
LB	1.00 Hz
GB (
PC	1.40










¹H-NMR **25b**




S121










¹H-NMR **27b**










¹³C-NMR **28b**




¹H-NMR **29b**










¹³C-NMR (*S*,*R*)-**30b**









¹H-NMR (R)-**S2b**







Current I NAME EXPNO PROCNO	Data Parameters Jun02-2020 41	
FROCIO	1	
F2 - Acqu	uisition Parame	ters
Date_	20200602	
Time	21.37	
INSTRUM	spect	
	5 mm PABBO BB-	
PULPROG	zgpg30	
TD	65536	
SOLVENT	CDC13	
NS	1024	
DS	4	
SWH	32894.738	
FIDRES	0.501934	
AQ	0.9961472	sec
RG	2580	
DW	15.200	usec
DE	10.00	
TE	296.0	
D1	2.00000000	
D11 TD0	0.03000000	sec
IDU	T	
	CHANNEL f1 ===	
NUC1	13C	
P1	10.20	11500
PL1	1.50	
PL1W	51.74793243	
SFO1	125.7761482	
	CHANNEL f2 ====	
CPDPRG[2	waltz16	
NUC2	1H	
PCPD2	100.00	
PL2	1,00	
PL12	19.99	
PL13	21.00	dB
PL2W	19.75309753	
PL12W	0.24925002	
PL13W SFO2	0.19753097 500.1550006	
SEUZ	200.1320006	MHZ
F2 - Broo	cessing paramet	o v.c
SI PIOC	32768	OTD
SF	125.7635720	MHz
WDW	EM	
	0	
LB	1.00	Hz
	0	0.000000
PC	1.40	









¹H-NMR (*S,S*)-**33b**







¹H-NMR (*R*,*R*,*S*)-**34b**







Current I	Data Parameters
NAME	Oct30-2020
EXPNO	51
PROCNO	1
F2 - Acan	isition Parameters
Date	20201030
Time	22.24
INSTRUM	spect
	5 mm PABBO BB-
PULPROG	zgpg30
TD	65536
SOLVENT	CDC13
NS	2048
DS	2010
SWH	32894.738 Hz
FIDRES	0.501934 Hz
AO	0.9961472 sec
RG	2580
DW	15.200 used
DE	10.00 used
TE	296.0 K
D1	2.000000000 sec
D11	0.03000000 sec
TD0	1
	CHANNEL f1 ======
NUC1	13C
P1	10.20 used
PL1	1.50 dB
PL1W	51.74793243 W
SF01	125.7761482 MHz
	CHANNEL f2 ======
CPDPRG[2	waltz16
NUC2	1H
PCPD2	100.00 used
PL2	1.00 dB
PL12	19.99 dB
PL13	21.00 dB
PL2W	19.75309753 W
PL2W PL12W	19.75309753 W 0.24925002 W
PL2W PL12W PL13W	19.75309753 W 0.24925002 W 0.19753097 W
PL2W PL12W	19.75309753 W 0.24925002 W
PL2W PL12W PL13W SF02 F2 - Proc	19.75309753 W 0.24925002 W 0.19753097 W 500.1550006 MHz
PL2W PL12W PL13W SF02 F2 - Proc SI	19.75309753 W 0.24925002 W 0.19753097 W 500.1550006 MHz cessing parameters 32768
PL2W PL12W PL13W SF02 F2 - Proc SI SF	19.75309753 W 0.24925002 W 0.19753097 W 500.1550006 MHz cessing parameters 32768 125.7635720 MHz
PL2W PL12W PL13W SF02 F2 - Proc SI SF WDW	19.75309753 W 0.24925002 W 0.19753097 W 500.1550006 MHz cessing parameters 32768 125.7635720 MHz EM
PL2W PL12W PL13W SF02 F2 - Proc SI SF WDW SSB	19.75309753 W 0.24925002 W 0.19753097 W 500.1550006 MHz dessing parameters 32768 125.7635720 MHz EM
PL2W PL12W PL13W SF02 F2 - Proc SI SF WDW SSB LB	19.75309753 W 0.24925002 W 0.19753097 W 500.1550006 MHz cessing parameters 32768 125.7635720 MHz EM 0
PL2W PL12W PL13W SF02 F2 - Proc SI SF WDW SSB	19.75309753 W 0.24925002 W 0.19753097 W 500.1550006 MHz cessing parameters 32768 125.7635720 MHz EM















Current I	Data Parameters
NAME	Nov06-2020
EXPNO	131
PROCNO	1
PROCNO	1
	uisition Parameters
Date_	20201107
Time	4.10
INSTRUM	spect
PROBHD	5 mm PABBO BB-
PULPROG	zgpq30
TD	65536
SOLVENT	CDC13
NS	2048
DS	4
SWH	32894.738 Hz
FIDRES	0.501934 Hz
AQ	0.9961472 sec
RG	2580
DW	15.200 usec
DE	10.00 usec
TE	297.0 K
D1	2.00000000 sec
D11	0.03000000 sec
TDO	1
IDO	1
	CHANNEL fl ======
NUC1	13C
P1	10.20 usec
PL1	1.50 dB
PL1W	51.74793243 W
SFO1	125.7761482 MHz
=======	CHANNEL f2 ======
CPDPRG[2	waltz16
NUC2	1H
PCPD2	100.00 usec
PL2	1.00 dB
PL12	19.99 dB
PL13	21.00 dB
PL2W	19.75309753 W
PL12W	0.24925002 W
PL13W	0.19753097 W
SFO2	500.1550006 MHz
F2 - Pro	cessing parameters
SI	32768
SF	125,7635720 MHz
WDW	EM
	0
SSB	
LB	1.00 Hz
GB	0
PC	1.40












¹³C-NMR (*S,S,R*)-**35b**










Current	
	Data Parameters
NAME	Apr08-2021
EXPNO	41
PROCNO	1
F2 - Acq	uisition Parameters
Date_	20210408
Time	15.47
INSTRUM	spect
PROBHD	5 mm PABBO BB-
PULPROG	zapa30
TD	65536
SOLVENT	CDC13
NS	1024
DS	4
SWH	32894.738 Hz
FIDRES	0.501934 Hz
AQ	0.9961472 sec
RG	2580
DW	15.200 usec
DE	10.00 usec
TE	296.0 K
D1	2.00000000 sec
D11	0.03000000 sec
TDO	1
	Marian Anna Marian Anna Anna Anna Anna Anna Anna Anna A
	CHANNEL f1 ======
NUC1	13C
P1	
	10.20 usec
PL1	1.50 dB
PL1W	1.50 dB 51.74793243 W
	1.50 dB
PL1W SF01	1.50 dB 51.74793243 W 125.7761482 MHz
PL1W SF01	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ======
PL1W SF01 ====== CPDPRG[2	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 ===== CPDPRG[2 NUC2	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 ====== CPDPRG[2 NUC2 PCPD2	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 waltz16 1H 100.00 usec
PL1W SF01 ====== CPDPRG[2 NUC2 PCPD2 PL2	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 waltz16 1H 100.00 usec 1.00 dB
PL1W SF01 ====== CPDPRG[2 NUC2 PCPD2	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 ====== CPDPRG[2 NUC2 PCPD2 PL2	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 ——————— CPDPRG[2 NUC2 PCPD2 PL12 PL12 PL13 PL2W	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2
PL1W SF01 ====== CPDPRG[2 NUC2 PCPD2 PL2 PL12 PL13	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 ——————— CPDPRG[2 NUC2 PCPD2 PL12 PL12 PL13 PL2W	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2
PL1W SF01 ====================================	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PLIW SF01 	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2
PL1W SF01 ======= CPDPRG[2 NUC2 PCPD2 PL12 PL13 PL2W PL13W PL13W SF02 F2 - Pro SI SF	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PLIW SF01 ====================================	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2 ===================================
PL1W SF01 ======= CPDPRG[2 NUC2 PCPD2 PL12 PL13 PL2W PL13W SF02 F2 - Pro SI SF WDW SSB	1.50 dB 51.74793243 W 125.7761482 MHz CHANNEL f2










¹H-NMR **25**c










¹³C-NMR **26c**













¹³C-NMR **28c**





¹H-NMR **29**c






















NAME	Data Parameters Jun25-2021	
EXPNO	121	
PROCNO	1	
	uisition Parame	ters
Date_	20210626	
Time	17.20	
INSTRUM	spect	
PROBHD	5 mm PABBO BB-	
PULPROG	zgpg30	
TD	65536	
SOLVENT	CDC13	
NS	1024	
DS	4	
SWH	32894.738	
FIDRES	0.501934	
AQ	0.9961472	
RG	2580	
DW	15.200	
DE	10.00	
TE	296.0	
D1	2.00000000	
D11	0.03000000	sec
TD0	1	
	CHANNEL fl ====	
NUC1	13C	
P1	10.20	
PL1	1.50	
PL1W	51.74793243	
SF01	125.7761482	MHZ
	CHANNEL f2	
CPDPRG[2 NUC2	waltz16	
PCPD2	100.00	usec
PL2	1.00	dB
PL12	19.99	dB
PL13	21.00	dB
PL2W	19.75309753	W
PL12W	0.24925002	W
PL13W	0.19753097	W
SF02	500.1550006	MHz
F2 - Pro	cessing paramete	ers
SI	32768	
SF	125.7635720	MHz
WDW	EM	
SSB	0	
LB	1.00	Hz
GB	0	
PC	1.40	










Current Dat	a Parameters	
NAME	Jun25-2021	
EXPNO	131	
PROCNO	1	
	ition Parame	ters
Date_	20210626	
Time	18.21	
INSTRUM PROBHD 5	spect mm PABBO BB-	
PULPROG	zqpq30	
TD	65536	
SOLVENT	CDC13	
NS	1024	
DS	4	
SWH	32894.738	Цz
FIDRES	0.501934	
AQ	0.9961472	
RG	2580	000
DW	15,200	usec
DE	10.00	
TE	296.0	K
D1	2.00000000	sec
D11	0.03000000	sec
TD0	1	
====== CH	ANNEL fl ===:	
	ANNEL f1 ====	
HOUC1	13C	
NUC1		usec
NUC1 P1 PL1 PL1W	13C 10.20	usec dB
NUC1 P1 PL1	13C 10.20 1.50	usec dB W
NUC1 P1 PL1 PL1W SF01	13c 10.20 1.50 51.74793243 125.7761482	usec dB W MHz
NUC1 P1 PL1 PL1W SF01	13C 10.20 1.50 51.74793243 125.7761482 ANNEL f2 ====	usec dB W MHz
NUC1 P1 PL1 PL1W SF01	13C 10.20 1.50 51.74793243 125.7761482 ANNEL f2 ==== waltz16	usec dB W MHz
NUC1 P1 PL1 PL1W SF01	13C 10.20 1.50 51.74793243 125.7761482 ANNEL f2 ====	usec dB W MHz
NUC1 P1 PL1 PL1W SF01 ————————————————————————————————————	13C 10.20 1.50 51.74793243 125.7761482 ANNEL f2 waltz16 1H	usec dB W MHz
NUC1 P1 PL1 PL1W SF01 ====== CH CPDPRG[2 NUC2 PCPD2	13C 10.20 1.50 51.74793243 125.7761482 ANNEL f2 ==== waltz16 1H 100.00	usec dB W MHz
NUC1 P1 PL1 PL1W SF01 ====== CH CPDPRG[2 NUC2 PCPD2 PL2	13C 10.20 11.50 51.74793243 125.7761482 ANNEL f2 waltz16 14 100.00 1.000 1.000 19.99 21.00	usec dB W MHz usec dB dB dB
NUC1 P1 PL1 PL1W SF01 ====== CH CPDPRG[2 NUC2 PCPD2 PL2 PL12 PL13 PL2W	13C 10.20 51.74793243 125.7761482 ANNEL f2 ==== waltz16 100.00 19.99 21.00 19.75309753	usec dB W MHz usec dB dB dB dB
NUC1 P1 PL1W SF01 ======= CH CPDPRG[2 NUC2 PCPD2 PCPD2 PL12 PL12 PL13 PL2W PL12W	13C 10.20 51.74793243 125.7761482 ANNEL f2 ==== waltz16 1H 100.00 19.99 21.00 19.75309753 0.24925002	usec dB W MHz usec dB dB dB dB W W
NUC1 P1 PL1 PL1W SF01 ===== CH CPDPRG[2 NUC2 PCPD2 PL2 PL12 PL13 PL2W PL13W	13C 10.20 10.20 51.74793243 125.7761482 ANNEL f2 waltz16 10.00 1.00 19.99 21.00 19.75309753 0.24925002 0.19753097	usec dB W MHz usec dB dB dB W W W W
NUC1 P1 PL1W SF01 ======= CH CPDPRG[2 NUC2 PCPD2 PCPD2 PL12 PL12 PL13 PL2W PL12W	13C 10.20 51.74793243 125.7761482 ANNEL f2 ==== waltz16 1H 100.00 19.99 21.00 19.75309753 0.24925002	usec dB W MHz usec dB dB dB W W W W
NUC1 P1 PL1 PL1W SF01 ======= CH CPDPRG[2 NUC2 PCPD2 PL12 PL12 PL13 PL13 PL2W PL13W SF02	13C 10.20 51.74793243 125.7761482 ANNEL f2 ===================================	usec dB W MHz usec dB dB dB W W W MHz
NUC1 P1 PL1 PL1W SF01 ======= CH CPDPRG[2 NUC2 PCPD2 PL12 PL12 PL13 PL13 PL2W PL13W SF02	13C 10.20 10.20 51.74793243 125.7761482 ANNEL f2 waltz16 10.00 1.00 19.99 21.00 19.75309753 0.24925002 0.19753097	usec dB W MHz usec dB dB dB W W W MHz
NUC1 P1 PL1 PL1W SF01 ====== CH CPDPRG[2 NUC2 PCPD2 PL12 PL13 PL2W PL13W PL12W PL13W SF02 F2 - Proces	13C 10.20 10.20 51.74793243 125.7761482 ANNEL f2	usec dB W MHz usec dB dB dB W W W MHz
NUC1 P1 PL1 PL1W SF01	13C 10.20 10.20 51.74793243 125.7761482 ANNEL f2 ===================================	usec dB W MHz usec dB dB dB W W W MHz
NUC1 P1 PL1 PL1W SF01 ====== CH CPDPRG[2 NUC2 PCPD2 PL12 PL13 PL2W PL13W SF02 F2 - Proces SI SF WDW SSB 0	13C 10.20 51.74793243 125.7761482 ANNEL f2 waltz16 10.00 1.00 19.99 21.00 19.75309753 0.24925002 0.1975309753 0.524925002 0.1975309753 0.24925002 0.1975309753 0.249250006	usec dB W MHz usec dB dB dB W W W MHz
NUC1 P1 PL1 PL1W SF01 ======= CH CPDPRG[2 NUC2 PCPD2 PL12 PL13 PL13W PL12W PL13W SF02 F2 - Proces SI SF WDW SSB 0 LB	13C 10.20 51.74793243 125.7761482 ANNEL f2 ===================================	usec dB W MHz usec dB dB dB W W W MHz
NUC1 P1 PL1 PL1W SF01 ====== CH CPDPRG[2 NUC2 PCPD2 PL12 PL13 PL2W PL13W SF02 F2 - Proces SI SF WDW SSB 0	13C 10.20 51.74793243 125.7761482 ANNEL f2 waltz16 10.00 1.00 19.99 21.00 19.75309753 0.24925002 0.1975309753 0.524925002 0.1975309753 0.24925002 0.1975309753 0.249250006	usec dB W MHz usec dB dB dB W W W MHz










¹H-NMR (*S,S,R*)-**34c**









¹³C-NMR (*S*,*S*,*S*)-**34c**





¹H-NMR **25d**





¹³C-NMR **25d**



























¹H-NMR **25e**






¹H-NMR **26e**







¹H-NMR **27e**




S193





¹H-NMR **28e**







¹H-NMR **29e**









¹³C-NMR (*R,S*)-**30e**






S201




¹H-NMR (*R,S*)-**32e**








Current NAME EXPNO PROCNO	Data Parameters Jan26-2021 61	
F2 - Accordance Date_ Time INSTRUM PROBHD PULPROG TD SOLVENT NS SWH FIDRES AQ DW DE TE D1 D11 TD0	5 mm PABBO BB-	Hz Hz sec usec usec K sec
NUC1 P1 PL1 PL1W SF01	CHANNEL f1 === 13C 10.20 1.50 51.74793243 125.7761482	usec dB W
CPDPRG[2 NUC2 PCPD2 PL12 PL12 PL13 PL2W PL12W PL13W SFO2	CHANNEL f2 waltz16 1H 100.00 1.00 29.99 21.00 19.75309753 0.24925002 0.19753097 500.1550006	usec dB dB dB dB W W
F2 - Pro SI SF WDW SSB LB GB PC	0 1.40	MHz




¹H-NMR (*R*,*R*)-**33e**












¹H-NMR **26f**







¹H-NMR **27f**




¹³C-NMR **27f**





¹H-NMR **28f**




¹³C-NMR **28f**









¹H-NMR (*S*,*S*)-**30f**




¹³C-NMR (S,S)-**30f**




¹H-NMR (*R,S*)-**30f**




¹³C-NMR (*R,S*)-**30f**





S220







¹H-NMR (*R,S*)-**32f**







¹H-NMR (*R*,*R*)-**31f**












¹H-NMR (*S,S,R*)-**34f**






¹H-NMR (*R,S,S*)-**34f**







NAME	Oct22-2020	
EXPNO	121	
PROCNO	1	
22100210		
F2 - Acqu	isition Parame	ters
Date_	20201023	
Time	0.59	
INSTRUM	spect	
	5 mm PABBO BB-	
PULPROG	zgpg30	
TD	65536	
SOLVENT	CDC13	
NS	1024	
DS	4	
SWH	32894.738	Hz
FIDRES	0.501934	
AQ	0.9961472	
RG	2580	
DW	15.200	
DE	10.00	
TE	296.0	
D1	2,00000000	
D1 D11	0.03000000	
TD0	0.03000000	sec
IDU	1	
	CHANNEL f1 ====	
NUC1	130	
P1	10.20	11000
	1.50	
PL1 PL1W	51.74793243	
SF01	125.7761482	
5501	123.1101402	PIFIZ
	CHANNEL f2 ====	
CPDPRG[2	waltz16	
NUC2	waitzio 1H	
PCPD2	100.00	
PL2	1.00	
PL12	19.99	
PL13	21.00 19.75309753	
PL2W	0.24925002	
PL12W		
PL13W	0.19753097	
SF02	500.1550006	MHZ
D0 D		
	essing paramete	ers
SI	32768	MIT
SF	125.7635720	MHZ
WDW	EM	
	0	T7
LB	1.00	HZ
	0	
PC	1.40	




¹H-NMR (*S,S,S*)-**34f**








¹H-NMR (*R,S,R*)-**34f**




¹³C-NMR (R,S,R)-34f













S239




¹H-NMR (*S,R,R*)-**36f**













¹H-NMR (*R*,*R*,*S*)-**35f**






¹H-NMR (*R*,*R*,*R*)-**35f**







¹H-NMR (R,R,S)-**36f**















Current Data Parameters
NAME Sep03-2021
EXPNO 21
PROCNO 1
F2 - Acquisition Parameters
Date_ 20210903
Time 12.08
INSTRUM spect
PROBHD 5 mm CPOCI 1H-
PULPROG zgpg30
ID 65356
SOLVENT CDC13
NS 1024
DS 4
SWH 40760.871 Hz
FIDRES 0.623675 Hz
AO 0.8017003 sec
RG 182.53
DW 12.267 usec
TE 298.0 K
D1 2.00000000 sec
D11 0.03000000 sec
TD0 1
====== CHANNEL f1 ======
SF01 176.1232717 MHz
NUC1 13C
P1 12.00 usec
PLW1 105.00000000 W
====== CHANNEL f2 ======
SFO2 700.3628014 MHz
NUC2 1H
CPDPRG[2 waltz16
PCPD2 65.00 usec
PLW2 9.89999962 W
PLW12 0.15564001 W
PLW13 0.07837200 W
1115 0.01051200 W
F2 - Processing parameters
SI 131072
SF 176.1056620 MHz
WDW EM


1.00 Hz 1.40















¹H-NMR **27**g





¹H-NMR **28g**





¹H-NMR **29**g

